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This dissertation starts with a brief description of one of our patients. It illustrates the 
interaction of psychiatric disorders with geriatric syndromes and how integrated psychiatric 
and geriatric care can lead to one interprofessional comprehensive treatment plan.
Mrs A was a 73-year-old married woman, who was referred to our outpatient clinic for a 
multidisciplinary consultation by a psychiatrist, geriatrician and psychologist. 
  Mrs A had a depressed mood, was inactive, felt tired and slept badly. She had withdrawn 
herself from pleasant activities such as playing bridge or visiting friends. Her appetite had 
decreased, resulting in a weight loss of 10 kilogram over the past three months. Moreover, 
Mrs A was becoming increasingly anxious and suspicious: she was afraid to stay at home 
alone, had panic attacks when her husband went out for shopping and was afraid of theft, 
resulting in her hiding objects. Most recently, Mrs A started to have trouble operating the 
washing machine, did not seem to know how to cook her meals properly, and forgot about 
things she had been told. In addition, her mobility was seriously restricted, caused by hammer-
toes on both feet and severe deconditioning. 
  Concerning her psychiatric and psychological symptoms, we concluded that Mrs A had 
a depressive disorder, accompanied by anxiety, suspicion and cognitive dysfunction. A diagnostic 
cerebral MRI showed severe white matter lesions. Concerning her physical complaints and 
clinical signs, we concomitantly identified geriatric syndromes: undernutrition, functional 
impairment, lack of mobility, and consequently sarcopenia, in addition to untreated hyperten-
sion as comorbid disorder. 
  In our interprofessional team we discussed the biological, psychological and social com-
ponents of her patient journey. We drew up a comprehensive plan, and tried to anticipate 
the complexity of the interactions between the psychiatric and geriatric morbidities. For 
example, with regard to her undernutrition, we proposed treatment by a dietician and for 
her mobility we advised referral to a podotherapist to adapt her shoes, in consultation with 
her own orthopaedic surgeon. For the depressive disorder and the accompanying symptoms, 
we advised initiating antidepressant medication, in addition to support by a psychiatric 
nurse at home to help her cope with the anxiety and to advise her and her husband on how 
to handle household tasks. Mrs A and her husband followed all our recommendations but 
one: they preferred a privately paid lady as a companion for Mrs A and declined help from 
a psychiatric nurse. They also agreed on consultation by an occupational therapist solely for 






Mrs A is a highly complex patient, with multiple health problems in the biological, psycholo-
gical, social domain, in addition to impairment in daily functioning. She represents a frail
person with an accumulation of geriatric syndromes and interactions with her depressive 
disorder. We have used an integrated, interprofessional approach in which her problems 
were diagnosed and treated simultaneously. However, our approach is not widely used 
in general medicine and mental health care. It is usual practice to diagnose and treat 
psychiatric disorders by psychiatrists or psychologists and have accompanying somatic 
symptoms, multimorbidity and geriatric syndromes diagnosed and treated separately by 
general practitioners or geriatricians in medical hospitals. This represents a tradition of 
separating body and mind in medical science and clinical practice. 
 However, from the perspective of an individual, body and mind are one entity, integrated 
in one person. This perspective becomes more important as people grow older: older persons
tend to have more somatic symptoms and a higher level of multimorbidity. They may have 
an increasing burden of geriatric syndromes such as functional dependence, problems in 
mobility, cognition and increasing frailty. These somatic and geriatric problems are likely 
to interfere with social and psychological well-being as well as with psychiatric disorders. 
This is probably also true the other way around.1,2 Psychiatric disorders such as somatoform
disorders present with ‘medically unexplained’ somatic symptoms, while depressive 
disorders are associated with unexplained medical symptoms, but also with somatic 
comorbidity. However, there may be a grey area when people get older: are medically unex-
plained symptoms as unexplained as they seem and is there an intermingling of geriatric 
syndromes and multimorbidity with psychiatric disorders, which is not always obvious at 
fi rst sight? 
 From this perspective we initiated clinical research, as much of the occurrence and 
impact of geriatric syndromes and multimorbidity in geriatric psychiatry is still unknown. 
Our research has been an explorative quest on how multimorbidity and geriatric syndromes 
interact with different psychiatric disorders in geriatric psychiatry.
 Aim of this thesis
The aim of our research was to investigate the occurrence, prevalence and associations 
of geriatric syndromes and multimorbidity in older adults with psychiatric disorders and 
their impact on treatment outcomes. 
I will start this introduction by describing what was known about somatic symptoms, 
multimorbidity and geriatric syndromes in relation to geriatric psychiatry at the time we 
started our various research projects between 2006 - 2010. 
 For readers who are not familiar with the meaning of concepts in geriatrics or the meaning 
of the psychiatric disorders, the defi nitions are described at the end of this introduction, 
followed by a list of abbreviations. 
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 Somatic symptoms, multimorbidity and associations with 
 psychiatric disorders
The prevalence of somatic symptoms, but also psychological symptoms, rises as people 
get older. Among community-dwelling adults aged 65 and older, women had four to fi ve 
somatic symptoms and men three to fi ve, increasing with number of diseases and age.3
Persons aged 75 and older who lived independently were found to have an average of six 
symptoms during one week and only 3% had no symptoms at all.4 Most frequently reported 
symptoms were pain, especially musculoskeletal pain, fatigue, impaired mobility, loss of sight 
and hearing, dizziness, swollen ankles, breathlessness, constipation, nocturia, gloominess,
anxiety and memory complaints.4-6
 However, not all symptoms were explained by actual diseases. In persons aged 65 or 
older a systematic review found that 5% - 18% of somatic symptoms remain unexplained 
in primary care.7 The increase in the number of reported symptoms in older age groups, 
the prevalence of unexplained symptoms and the increasing prevalence of diseases in older 
age make somatic and psychiatric symptoms more diffi cult to interpret for physicians, not 
the least for psychiatrists. 
 In addition to associations between somatic symptoms and medical diseases, associa-
tions were also found between the presence of somatic symptoms, irrespective of aetiology, 
with psychiatric morbidity. In the case of non-medically explained symptoms, there was a 
clear linear relationship, while with medically explained symptoms psychiatric morbidity 
rose sharply in the presence of more than 11 symptoms.8
In psychiatry the term comorbidity usually refers to the presence of one or more psychiatric 
disorders in addition to an index disorder. As this thesis focusses on the presence of more 
than one medical (or somatic) disease in addition to the psychiatric index disorder, we use 
the term medical (or somatic) comorbidity.
 Depression in later life was found to be bidirectionally associated with prevalence and 
negative outcomes of cardiovascular diseases.9-11 This is in line with studies in adults of 
all age groups, where associations between depression and cardiovascular disorders and 
diabetes mellitus were found.12-15
 The prevalence of medical comorbidity in patients with other severe mental disorders 
was also known to be higher than in age-matched controls,16-18 especially diabetes mellitus17, 
cardiovascular disorders,19 but also pulmonary diseases.18 This association is also the 
main cause of the clearly lower life expectancy (at least 10 years) of persons with psychiatric 
disorders compared to age-matched controls,15,20-22 which extends to later life.23
 In geriatrics, focus has shifted gradually away from medical comorbidity to multi-
morbidity,24 including mental disorders.24-26 This indicates a shift of interest from specifi c 
diseases to multiple chronic diseases, as this is more relevant and highly prevalent in 




of mortality.28 Multimorbidity is not a geriatric syndrome, but it is associated with frailty
and functional impairment,27,29 and can cause geriatric syndromes.30 Multimorbidity has 
gained attention in psychiatry since 2013.31 The combination of somatic and mental 
multimorbidity increases steeply in older age.32
 An individual patient with multimorbidity requires patient-centred, goal-oriented and 
well-coordinated care.33
 Geriatric syndromes
The term syndrome usually refers to a set of symptoms that appear in a fi xed relationship to 
each other. Most psychiatric disorders are syndromes without clear aetiology: to diagnose 
a major depressive disorder, a person needs to have at least fi ve out of nine symptoms, 
such as depressed mood, diminished interest or pleasure, but also weight loss or loss of 
energy, but there is no one underlying condition. 
 Geriatric syndromes are more or less the opposite: they refer to atypical, mostly single 
symptoms, that are highly prevalent in older age. These symptoms are linked to multiple 
aetiological factors (e.g. presence of several disorders at the same time) and render an 
older person vulnerable to situational challenges. Geriatric syndromes have a high impact 
on health and quality of life30,34 and may occur acutely (delirium, syncope), or more chroni-
cally (frailty, functional impairment, undernutrition, cognitive dysfunction, problems in 
mobility, falls or dizziness).35
 This thesis focusses on four chronic geriatric syndromes: frailty, functional impairment, 
undernutrition and cognitive dysfunction. 
 Frailty increases the risk of adverse outcomes,36 such as institutionalisation or mortality 
in community-dwelling older populations37,38 and it may be considered as an overarching 
geriatric syndrome: it increases the risk of other geriatric syndromes. For example, someone 
who is frail has a higher risk of delirium or falls in the case of a lower urinary tract infection. 
 In addition to frailty, functional impairment39,40 and cognitive dysfunction41 were also 
known to be predictors of adverse health outcomes (low quality of life, institutionalisation, 
mortality) in community-dwelling older adults. 
 Models of frailty
Two models of biomedical frailty are best validated and most widely used. The fi rst is the 
‘defi cit accumulation’ model: a Frailty Index (FI) is constructed based on the concept that 
the more defi cits individuals have, the frailer they are. Symptoms, signs, disabilities and 
diseases are all counted as defi cits.42
 The other model of frailty is the ‘Physical Frailty Phenotype’ (PFP). It consists of fi ve items: 
slow gait speed, weak handgrip strength, unintentional weight loss, self-reported exhaustion 
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and low energy expenditure. Every item is considered as present when an individual has a 
score that is in the lowest quintile score compared to a population-based cohort.37
 Walking speed43 and handgrip strength44 were being explored as sole frailty measures 
at the time we started our research. 
 Geriatric syndromes and geriatric psychiatry
Although an association between frailty and psychiatric disorders in late life, mainly
depression, was found in a large population-based study45, there were as yet no studies on 
prevalence and consequences of this association in older adults with psychiatric disorders 
when we started our different research projects. 
 However, functional impairment had been investigated comprehensively in late life 
depression: it was known to be a risk factor for depression10,46-48 and conversely, depression 
was known to be a risk factor for functional impairment.46,48
 Loss of weight is one of the symptoms of a depression and undernutrition was found to 
be associated with the prevalence of depression.49-52
 In older persons with depression, cognitive dysfunction was known to be highly prevalent, 
especially slowed information processing, which affects all realms of cognition.53 Cognitive 
dysfunction was found to be predictive of depression.10 Research on whether depression was 
conversely a risk factor for cognitive decline and dementia gave inconclusive results,54,55
but cognitive dysfunction seemed usually to persist in patients with recovery from 
depression.55 Cognitive dysfunction in depression is associated with cerebral white matter 
lesions.56,57 These were found to be connected to cardiovascular risk factors58 and have 
negative effects on treatment response in depression.59,60
 Some studies showed older adults with anxiety disorders to have more memory problems
than age-matched controls.61 In older patients with schizophrenia, cognitive disorders 
were found to be heterogenous and not in line with a distinct neurodegenerative disease.62
 Model of care and research setting
The diagnostic trajectory of Mrs A started with performing a Comprehensive Geriatric 
Assessment (CGA).63 A CGA has been proven effective in home-based care64 and for older 
adults admitted to hospitals65 in the sense that performing a CGA increases patients’ 
likelihood of survival and of remaining in their own homes. Feasibility and effectiveness of 
performing a CGA in geriatric mental health care has not been investigated yet. 
 Nevertheless, because of the complexity of patients like Mrs A we used to incorporate 
a CGA in outpatient and inpatient psychiatric diagnostic and treatment trajectories, and 
thus delivered goal oriented, interprofessional care.66
 Both our inpatient and outpatient interprofessional teams included psychiatrists, geria-




and when indicated, an occupational therapist, creative therapist, psychomotor therapist 
or physical therapist. On our inpatient acute wards the teams also included nurses and a 
dietician. We conducted our clinical research projects together with these interprofessional 
teams.  
 Outline
As our research has been an explorative quest on how multimorbidity and geriatric 
syndromes interact with different psychiatric disorders in geriatric psychiatry, this thesis is 
divided into three parts that cover three such interactions:
 Part 1: Geriatric and psychiatric characteristics in patients with medically unexplained  
 somatic symptoms and somatoform disorders
In a pilot study, we investigated the psychiatric and geriatric characteristics (frailty, functional 
status, somatic symptoms and multimorbidity) of 32 patients with somatoform disorders. 
Chapter 2 focusses mainly on the geriatric characteristics and chapter 3 on the psychiatric 
characteristics of such patients. 
 Following our pilot study, we were able to conduct a larger study, the Older Persons 
with Medically Unexplained Symptoms Study (OPUS) in which frailty and multimorbidity 
are compared between 118 patients with insuffi ciently explained somatic symptoms and 
154 patients with medically explained symptoms (chapter 4).
 Part 2: Geriatric characteristics in randomised controlled trials on antidepressants
In the second part of this thesis, we have focussed on the interaction of geriatric syndromes
with depressive disorders. Several meta-analyses have shown the effectiveness of anti-
depressants in late-life depression.67-69 Some meta-analyses, however, suggest that the 
therapeutic effect decreases with increasing chronological age.70,71 The hypothesis that 
geriatric syndromes and medical comorbidity negatively interfere with treatment outcomes 
of late-life depression has led to a systematic review in which we investigated whether and 
how frailty, medical comorbidity, disability, cognitive (dys)function and malnutrition are 
taken into account in studies on antidepressant drug treatment for late-life major depressive 
disorder (chapter 5).
 Part 3: Frailty, multimorbidity and functional status in older adults admitted to acute 
 psychiatric wards 
Finally, we conducted an observational cohort study with fi ve years follow-up in 120 older
patients, who were admitted to acute wards for geriatric psychiatry. We describe the 
prevalence of geriatric measures on admission and investigated whether separately they 
are independent predictors of the psychiatric outcome measures at discharge and of 
discharge destination (chapter 6). 
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 Six years later we performed a follow-up study, in which we investigated mortality within 
fi ve years after admission in the same study population. We primarily focused on the question
whether frailty, measured with a FI, is an independent predictor of mortality (chapter 7). 
This thesis concludes with a summary of the main fi ndings, a general discussion on our 
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 Defi nitions of concepts, 
 order of appearance in the Introduction
Somatoform disorder, undifferentiated, core characteristics
A. One or more physical complaints
B. Either 1 or 2: 
 1. after appropriate investigation, the symptoms cannot be fully explained by a known 
  general medical condition or the direct effects of a substance (e.g. a drug of abuse, 
  a medication),
 2. when there is a related general medical condition, the physical complaints or resulting 
  social or occupational impairment are in excess of what would be expected from
   the history, physical examination, or laboratory fi ndings. 
C. The symptoms cause clinically signifi cant distress or impairment in social, occupational, 
 or other important areas of functioning.  
D. The duration of the disturbance is at least 6 months.1 
Depressive disorder
A mood disorder, with at least 1. depressed mood or 2. loss of interest or pleasure. The 
diagnosis implies there have to be at least fi ve symptoms, including at least one from 
1. and 2. The other symptoms are: signifi cant weight loss or weight gain, insomnia or 
hypersomnia, fatigue or loss of energy, psychomotor retardation or agitation, feelings of 
worthlessness, diminished ability to think or concentrate and recurrent thoughts of death.1
Comorbidity 
The co-occurrence of one or more diseases in addition to an index disease, in this thesis 
medical comorbidity (see below).2
 In psychiatry comorbidity mostly refers to other psychiatric disorders. 
Medical (or somatic) comorbidity refers to the presence of more than one medical (or somatic)
disease, in addition to the psychiatric index disorder. 
Multimorbidity
The co-occurrence of two or more diseases.3
Medically unexplained somatic symptoms
Physical symptoms that have existed for more than several weeks and for which adequate 
medical examination has not revealed any condition that suffi ciently explains the symp-
toms.4 
 During our research this concept changed gradually to Medically insuffi ciently explained 





Atypical, highly prevalent, mostly single symptoms in older age that are linked to multiple 
aetiological factors, rendering an older person vulnerable to situational challenges.5
Frailty: the age-related state of increased vulnerability to poor resolution of homeostasis 
after a stressor event (e.g. urinary tract infection).6
Functional impairment, also called (physical) disability
Diffi culty, restriction or dependence on others in Activities of Daily Living (ADL) such as: 
eating, bathing, grooming, dressing, continence or in Instrumental Activities of Daily 
Living (IADL), such as transport, taking medication, handling fi nances or performing 
domestic tasks.7,8
 In younger psychiatric populations functioning and disability have a broader meaning: 
work, social and family relations are included and disability is defi ned as diffi culty in functioning 
at the body, person or societal levels, in one or more life domains, as experienced with 
contextual factors.9
Cognitive dysfunction
Signifi cant lower performance than expected on a domain of cognitive functioning, compared
to persons with the same age, sex or education.
 Undernutrition (often used interchangeably with malnutrition)
A state resulting from lack of intake of nutrition that leads to altered body composition 
(decreased fat-free mass) and body cell mass, leading to diminished physical and mental 
function and impaired clinical outcome form disease.10
Sarcopenia
A complex medical condition, characterised by a progressive loss of mass, quality and function
of skeletal muscles associated with ageing.11
Geriatric characteristics
Geriatric syndromes and multimorbidity.
Comprehensive Geriatric Assessment (CGA)
A multidisciplinary evaluation in which the multiple problems of older persons are 
uncovered, described, and explained, if possible, and in which the resources and strengths 
of the person are catalogued, need for services assessed, and a coordinated care plan 
developed to focus interventions on the person’s problems.12
 Interprofessional collaboration
The process by which different health and social care professional groups work together 
to positively impact care.13
1
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ADL Activities of Daily Living
AGS American Geriatrics Society
APA American Psychiatric Association
BPSD Behavioural and Psychological Symptoms of Dementia
CGA Comprehensive Geriatric Assessment
CIRS-G Cumulative Illness Rating Scale for Geriatrics
DSM Diagnostic and Statistical Manual of Mental Disorders
FI  Frailty index
IADL Instrumental Activities of Daily Living
MNA Mini Nutritional Assessment
MUS Medically Unexplained Symptoms or Insuffi ciently Explained Somatic Symptoms
MES Medically Explained Somatic Symptoms
NPS Neuropsychiatric Symptoms
PFP Physical Frailty Phenotype
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The primary objective of this study was to systematically examine the physical functioning 
of older persons with somatoform disorders, as this has never been carried out before. 
Second, we wanted to test our hypothesis that higher somatic disease burden in patients 
with somatoform disorders is associated with a higher level of somatisation. 
 Design and Setting
Observational study of patients referred for medically unexplained symptoms (MUS) 
to our outpatient mental health centre for older adults. The patients were offered a 
standardized, multidisciplinary diagnostic procedure, including a comprehensive geriatric 
assessment. Inter-rater reliability between two geriatricians assessing the contribution of 
somatic pathology to the main somatic symptom was assessed.
 Participants 
A total of 37 patients referred for MUS (mean age 75 ± 6 years).  
 Measurements
Timed Up and Go Test (TUG) and hand grip strength were used as measures for frailty; 
the Cumulative Index Rating Scale for Geriatrics (CIRS-G) sum score and severity index 
measured the burden of cumulative somatic morbidity. The Groningen Activity Rating 
Scale (GARS) measured functional status. The Whitely Index was used as measure for 
somatisation. 
 Results
Patients’ main symptom could be completely explained by a somatic disease in 3/37 (8%) 
patients (kappa between geriatricians = 0.72). A total of 32 patients met the criterion for 
a Somatoform Disorder according to DSM-IVTR criteria, but somatic comorbidity partially 
explained the main symptom in 15/32 patients. These patients were older (p = 0.049), 
had more somatic comorbidity (p = 0.049), a slower gait speed (TUG, p = 0.035), a lower 
hand grip strength (p = 0.050) and a lower functional status (p = 0.30) compared to the 
17 patients without any explanation for their main somatic symptom. In contrast to our 
hypothesis, a higher level of somatisation was associated with less somatic disease burden.
 Conclusion
Geriatric assessment has important added value in older patients referred with medically 
unexplained symptoms, as in half of the patients symptoms can be partially or fully explicable 





Medically unexplained symptoms (MUS) are a common phenomenon. In primary care 
15% - 39% of presented somatic symptoms remain unexplained.1,2 MUS become burdensome 
when they persist over time and people persevere in seeking medical help. Psychological 
processes like somatisation and hypochondriasis are thought to predispose, precipitate
or perpetuate the persistence of MUS. Somatisation is conceptualised as a tendency 
to express psychological distress with somatic complaints. In the medical literature, 
somatisation is often defi ned according to Lipowski (1998) as “the tendency to experience 
and communicate somatic distress and somatic symptoms unaccounted for by relevant 
pathological fi ndings, to attribute them to physical illness, and to seek medical help for 
them”.3 Hypochondriasis is a persistent preoccupation or worry about having a disease 
despite reassurance given after thorough medical examination.4 Although hypochondriasis 
can be present without having any medical symptoms, approximately 75% of the people 
suffering from hypochondriasis also have MUS.5 In the Diagnostic and Statistical Manual 
of Mental Disorders IVTR (DSM IVTR), a widely used classifi cation system for psychiatric
disorders, MUS are considered as the core criterion for a somatoform disorder. Nonetheless,
depending on type and combinations of symptoms, duration, intensity and level of distress, 
patients suffering from MUS may or may not meet the criteria for a specifi c somatoform 
disorder like somatisation disorder, pain disorder, conversion disorder, hypochondriasis, 
or somatoform disorder not otherwise specifi ed. It is important to note that a somatoform 
disorder can be present when a patient has partially explained somatic symptoms: the 
adverse effects of the somatic symptoms on everyday life are substantially more severe 
than expected. 
 The burden of MUS and somatoform disorders is large: patients often report a low 
quality of life and suffer from comorbid anxiety and depressive disorders.6 Furthermore, 
MUS give rise to high levels of health care consumption in search for an organic origin 
of complaints, which places patients at risk for extensive and potentially iatrogenic inves-
tigations.7 In 10% to 30% of MUS, and 50% to 70% of hypochondriasis, the condition 
becomes chronic.8
 Although empirical data are scarce, prevalence rates range from 1.5% through 18% for 
MUS and from 5% through 13% for somatoform disorders in people aged 65 years and 
over.9 These fi gures are somewhat lower than those reported for younger people, which 
may be explained by diagnostic problems of MUS or somatoform disorders in later life. 
At an older age, somatisation often occurs in the context of chronic somatic diseases,10
and thus more pathological fi ndings have to be examined in an attempt to account for 
the physical complaints.11 Higher comorbidity rates as well as higher a priori chances of 
underlying physical illnesses as explanation for physical complaints in older people probably 
cause physicians to consider these symptoms as explained.12
 To date, several etiological models for (the persistence of) MUS have been proposed.13-17 
Although consensus exists on the interplay between biological, psychological and social 
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elements in the aetiology of MUS, models differ in the relative contribution of these factors. 
Psychological and social processes can be a precipitating factor, but are most often assumed
to be predisposing and perpetuating factors. Biological processes, by contrast, are only
included as a precipitating factor. In most models, bodily sensations that give rise to 
somatic symptoms are thought to originate from both normal physiological processes 
(e.g. bowel peristaltic), from pathophysiological processes due to sub threshold medical 
conditions (e.g. elevated blood glucose levels without actual diabetes), or from clinical 
diseases. The contribution of pathophysiological processes is also refl ected by the criterion 
for somatoform disorders that complaints have to be more severe than can be explained 
by the underlying somatic condition. Further support for the contribution of these processes 
can be deduced from the fi nding that in depressed older adults the level of somatisation 
increases with the number of chronic somatic conditions.18 Thus, we might expect somati-
sation problems to increase parallel with an increase in somatic diseases. Therefore, more 
emphasis should be placed on the physical functioning of patients suffering from MUS or 
somatoform disorders, particularly in later life.
 The objective of the present study was 1. to describe the physical morbidity and func-
tioning of a convenience sample of patients referred for MUS to an outpatient mental 
health centre for older adults in the Netherlands and 2. to explore the association between 
the level of somatisation and physical performance. We hypothesized a positive association 
between a higher level of somatisation and lower level of physical performance. 
 METHODS
 Design
All patients aged 60 years or over, referred for MUS to an outpatient mental health centre 
for older adults in Nijmegen in the Netherlands between September 2006 and October 
2007 underwent a standardized examination by a geriatrician (CB), old-age psychiatrist 
(PH) and clinical psychologist (DvD) within two weeks after referral. The psychiatric 
characteristics of this cohort have been described elsewhere.19 In short, psychiatric disorders
were assessed by an experienced old-age psychiatrist (PH) according to the criteria of the 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) using
the Mini International Neuropsychiatric Interview version 5.0.0. The senior clinical 
psychologist (DvD) focussed on the consequences of the somatic symptoms in everyday 
life, in order to prepare for and motivate patients for cognitive-behavioural treatment. 
The Whiteley Index (WI) was administered to assess the severity of hypochondric beliefs 
and attitudes as a measure of somatisation.4,20 This self-report questionnaire includes 14 
dichotomised items (yes/no) related to bodily preoccupation, disease phobia and conviction 
of the presence of disease. The sum score range from 0 - 14, with higher scores being 
indicative of more severe somatisation levels and hypochondric beliefs. The Dutch version 
has been validated in different populations, showing good test-retest reliability (0.90) and 




for clinically relevant levels of somatisation is not available, the WI appeared to discriminate 
reasonably well between hypochondriacal and non-hypochondriacal subjects.21
 Geriatric assessment
The geriatrician performed a complete geriatric assessment including an electrocardiogram
(ECG), routine blood chemistry, somatic disease burden, activities of daily living and 
cognitive screening with the Mini-Mental State Examination (MMSE).22 All correspondence 
of previous medical examinations was evaluated and when relevant, previous medical 
specialists were consulted by telephone. If considered necessary, further investigations 
were carried out. The duration of the main symptom was estimated in months and patients 
had to rate the current intensity of their main symptom on a visual analogue scale (VAS). 
 The geriatrician (CB) who did the geriatric assessment judged the main symptom as 
completely explained, partially explained or unexplained by an underlying somatic disease. 
As there is no objective criterion to decide whether a bodily complaint is medically explained 
or not, a second geriatrician (LD) also classifi ed the patients’ symptoms according to 
these three categories. This classifi cation was based on the medical records (including 
fi ndings of the fi rst geriatrician), but blind for the fi nal judgement of the fi rst geriatrician. 
Subsequently, discrepancies were discussed between both geriatricians in order to achieve 
consensus. In case no consensus could be reached, a third geriatrician made the fi nal 
classifi cation for that patient (MOR).
 Somatic comorbidity 
The Cumulative Illness Rating Scale - Geriatric (CIRS-G) was used to measure cumulative 
burden of diagnosed somatic diseases.23 This scale was scored by a clinician and contains 
14 domains: 13 domains of different somatic organ systems and 1 psychiatric domain, 
which was left out. Each item can be scored from 0 - 4 (range 0 - 52, higher score: more 
comorbidity). In our study we used the sum score and the ‘severity index’ of the CIRS-G: 
the total score divided by the number of domains on which the score was > 0.24
 Frailty
As a gold standard for frailty does not exist and available frailty indices at least partly overlap 
with the criteria for psychiatric diseases,25,26 we administered two proxy measurements for 
physical frailty: the Hand grip strength27 and the Timed Up and Go Test (TUG).28 Hand 
grip strength was measured using the Jamar Dynamometer as the best score of two 
consecutive attempts. The TUG is a measure that scores the time needed by a patient to 
get up from a chair, walk 3 metres, turn around, walk back to the chair and sit down again. 
Both tests have high inter-rater and test-retest reliability. 
 Functional status
We used the Groningen Activity Restriction Scale (GARS) to measure activities of daily 
living.29 This self-assessment scale contains 18 items of ADL and IADL, with 1 - 4 points per 




First, we evaluated the main symptoms origin of the patients. We categorised patients 
referred for MUS in those having completely explained, partially explained and unexplained 
medical symptoms. Inter-rater reliability of this classifi cation into three categories by both 
geriatricians was estimated by calculating the kappa (Ƙ). 
 Second, we compared patients suffering from somatoform disorders with partially 
explained or unexplained main symptoms with respect to physical functioning. Differences 
were tested by χ2 and by two-sample t-test or Mann-Whitney U-test. As ours was a pilot 
study and data-analysis was mainly explorative, we did not apply a Bonferroni correction 
and considered p-values of less than 0.05 to be signifi cant.
 Third, correlations between measures of somatisation Whiteley Index (WI) and measures 
of somatic disease burden (CIRS-G, GARS) and frailty (hand grip strength, TUG) were 
calculated by Pearson’s correlation. Correlation coeffi cients 0.10 and 0.30 are considered 
small, between 0.30 and 0.50 medium and between 0.50 and 1.00 strong.30
 RESULTS
 Patient characteristics
A total of 48 patients were referred for medically unexplained symptoms (MUS) of which 
37 patients agreed to a diagnostic assessment. Reasons for refusal were: lack of motivation 
(n = 4), aversion against mental health organization (n = 2), hospitalization for an acute 
disease (n = 2), age below 60 years (n = 1), moved homes (n = 1), unknown (n = 1).
 The 37 patients who went through the diagnostic procedure had a mean age of 74.8 
years (SD = 7.0 years) and 31/35 (84%) patients were female. 15 Patients (41%) were 
married and lived with their partner; the other 22 patients lived alone (widowed, n = 18; 
divorced, n = 2; never married, n = 2). The mean MMSE score was 27.5 (SD = 2.4) indicative 
of good cognitive functioning. 
 Classifi cation of the primary symptom
The Ƙ of inter-rater agreeability between the overall classifi cation of the main somatic 
symptom as completely explained, partially explained, or unexplained by both geriatricians 
was 0.67. 
 The fi rst geriatrician (CB) classifi ed three out of these 37 patients as having a completely
explained main somatic symptom. The second geriatrician (LD), who blindly evaluated 
the medical records, classifi ed these same three patients as having a somatic disorder 
that completely explained their symptoms. In addition he scored also two other patients 
as such. This resulted in a Ƙ of 0.72 for the comparison between completely explained 
versus partially explained/unexplained symptoms. After discussing these two patients, 





Of the remaining 34 patients, the main symptom spontaneously resolved in two patients, 
whereas the other 32 patients all met DSM-IVTR criteria for a somatoform disorder (see 
for details also Hilderink et al., 2010).17 Among the 32 patients with a somatoform disorder, 
the Ƙ of inter-rater agreeability of main complaints that could be partially explained by an 
underlying somatic disorder versus those that were unexplained between the fi rst (CB) 
and second (LD) geriatrician was 0.69. Nonetheless, consensus could quite easily be reached
in discrepant cases when both geriatricians presented their arguments to each other. This 
consensus meeting resulted in a fi nal classifi cation of 15 patients with a partially explained 
and 17 with a unexplained main symptom. 
Table 1 
Comparison of somati c disease burden in pati ents suff ering from somatoform disorder with and 
without a parti ally explained medical symptom (n = 32)
                                                                          Explanati on for primary complaint Stati sti cs
Variables Unexplained Parti ally  P
  (n = 17)  (n = 15) 
Demographics:   
• Age (years)  73.0 (6.6) 77.7 (6.2) 0.049
• Female sex  13 (77) 13 (87) 0.46
MUS characteristi cs:   
• Durati on of MUS (months)  70 (71) 71 (72) 0.99
• Intensity primary symptom (VAS)  7.2 (21) 7.7 (24) 0.67
Psychiatric morbidity   
• Depressive disorder  11 (65) 7 (47) 0.31
• Anxiety disorder  6 (35) 4 (27) 0.60
Physical functi oning:   
• CIRS total score 6.5 (4.2) 10.5 (6.0) 0.049
• CIRS severity index 1.4 (0.4) 1.8 (0.6) 0.076
• Grip strength 32.7 (13.7) 22.2 (11.5) 0.050
• TUG 7.9 (2.9) 11.8 (5.4) 0.035
• GARS 23 (10) 34 (14) 0.030
Level of somati sati on   
• Whiteley Index 6.9 (4.0) 4.6 (3.4) 0.068
Note: between brackets: % for number of pati ents, and SD, standard deviati on for conti nuous measures; p, p-value.
Abbreviati ons: MUS, medically unexplained symptoms; GARS, Groningen Acti vity Restricti on Scale. CIRS-G: Cumulati ve 
Illness Rati ng Scale Geriatric. VAS, visual analogue scale.
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 Physical functioning in somatoform disorders in later life (n = 32) 
During the geriatric assessment, 20 patients reported pain as their primary symptom 
(head, n = 6; whole body, n = 4; abdominal, n = 4; mouth, n = 3; back, n = 2; joints, n = 1). 
The other primary complaints were shortness of breath/coughing (n = 5), dizziness (n = 3), 
and further dysarthria, paraesthesia, anxiety/loneliness, and fatigue.
 Table 1 presents the characteristics of all patients diagnosed with a somatoform 
disorder, stratifi ed for patients with partially explained and unexplained main symptoms. 
The mean duration of the main symptom was almost 6 years in both groups. Patients in whom 
the main symptom was partially explained by a somatic condition were older (p = 0.049), more 
functionally impaired (GARS p = 0.030), had higher chronic disease burden as measured 
by the CIRS-G total score (p = 0.049), a lower gait speed (TUG p = 0.035) and lower hand 
grip strength (p = 0.050) compared to patients with no explanation for their main symptom. 
This latter group, however, had numerically higher levels of somatisation on the WI, although
the difference did not reach statistical signifi cance (p = 0.068). 
 Associations between somatisation and parameters of physical functioning
Somatisation, as indexed with the WI, had a substantial but inverse relationship with gait 
speed (TUG, r = - 0.44, p = 0.015) and a defi nite, but small relationship with hand grip 
strength (r = 0.27, p = 0.16). There was also a small inverse relationship with the CIRS 
severity index (r = - 0.21, p = 0.27) and the Groningen Activity Restriction Scale (GARS, 
r = - 0.32, p =  0.078). We found virtually no relationship with the CIRS-G total score (r = - 0.02,
p = 0.91).
 DISCUSSION
This is the fi rst study on a multidisciplinary assessment of patients referred for MUS in 
an older population. Our patients were suffering on average for 6 years with their somatic
symptoms and their referring physicians referred them specifi cally for psychological 
treatment having fi nalised their somatic diagnostic work-up probably much earlier. We 
know that behavioural problems are an important reason for admission in long term care 
institutions, thus chronic problems like MUS and somatoform disorders probably relevantly 
contribute to disease burden in long term care.
 We showed that these patients referred to an old age psychiatry setting still importantly 
benefi t from a comprehensive geriatric assessment. A small proportion (8%) of patients 
with seemingly inexplicable symptoms still could be explained, while nearly half of the 
formerly unexplained symptoms could be partially explained. Moreover, patients felt taken 
seriously by the geriatric assessment and it helped them accepting a psychological treatment. 
 There are several limitations inherent in such a small pilot study on a convenience 
sample referred to an old age psychiatry setting. Here we would like to address the lack 
of statistical power and the fact that the cross-sectional nature hampers fi rm conclusions 




 Nevertheless, although preliminary, our results are important. MUS and Somatoform 
disorders in later life are largely neglected in geriatric literature, whereas the chronic nature 
of the complaints, the physical functioning and frailty of this older age group may have 
considerable clinical consequences. 
 Although referred for MUS, in three (8%) out of 37 patients in our sample there did 
turn out to be a completely somatic explanation for the main symptom. In previous studies, 
misdiagnosis of MUS has mainly been focused on misdiagnosis in conversion: in a review 
a mean percentage of 4 % misdiagnosis was found in 22 studies published since 1970,31,32
which is lower than in our study. 
The overall agreement between two geriatricians judging the main symptom as completely
explained, partially explained or unexplained was moderate to good. We found only two 
studies on medical judgment of symptoms in these three categories. Our Ƙ is in line 
with these studies, which used a different methodology and were conducted in younger 
populations. In the fi rst study, a Ƙ of 0.76 was found on agreement between two 
psychiatrists and one general physician using a chart review method.33 The second study, 
a retrospective chart study, reported an agreement in diagnosis of only 43% between 
paediatricians in a panel for children who were referred for unexplained chronic pain.34
Comparison of the groups of patients with a partially explained and unexplained main 
somatic symptom showed that the patients in the fi rst group were signifi cantly older, 
had more somatic comorbidity, a lower hand grip strength, and a slower gait speed. The 
CIRS-G total score for the group of patients with partially explained somatic complaints 
was comparable with a group of patients on an acute geriatric ward,23 but the CIRS-G 
‘severity index’ was low and not signifi cantly different for both groups. This indicates that, 
although the number of somatic diseases was higher in the partially explained group, the 
severity of the underlying somatic diseases was low to moderate. Overall, the comprehensive
geriatric assessment data indicate that the group of persons with unexplained symptoms is 
a strikingly healthy population from a somatic point of view, whereas the group of persons 
with partially explained symptoms is less healthy and more frail. Particularly this latter 
group may benefi t from a multidisciplinary approach including geriatric assessment.
 In contrast to our hypothesis, a higher level of somatisation was associated with a 
better physical performance. First, the strong trend towards higher level of somatisation, 
as measured with WI, was associated with a lower degree of frailty, of which the TUG 
reached statistical signifi cance. Second, we did not fi nd an association with the CIRS-G 
sum score, whereas the severity index of the CIRS-G was negatively associated with 
somatisation: more somatic conditions, be it of moderate severity, was associated with 
less somatisation. 
 There might be several explanations for this unexpected fi nding; physical problems in 
later life might result in more adequate interpretation of bodily sensations and physical 
problems might have validated people’s help-seeking behaviour and thereby have had a 
dampening effect on the level of somatisation. This also offers an alternative explanation 




A geriatric assessment has added value in diagnosing older patients referred for MUS, 
even when symptoms exist for years. One-half of the patient symptoms, which could not be 
explained before, proved to be partially or fully explicable following such a comprehensive
assessment. Moreover, a high somatic disease burden was found in those patients with 
partially explained symptoms. Longitudinal research is necessary to disentangle the 
relationship between somatisation and somatic disease burden in later life as this will 
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To examine the somatic complaints, functional impairment and psychiatric comorbidity in 
elderly patients with medically unexplained symptoms (MUS).
 Method
A consecutive case series of 37 patients referred for MUS to a multidisciplinary, outpatient 
clinic at a secondary care mental health center in the Netherlands. All patients underwent 
a standardized examination by a geriatrician, psychiatrist and psychologist.
 Results
For three patients a somatic explanation was found and in two patients symptoms 
spontaneously resolved before a diagnosis could be made. Of the remaining 32 patients 
with MUS, depressive disorders were present in 18 (56%), anxiety disorders in 10 (31%) 
and substance use disorders in 6 patients (19%). Compared with non-depressed patients 
with MUS, depressed patients had more severe somatic symptoms, more psychological 
symptoms, and more functional impairment.
 Conclusions
As the authors found a high comorbidity with other psychiatric disorders in elderly patients 







Medically unexplained symptoms (MUS) are usually defi ned as physical symptoms of 
which presence, severity or consequences cannot be explained by any detectable physical 
disorder.1 A study among general practice visitors showed that 7% of patients aged 65 
years or over were suffering from a somatoform disorders versus 22% - 28% of those aged 
below 65 years.2 However, in older persons, the diagnosis of MUS is diffi cult for several 
reasons. First the increased prevalence of physical morbidity with age will lead to more 
pathological fi ndings, for which the causal relationship with the presented symptoms 
has to be evaluated. Second, depressed elderly patients more often present only physical 
symptoms. Despite these diffi culties, there are no age-specifi c Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for somatoform disorders. 
These issues may result in underrecognition of somatoform disorders in elderly patients.3
These diffi culties may be overcome by a biopsychosocial approach. For this reason, we 
started a multidisciplinary outpatient clinic for older patients with MUS. This report 
presents the fi rst results with respect to the somatic complaints, functional impairment 
and psychiatric comorbidity. 
 METHODS
A consecutive case series of patients aged 60 years or over who were referred for MUS 
to our multidisciplinary outpatient clinic from September 2006 until October 2007. This 
outpatient clinic was part of a secondary care, old-age psychiatric service of the Nijmegen 
Mental Health Center.
 All patients underwent a standardized examination of a geriatrician (CB), old-age 
psychiatrist (PH) and clinical psychologist (DvD) within two weeks. The geriatrician 
performed a full physical examination, electrocardiogram, routine blood chemistry, and 
cognitive screening with the Mini Mental State Examination (MMSE). Psychiatric disorders
were assessed according to the criteria of the DSM-IV-Text Revision (TR) using the Mini 
International Neuropsychiatric Interview version 5.0.0 by an old-age psychiatrist (PH) in 
addition to observer rated psychiatric instruments (see later). Severity of the presenting 
symptom (visual analog scale (VAS) from 0, no burden, through 10, unbearable symptoms)
and its functional limitations were assessed in a clinical interview by a senior clinical 
psychologist (DvD). 
 The number and severity of somatic symptoms in the past month was assessed by the 
well-validated Patient Health Questionnaire somatic symptom severity scale (PHQ-15).4 
Patients had to report the burden of 15 symptoms that cover 90% of potential somatic 
symptoms found in patients with somatoform disorders, rated on a three-point scale (no, 
little or much). The item about menstrual discomfort was omitted. In an adult population, 
a score of 5, 10, and 15, is used as threshold for mild, medium, and high level of somatisation,
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respectively. The impact of the MUS on the patients’ everyday living was assessed by 7 (of the 
originally 15) subscales of the Sickness Impact Profi le (SIP), i.e. ‘household’, ‘social inter-
action’, ‘sleep’, ‘mobility’, ‘walking’, ‘alertness’ and ‘recreation’. The SIP has been developed 
to measure behavioural limitations due to physical illness. 
 General psychopathology was measured by the Symptom Checklist 90 item version 
(SCL-90), a self-report questionnaire assessing 8 domains of psychological functioning in 
the past week. The severity of depressive symptoms was measured by the observer-rated 
Montgomery Åsberg Depression Rating Scale and the severity of hypochondriacal beliefs 
and attitudes with the Whiteley Index, a 14-item self-report questionnaire. 
Data are presented as absolute numbers and percentages within groups in case of 
nominal variables, and for continuous measures as means with standard deviation (SD) 
or median with interquartile ranges (IQR) for normal and non-normal distributions. 
Patients with and without depression were compared by χ2, two-sample t test or Mann-
Whitney U-test.
 RESULTS
Forty-eight patients were consecutively referred for MUS, of whom 37 patients gave informed
consent. Reasons for refusal were: lack of motivation (n = 4), aversion against mental 
health organization (n = 2), hospitalization for an acute disease (n = 2), moving homes 
(n = 1), or unknown reasons (n = 1). One subject was excluded because of age below 60 years.
 Patients had a median age of 75 years (range = 60 - 92) and 31 of 37 (84%) patients 
were women. Fifteen patients (41%) were married and lived with their partner, and the 
other 22 patients lived alone. The mean Mini Mental State Examination score was 27.5 
(SD = 2.4).
 In three patients, a somatic disorder was found that fully explained their symptoms, 
namely herpes zoster infection of the cranial nerves combined with pulmonary fi brosis 
(n = 1), a cerebrovascular accident (n = 1) and spinal canal stenosis (n = 1). A further two 
patients reported psychosocial problems as their primary complaint. This leaves a total 
sample of 32 patients, who met DSM-IV criteria for a somatoform disorder: undifferentiated 
somatoform disorder (n = 16), pain disorder (n = 8), hypochondriasis (n = 4), somatisation 
disorder (n = 1), and a combination of hypochondriasis with a pain disorder (n = 3). Fifteen 
(47%) patients had pathological fi ndings or somatic diseases that partly explained their 
primary somatic complaint.
 Seventeen out of the 32 patients had symptoms for more than 5 years; only one patient 
had symptoms for less than 6 months. Twenty patients reported pain as their primary 
symptom (head, n = 6; whole body, n = 4; abdominal, n = 4, mouth, n = 3, back, n = 2, 
joints, n = 1). The other primary complaints were shortness of breath/coughing, (n = 5), 
dizziness, (n = 3) and further dysarthria, paraesthesia, anxiety/loneliness, and fatigue. The 




 The impact on functioning was substantial given the mean scores on the SIP sub scale 
for social interaction (17, SD = 15), sleep (24, SD = 20), household activities (18, SD = 19), 
mobility (16, SD = 20), walking (11, SD = 13), alertness (28, SD = 22), and recreation (29, 
SD = 25). The PHQ-15 (Table 1) showed a medium severity of somatisation with a mean 
total score of 8.7 (SD = 4.1).
The mean Montgomery Åsberg Depression Rating Scale score of 12.2 (SD = 7.6) indicated
mild depressive symptoms, the mean SCL-90 sum score of 171 (SD = 46) indicated a 
moderate level of overall psychopathology and the mean Whiteley Index of 5.8 (SD = 3.9) 
indicated a moderately high level of hypochondriacal beliefs. 
Twenty-two (69%) of the patients diagnosed with a somatoform disorder had one or more 
comorbid psychiatric disorder (one, n = 11; two, n = 8, three, n = 3). The most common
group of comorbid disorders were depressive disorders (n = 18 (56%)): major depressive 
disorder, n = 13; dysthymia, n = 5). Depressed patients had a signifi cantly longer duration 
of psychiatric treatment (Mann-Whitney U Z = -2.22, p = 0.026), higher somatic symptom 
burden (PHQ-15, t = - 2.99 df = 30, p = 0.005; higher SCL-90 subscale scores (depression: 
t = - 3.16, df = 26, p = 0.004; anxiety: t = - 2.48, df = 26, p = 0.020; somatisation: t = - 2.70, 
df = 26, p = 0.012; insuffi ciency: t = - 2.67 df = 26, p = 0.013; hostility: t = - 2.5, df = 26, 
p = 0.017), and more functional impairment assessed with the SIP (social interactions, 
t = - 3.15, df = 28, p = 0.004; alertness, t = - 2.80, df = 28, p = 0.009).
Table 1
Prevalence of somati c complaints according to the Pati ent Health Questi onnaire (PHQ-15) (n=31).
  Burden   
 Prevalence Litt le Severe 
Symptom  % (n)   % (n)  % (n)
Abdominal pain 35  (11)  23  (7) 13  (4)
Back pain 61  (19)  32  (10) 29  (9)
Joint pain 75  (23)  35  (11) 39  (12)
Headache 35  (11)  13  (4) 23  (7)
Chest pain 35  (11)  29  (9) 6  (2)
Dizziness 45  (14)  19  (6) 26  (8)
Syncope 6  (2)  3  (1) 3  (1)
Heart pounding 35  (11)  23  (7) 13  (4)
Shortness of breath 45  (14)  19  (6) 26  (8)
Sexual problems 6  (2)  3  (1) 3  (1)
Intesti nal problems 68  (21)  52  (16) 16  (5)
Nausea  42  (13)  19  (6) 22  (7)
Fati gue  52  (16)  29  (9) 23  (7)
Sleeping problems 58  (18)  29  (9) 29  (9)
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 Anxiety disorders were present in 10 patients (2 patients had 2 anxiety disorders): 
generalized anxiety disorder (n = 4), social fobia (n = 3), panic disorder (n = 3), agoraphobia
(n = 1), specifi c phobia (n = 1). Finally, 6 patients (19%) met criteria for substance use 
disorders, i.e., dependence of opioids (n = 4), dependence of benzodiazepines (n = 1), and 
fi nally dependence on an unknown agent (n = 1).
 DISCUSSION
To our knowledge this is the fi rst study presenting results of a standardized multidiscipli-
nary examination of elderly patients suffering from MUS. The main fi nding of our study is 
the high prevalence of somatoform disorder with psychiatric comorbidity of depression, 
anxiety and substance use disorders. For interpretation, several limitations should be 
acknowledged: the sample size, the multiple comparisons, the cross-sectional nature 
hampering causal interferences and lack of generalization to other levels of healthcare 
and healthcare systems by describing a secondary care, convenience sample. 
 Thirty-two of 37 elderly patients (86%) referred with MUS were suffering from a somato-
form disorder. In only three patients we found a somatic reason for the complaints. This 
prevalence rate is quite low and comparable with fi gures that have been reported for patients 
referred for conversion.5 As might have been expected in an elderly population, we found in 
almost half of the patients (47%) pathological fi ndings that partly explained their primary 
complaint. Pain was the most common symptom. The severity and presenting physical 
symptoms as measured with the PHQ are comparable with patients presenting MUS in 
primary care.6 In primary care, about a quarter of the patients with MUS met DSM-IV 
criteria for a somatoform disorder.7 In our study, nearly all patients met DSM-IV criteria 
for a somatoform disorder. This is most likely explained by the fact that only patients with 
persistent symptoms who sustain after the ‘wait and see’ period will be referred and that 
in this patient group the burden on patients is large enough to justify classifi cation as a 
somatoform disorder. The fi nding of only one case of somatisation disorder is in accordance 
with the low prevalence of this condition in the general population.
 The prevalence of psychiatric comorbidity was high (overall 69%), particularly for 
depressive disorders (56%). Similar fi gures have been reported in primary care.8 Comorbid
depression was associated with a higher severity of the primary somatic complaint, 
a higher level of somatisation, and more functional impairments. The recognition of 
depression often is reduced by a somatic presentation and often leads to the perception 
of the patient as diffi cult.9 Several trials showed that antidepressant drugs are effective in 
adult patients with MUS. To what extent this effect might be mediated by the reduction of 
comorbid depressive symptoms has not been elucidated.10
 We conclude that identifying psychiatric comorbidity in older patients with MUS is highly 
relevant, in addition to attention for the physical causes of the complaints. Therefore, we 
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To examine the level of frailty and somatic comorbidity in older patients with medically 
unexplained symptoms (MUS) and compare this to patients with medically explained 




Community, primary care, and secondary health care to recruit Patients with MUS in 
various developmental and severity stages and primary care to recruit Patients with MES.
 Participants
In total, 118 patients with MUS and 154 patients with MES, all aged ≥60 years.
 Methods 
Frailty was assessed according to Fried’s criteria (gait speed, handgrip strength, unintentional 
weight loss, exhaustion, and low physical activity), somatic comorbidity according to the 
self-report Charlson comorbidity index and the number of prescribed medications.
 Results 
Although patients with MUS had less physical comorbidity compared to patients with 
MES, they were prescribed the same number of medications. Moreover, patients with 
MUS were more often frail compared to patients with MES. Among patients with MUS, 
physical frailty was associated with the severity of unexplained symptoms, the level of 
hypochondriacal beliefs, and the level of somatisation. 
 Conclusion and Implications
Despite a lower prevalence of overt somatic diseases, patients with MUS were more frail 
compared to older patients with MES. These results suggest that at least in some patients 






Reported prevalence rates of medically unexplained symptoms (MUS) in people aged 
≥ 65 years range between 1.5% and 18%.1 People with MUS often describe a low quality of 
life and frequently suffer from comorbid anxiety and depressive disorders.2 Furthermore, 
MUS itself gives rise to high levels of health care consumption in the search for an organic 
origin of complaints and places especially older persons at risk for iatrogenesis.3
 When people persist in seeking medical help, although no organic explanation for these 
somatic symptoms can be found, it is assumed that these symptoms occur as a result 
of social or psychological factors, also referred to as somatisation.4 Studies also suggest 
that (the interaction with) physicians plays a role in the persistence of these symptoms.5 
Persistence of MUS and somatisation are classifi ed as somatoform disorders and somatic 
symptom disorders in the DSM-IVTR and DSM-5, respectively. 
 Most etiological models for MUS are built from a bio-psycho-social perspective.6-10 
Nonetheless, biological processes are uniquely included as precipitating factors, whereas 
psychological and social processes can be either precipitating factors, but also predisposing 
or perpetuating factors. Most models describe biological processes as bodily sensations, 
which may originate from normal physiological processes (e.g. bowel peristalsis), from 
pathophysiological processes because of sub-threshold medical conditions (e.g. elevated 
blood-glucose levels without actual diabetes), as well as overt diseases, accompanied by a 
misinterpretion by the patient regarding their origin. Furthermore, in the case of DSM-IVTR
defi ned somatoform disorders, biological processes play a role by defi nition as the core 
diagnostic criteria are the presence of somatic complaints that are more severe than 
can be explained by the underlying somatic condition. Therefore, we might expect that 
somatisation problems increase parallel to an increase in somatic disease burden. 
 Besides a small pilot study of our group,11 no studies have been conducted on the physical
performance of older patients with MUS. The somatic disease burden can be distinguished 
in overt (e.g. number of chronic somatic diseases) and covert (e.g. frailty) somatic conditions.
 Frailty is ‘a condition in which the individual is in a vulnerable state at increased risk 
of adverse health outcomes and/or dying when exposed to a stressor’.12 The prevalence of 
frailty is estimated at 9.9% among community-dwelling older persons.13 In our pilot study 
on older patients with MUS, the level of somatic comorbidity as well as frailty parameters 
were signifi cantly higher among patients with MUS which was partially explained by a 
somatic origin compared to patients with MUS for which no explanation at all was found. 11
 The objective of the present study was to compare the level of frailty and somatic 
comorbidity between a well-characterised and representative cohort of older patients with 
MUS and older patients with Medically Explained Symptoms (MES). Subsequently, we 





The present study is embedded within the Older Persons with Medically Unexplained 
Symptoms (OPUS) study, a comparative study including 118 patients suffering from MUS 
and 154 patients suffering from MES. Data of the OPUS study were collected between 
September 2011 and March 2014. The OPUS study has been described before,14,15 but will 
be summarized below.
 To recruit patients with MUS in various developmental and severity stages, recruitment 
took place in the community by advertisements in local newspapers, in primary care, and 
in secondary healthcare. To assist general practitioners (GPs), we preselected the top 20% 
of older frequent attending patients in their own practice from the GP Information System. 
The list of frequent attenders had to be checked by the GP for older patients with MUS. 
This pre-selection method was chosen, based on previous research projects on MUS in 
primary care.16,17 Patients with MES were selected from the same frequent attenders list to 
strive for a comparison group with current physical symptoms with a severity comparable 
to those of the patients with MUS. As selection bias is inevitable and may especially play a 
role in older and/or vulnerable population,18 adding a comparison group of patients with 
MES enables interpretation of the absolute level of the somatic disease burden.
 Inclusion criteria for patients with MUS were 1) age of ≥60 years, 2) MUS ≥3 months 
according to their general practitioner (GP), 3) meeting the defi nition for MUS of the 
Dutch College of GPs (i.e. physical symptoms that have existed for more than several 
weeks and for which adequate medical examination has not revealed any condition that 
suffi ciently explains the symptoms).19 Patients suffering from functional syndromes like 
fi bromyalgia, chronic fatigue syndrome, irritable bowel syndrome or a whiplash-syndrome, 
were also included as Patients with MUS.20 The unexplained nature of the MUS was checked 
by either a comprehensive assessment conducted by geriatrician (n = 70) or an additional 
chart review of the GP for patients who refused this geriatric assessment (n = 48) but 
agreed with the other study procedures.
 Exclusion criteria for patients with MUS and patients with MES were 1) a primary 
psychotic disorder; 2) established or suspected diagnosis of dementia; 3) suffering from 
terminal illness; 4) insuffi cient mastery of the Dutch language; 5) auditory or visual 
impairment interfering with reliable data collection; and 6) a physical symptom than can 
be explained by a psychiatric disorder other than a somatoform disorder.
 All participants of the OPUS study gave written informed consent. The local Medical 
Ethical Committee of the Radboud University Nijmegen Medical Center has approved the 
OPUS-study. 
 Procedures OPUS-study
All participating patients with MUS were offered a multidisciplinary diagnostic procedure,
consisting of a comprehensive geriatric assessment and a semistructured psychiatric 




After the diagnostic procedure, a researcher (DH) visited the patient at home to examine 
social and cognitive functioning in more depth. 
 If patients with MUS refused to participate in the multidisciplinary diagnostic procedure 
or were physically not able to visit the clinic, but nevertheless agreed to participate in the 
OPUS-study, the researcher (DH, supervised by PN) performed two home-visits (40.7%;




Several aspects of physical functioning were assessed, i.e. somatic comorbidity, the number 
of prescribed medications, and physical frailty.
 We assessed somatic comorbidity using a self-report version of the Charlson Index.21,22
In this questionnaire 16 categories of possible somatic comorbidities were assessed with 
yes/no answering categories. Since we were interested in differences in somatic comorbidity 
and not in mortality risk, we did not include age as a factor in the total score.
 The number of prescribed medications was based on self-report and checked by the 
researcher at the patients’ home by collecting all medication containers. 
 The physical frailty phenotype was assessed according to Fried’s criteria,23 (i.e. the 
presence of ≥3 of the following fi ve criteria: weight loss, weakness, exhaustion, slowness 
and low physical activity). The operationalisation and/or cut-off used for the dichotomized 
criteria have been described before.24 
 In addition to the syndromal defi nition of frailty based on the Fried criteria, we also 
included two unidimensional proxies for frailty based on previous research into physical 
frailty, (i.e. muscle weakness25 and gait speed).26 These proxies are based on the maximum 
handgrip strength, (i.e. the best of two squeezes using their dominant hand (in kg) and 
the time to walk six metres as described above).
 MUS severity indicators
Several indicators of the severity of MUS have been measured, i.e. 1) the severity of the 
primary physical complaint using a 10-cm visual analogue scale (VAS); 2) the level of 
somatisation with the 7-item somatisation subscale of the Brief Symptom Inventory (BSI-
53);27,28 3) the presence of hypochondriac cognitions with the Whiteley-Index (WI)29 ; 4) 
the presence of a DSM-IVTR diagnosis of a somatoform disorder, and fi nally 5) comorbid 
psychiatric disorders according to the  DSM-IVTR. 
 All psychiatric disorders were diagnosed with a semi-structured psychiatric interview, 
(i.e. the Mini International Neuropsychiatric Interview (MINI), v 5.0).30,31
 The somatisation subscale of the BSI-5327,28 consists of seven items that have to be 
rated on a 5-point Likert scale referring to the severity of physical symptoms in younger 
persons associated with functional syndromes, (i.e. dizziness, chest pain/discomfort, 
nausea, shortness of breath, hot fl ushes, paresthesias, and faintness/general weakness). 
56
CHAPTER 4
The somatisation subscale of the BSI-53 is considered the best self-report somatisation 
scale for usage in large-scale epidemiological studies.28 In our study, the subscale had a 
Cronbach’s alpha of 0.77.
 The WI consists of 14 statements that have to be rated as yes/no, with higher scores 
being indicative of a greater severity of hypochondriasis.29
 Covariates 
Demographic and lifestyle characteristics were included as covariates. As demographic 
characteristics, we included age, sex, and the highest level of completed education (low, 
middle or high) as the basic covariates when comparing patients with MUS and patients 
with MES.32
 As lifestyle characteristics, we included smoking, use of alcohol and body mass index 
(BMI) (kg/m2). Smoking was based on self-report questions and dichotomized as currently 
smoking (yes/no). Alcohol use was measured with the fi rst two questions of the Alcohol 
Use Disorder Identifi cation Test (AUDIT).33 Based on these two questions, (i.e. number of 
days drinking and number of drinks on a typical day), we categorized patients in completely 
abstinent, severe users defi ned as >14 drinks a week for women and >21 drinks a weeks 
for men, and fi nally  moderate use for those in between fully abstinent and severe use.
 Analyses
First, all variables of interest were checked for signifi cant differences between patients 
with MUS and MES by either Student t-tests (normally distributed continuous variables) 
or χ2 tests in case of categorical variables. The variables comorbidity (Charlson Index) and 
gait speed had a skewed distribution which achieved normality after ln-transformation. 
For interpretation, the mean values, standard deviations and standard errors presented in 
tables were back-transformed.
 Subsequently, the parameters refl ecting physical functioning were compared between 
patients with MUS and MES by analysis of covariance (ANCOVA) adjusted for age, sex, level 
of education (as dummies), smoking (yes/no) and BMI. Physical frailty was examined 
both as a continuous variable (number of components met) and dichotomized (present
yes/no). Logistic regression was applied in order to calculate the odds of being frail 
(dependent variable) with group status (patients with MUS versus patients with MES) as 
the independent variables and adjusted for covariates described above.
 Finally, within the subgroup of patients with MUS, linear regression models adjusted 
for the same covariates were conducted to examine the association between each severity
index of MUS as the independent variable of interest and each physical functioning
parameter as the dependent variable of interest.
 P-values < 0.05 were considered statistically signifi cant. Analyses were conducted in 





Comparison of the demographic and lifestyle characteristics revealed that patients with 
MUS were signifi cantly younger, more often female, and had a higher BMI compared 
to patients with MES (see table 1). The two groups did not differ with respect to level of 
education, cognitive functioning, smoking, and alcohol usage.   
Physical functioning in patient with MUS versus patients with MES
Table 2 compares the two groups with respect to parameters of physical functioning adjusted 
for covariates. Because of the level of disability, performance-based frailty components 
were signifi cantly more often missing for patients with MUS compared to patients with 
MES (gait speed: 20 versus 11; χ2 = 6.4, df = 1, p = 0.012; handgrip strength: 13 vs. 6, χ2 = 5.2,
df = 1, p = 0.022).
 Patients with MUS had signifi cantly lower Charlson Index, a lower maximum handgrip 
strength and a higher number of frailty components compared to patients with MES. The 
number of prescribed medications did not differ between the two groups. Logistic regression
revealed that the odds of being frail was three times higher for patients with MUS compared 
to those with MES when adjusted for covariates (OR = 3.0 [95% CI 1.1- 8.4], p = 0.035).
Association between physical functioning and MUS-severity indicators 
 in patients with MUS
Of the 118 patients with MUS, 63 (53.4%) had a somatoform disorder according to DSM-IVTR
criteria and 39 (33.1%) suffered from a comorbid mood-, anxiety or substance use disorder. 
The mean (standard deviation) item-score (range 0 - 4) on the BSI-53 somatisation scales 
was 0.81 (0.65), on the Whitely-Index was 4.3 (2.9), and the severity of the primary complaint 
was rated at 6.3 (2.1) cm on the 10 cm VAS.
 As shown in table 3, a higher number of physical frailty components was associated with 
a higher severity level of the unexplained symptoms, with stronger hypochondriacal beliefs 
and a higher level of somatisation. The higher level of somatisation according to the BSI-53 
subscale, however, was associated with nearly all physical functioning parameters, (i.e. 
a higher score on the Charlson Index, a higher number of prescribed medications, more 
frailty parameters and a lower handgrip strength). As this may raise the question whether 
the somatisation scale indeed measures somatisation and not somatic disease burden, 
we post-hoc tested the associations between this scale and the other MUS-severity indicators
(with linear regression adjusted for the same covariates). This revealed that the BSI-53 
somatisation subscale was signifi cantly associated with the severity of hypochondriacal 
beliefs (β = 0.45, p < 0.001) and the presence of comorbid psychiatric disorder (β = 0.35, 
p = 0.001), but neither with the presence of a somatoform disorder (β = 0.01, p = 0.90), 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































Somati c and physical functi oning of MUS versus MES pati ents by ANCOVA*
                                                                             
   MUS pati ents MES pati ents 
Characteristi cs  (n=118) (n=154) Stati sti cs
Somati c & physical functi oning:   
Somati c comorbidity  EMM (SEM) 1.83 (1.06) 2.15 (1.05) F=4.0, df=1,238  p=.045
(Charlson Index)**
Number of prescribed EMM (SEM) 5.8 (0.4) 5.5 (0.3) F=0.3, df=1,209  p=.591
medicati ons
No of frailty components EMM (SEM) 1.25 (0.11) 0.87 (0.09) F=7.2, df=1,225  p=.008
(sum score)
Gait speed (m/s)** EMM (SEM) 1.07 (1.03) 1.04 (1.02) F=0.4, df=1,227  p=.526
Hand grip strength (kg) EMM (SEM) 28.4 (0.8) 32.1 (0.7) F=10.3, df=1,239  p=.002
* adjusted for age, sex, level of educati on, smoking, alcohol use, and BMI
** ANCOVA with ln-transformed values, presented values are back transformed for interpretati on.
Abbreviati ons: EMM, esti mated marginal means; SEM, standard error of the mean; kg, kilogram. Signifi cance level of 0.05.
Table 3 
Associati ons between severity measures of MUS and parameters of somati c and physical functi oning 
in MUS pati ents (n=118)*
Charlson No. of  Frailty sum Gait speed Handgrip
 Index prescribed score (s) strength
  medicati ons (Fried)  (kg)
Severity measures of MUS β p β p β p β p β p
Severity of primary .13 .204 .07 .516 .23 .038 .12 .250 -.11 .112
complaint (VAS)
Primary somatoform .08 .421 -.01 .941 <-.01 .965 -.04 .651 <.01 .989
disorders (yes)
Comorbid psychiatric .12 .207 .12 .245 .14 .181 .06 .576 -.09 .221
disorder (yes)
Hypochondriacal .09 .339 .22 .030 .22 .027 .09 .337 -.08 .259
beliefs (Whitely Index)
Level of somati sati on .42 <.001 .36 .002 .44 <.001 .16 .146 -.21 .011
(BSI subscale)
* Linear regression models adjusted for age, sex, level of educati on, smoking, use of alcohol, BMI. 




Two important fi ndings have emerged from our study. First, older patients with MUS had a 
signifi cantly lower somatic disease burden compared to their counterparts with MES, whereas
they were prescribed the same number of medications. Second, patients with MUS were 
signifi cantly more frail compared to patients with MES and thus can be considered to have 
a “higher biological age” compared to patients of the same chronological age who suffer 
from MES. 
 While the overt somatic disease burden was signifi cantly higher among patients with 
MES, both patient groups were prescribed a similar number of medications. An explanation 
might be sought in the higher level of medical consumption generally associated with 
MUS.34 In up to 18% of hospital outpatient consultations no somatic explanation can be 
found for symptoms like abdominal pain, back pain, chest pain, and headache.1,35 Physicians 
are generally inclined to help these patients and easily prescribe some drugs even though 
they might not be convinced of its benefi t.5,36,37 On the other hand, studies mentioned
above do not analyse older persons separately, while many somatic symptoms are common 
in older people and occur in the context of chronic somatic diseases. Higher comorbidity 
rates as well as higher a priori chances of underlying physical illnesses as explanation for 
physical complaints makes it more diffi cult to distuingish explained from unexplained 
symptoms in older people. 
 To our knowledge, physical frailty has never been related to MUS. Previously, it has 
been consistently shown that physical frailty differs from comorbidity and disability,12,23 
and should be regarded as indicative of lack of resilience to internal and external stressors. 
Even mild stressors can disturb the “frail” homeostasis of physiological systems in a body 
and provoke a cascade of negative health outcomes.12 Our fi ndings suggest that this frail 
level of homeostasis might provoke some physical sensations or non-specifi c physical
symptoms which can not be attributed to overt somatic diseases, but trigger these 
patients to seek help. Based on the theoretical framework of the “frailty identity crisis”, denial
of frailty may lead to excess health seeking behaviour (“doctor shopping” syndrome) and 
polypharmacy.38 Our empirical fi ndings fi ts in this framework and if true, at least in some 
patients, MUS may be a symptom of frailty and thus refl ect the aging process. 
 Being a cross-sectional study, an alternative explanation might be that the presence of 
MUS is a causative factor of accelerated aging. Affective disorders, primarily depressive 
disorders, have been postulated as a cause of accelerated aging.39 Proposed mediating
pathways for which some evidence has been found include infl ammatory-metabolic 
dysregulation and an unhealthy lifestyle.40 Nonetheless, the impact of affective disorders 
on accelerated aging is generally small and seems particularly relevant in middle-aged but 
not older depressed persons.41 We are not aware of studies that have examined lifestyle 
changes among patients suffering from MUS. As patients with MUS are generally concerned 




of MUS. Nonetheless, we all know patients with a high level of somatisation who “protect” 
themselves against worsening of their symptoms by a self-infl icted reduction in exercise, 
socialisation or participation in meaningful activities. Therefore, the association between 
MUS and frailty is probably bidirectional and may involve different mechanisms in different 
subgroups. Longitudinal studies should therefore address potential mediating mechanisms 
in order to deepen our understanding of this association.  
 Albeit not a primary aim of the present study, the somatisation subscale of the 53-item 
BSI appeared to be associated with parameters of physical functioning as well as severity 
parameters of MUS. This can be explained by the fact that this scale consists of common 
somatic symptoms usually associated with functional syndromes in younger age groups. 
In older age groups, these symptoms do not necessarily refl ect unexplained symptoms 
anymore but also refl ect the increase in somatic disease burden with age, as mentioned 
above. Although this problem has been identifi ed before, a systematic review of assessment 
scales suggests that it still is one of the best options we have to assess the level of soma-
tisation in population-based studies of older people.42
For proper interpretation, some methodological issues need to be addressed. A fi rst
strength of the present study is the well-characterised and representative sample of older 
patients with MUS and MES. The fact that patients with MUS were examined by different 
professionals can be seen as a strength of the study design, since the diagnosis of MUS 
is diffi cult to distinguish from common mental disorders and chronic somatic illnesses.14
However, some limitations should also be acknowledged. First of all, the cross-sectional 
study design precludes causal interpretations. Therefore, we do not know the direction 
of the associations presented. Secondly, our sample size is relatively small. Nonetheless, 
the number of patients with MUS and MES is comparable to previous studies in this fi eld 
of research.35,43 Secondly, the overall prevalence of frailty of 8.8% was quite low in our 
population, but in line with estimates in the general population.13 Moreover, differences 
with respect to frailty between the two groups are probably underestimated, as signifi cantly 
more patients with MUS were too disabled to test gait speed or handgrip strength. None-
theless, the low prevalence rate increases the risk of chance fi ndings, which argues for 
replication.
 CONCLUSIONS AND IMPLICATIONS
The key fi ndings of this study are that older patients with MUS have a signifi cantly lower 
somatic disease burden, are signifi cantly more frail, and thus can be considered to have a 
“higher biological age” compared to patients with MES. Therefore, MUS is a challenging 
problem for physicians and this seems to even increase in older patients where MUS and 
MES can be intermingled. Based on our fi ndings, two pieces of advices can be given. The 
fi rst piece is to consider the presence of frailty as a potential explanation for non-specifi c 
complaints before classifying these symptoms as MUS and thus to ensure access to geriatric
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care models for these patients. Albeit these symptoms may be explained by physical frailty, 
they still may need a psychological approach as frailty itself is associated with low levels 
of well-being44 and decreases quality of life over time.45 The second is to be very careful 
with prescribing new medications, especially as older patients are at increased risk for 
side-effects, interactions due to polypharmacy, and worsening of frailty.46,47 Although treatment 
strategies to reverse or slow down the progression of frailty (which is considered a dynamic
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Meta-analyses of antidepressant treatment trials have found that increasing age is asso- 
ciated with a less favourable outcome. Since the prevalence of geriatric characteristics, like 
disability, medical comorbidity, malnutrition, cognitive (dys)function and frailty increase 
with age and are associated with depression, these characteristics are likely to modify the 
treatment outcome of antidepressants in late-life depression. This review examines how 
these five characteristics are taken into account in Randomised Controlled Trials (RCTs) with 
anti-depressants for major depressive disorder in patients aged 60 years or above.  
 Design
A systematic search in PubMED, PsychInfo and EMBASE, from the year 2000 onwards, 
yielded 27 RCTs, with a total of 6356 subjects with a median age of 71 years. Two reviewers 
independently assessed whether each characteristic was considered as inclusion or exclusion 
criterion, descriptive variable, stratification variable, covariable, outcome measure, or in 
adverse effect monitoring.
 Results
Malnutrition and frailty were not taken into account in any study. Disability was used as 
an outcome measure in five studies. Two studies explicitly included a population with 
possibly serious medical comorbidity. Cognitive status was the only condition taken into 
account as co-variable (n = 3) or stratifying variable (n = 1), and was used as outcome 
measure in seven studies. 
 Conclusions
We conclude that geriatric characteristics are rarely taken into account in RCTs on anti- 
depressants in late-life depression and studies including the oldest adults, are under- 
represented. This warrants recruitment of the oldest adults and adjustment of treatment 





Meta-analyses have estimated the point prevalence rate of major depressive disorder as 
1.8% amongst adults aged 55 years and over in the community1 and as 7.2% amongst 
people aged 75 years, including both community-dwelling and institutionalized individuals.2
Several meta-analyses have shown the effectiveness of antidepressants in late-life depres-
sion.3-5 Some meta-analyses, however, suggest that the extent of effect decreases with 
increasing chronological age.6,7 How can this be explained?
 Supposed mechanisms to this age-related effect include an age-related increase of 
medical comorbidity and geriatric syndromes. Many studies have shown that depression 
is associated with multimorbidity8,9 and medical comorbidity of, for example, cardio- and 
cerebrovascular disease, diabetes mellitus, arthritis and cancer.10  Depression is also asso-
ciated with so-called ‘geriatric syndromes’, to be defi ned as multi-causal health problems 
with high prevalence in old age11, such as disability12 malnutrition13,14, cognitive (dys)function15
and frailty.16-18 Currently, many studies have shown a negative effect of cerebrovascular 
disease19-21 as well as cognitive (executive) dysfunction20 on depression treatment outcome,
while some studies also suggest a negative impact of medical comorbidity22,23 and physical 
frailty17. 
 The hypothesis that geriatric syndromes and medical comorbidity (called ‘geriatric charac-
teristics’ in our systematic review) negatively interfere with treatment outcome of late-life 
depression emphasizes the need to take geriatric characteristics into account in treatment 
trials for late-life depression. These characteristics defi ne the study population enabling 
generalisation of fi ndings to specifi c clinical populations and facilitating interpretation of 
the extent of effect relative to other studies.24  Moreover, geriatric characteristics, e.g. disability
or cognitive (dys)function are relevant as (secondary) outcome measures, as geriatric 
patients can have more general goals for their depression treatment  besides remission of 
depressive symptoms.25 Therefore, the aim of the present systematic review was to assess 
whether and how disability, medical comorbidity, malnutrition, cognitive (dys)function 
and frailty are taken into account in studies on antidepressant drug treatment for late-life 
major depressive disorder. 
 METHODS
We performed a systematic review of randomized controlled trials (RCTs) on the pharma-
cological treatment with anti-depressants of major depressive disorder published in
PubMed, PsychInfo and EMBASE databases. 
Search Strategy
The search on 29 January 2014 was conducted from January 2000 and onwards. Many 
antidepressants have been developed and evaluated well before 2000, but knowledge on 
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the potential impact of disability, medical comorbidity, malnutrition or cognitive (dys)-
function was only deemed suffi ciently available after the year 2000. Search terms on 
depression, antidepressive agents and older age were combined (see supplementary table 
for the complete search strategy). In addition, references of trials and reviews were checked
manually for studies not yet included. After fi rst selection (CB) on title and abstract, all 
possible eligible studies were evaluated independently (CB and FK) on inclusion and 
exclusion criteria. Differences in judgment were settled by discussion and agreement 
within the complete study group. 
Inclusion and Exclusion Criteria
The following criteria were applied for inclusion in the systematic review:
• A double or single blind RCT, evaluating treatment with an antidepressant for at least 
 six weeks and evaluated against a placebo, other antidepressant drug, or non-pharmaco-
 logical intervention. 
• Only participants aged 60 years or over were included, with a mean age of the study 
 population as a whole of 65 years or over. 
• Only participants suffering from a major depressive disorder according to DSM III/III 
 R/IV/IVTR, or ICD 10 criteria were included, established with a validated (semi) structured 
 psychiatric interview.
• Quantitative depression outcome measurements comparing  baseline and endpoint 
 measurements were reported. 
• Publications were in English, German or French languages.
Excluded were studies including patients who suffered from clinically relevant depressive 
symptoms, defi ned as scoring above a cut-off of self-report questionnaires, as well as studies
including patients with dysthymia or minor depression as the somatic symptoms of 
depression, such as tiredness, slowness, lack of energy and loss of appetite, can easily be 
confounded by underlying somatic illnesses in older patients.26,27 Studies of patients with 
primary psychotic disorder or bipolar disorder were also excluded, as well as studies with 
a focus on patients with dementia as a primary diagnosis. Finally, studies on additional 
treatment with mood stabilizers or anti- psychotics and studies on relapse prevention 
were excluded.
 No restrictions were imposed with respect to treatment setting. When more papers 
were found on one particular study, only the primary outcome paper was included in the 
systematic review, as the geriatric characteristics were considered of eminent importance 
for interpretation of results (and secondary papers are often published years after the 
primary paper). 
Data Extraction and Quality Assessment
Data were extracted independently (CB, FK) and any items that were judged differently or 





The following study data were collected: author, journal and year of publication, minimal age 
at study inclusion, mean age with standard deviation of the study population, percentage 
of females, setting (community, residential home, nursing home, outpatient clinic, acute
psychiatric ward), study design (single versus double blind), treatment and control 
conditions, length of study period, diagnostic procedure, depression severity measurement, 
outcome measures and results on outcome measures. 
 Because recruitment and attrition could have interfered with the generalizability 
of study results, data were extracted on the number of patients who were 1. screened, 
2. included, 3. randomized, 4. analyzed with the intention to treat analysis, 5. completed 
the study, and 6. dropped out because of adverse events. The attrition rate was defi ned 
as the number of participants who did not complete the study period after randomisation 
divided by the size of the randomised population. According to general advices from 
evidence based medicine technology, we considered an attrition rate less than 30% 
acceptable and less than 20% good.28,29 Finally, as geriatric patients in general are more 
vulnerable for drug side effects, the methods of how adverse events were measured were 
collected: e.g. by spontaneous reporting or structured assessment instruments, and if so, 
which instruments were used. 
Assessment of Geriatric Characteristics of Interest
For all geriatric characteristics, assessment was made of whether the characteristic was 
considered as: 1. an inclusion or exclusion criterion, 2. a descriptive variable at baseline, 
3. a stratifi cation variable for randomisation, 4. a co-variable, or 5. an outcome measure. 
How these characteristics were defi ned and measured was also extracted. If relevant, for 
example, when used as outcome measure, quantitative data were also extracted.
Disability is defi ned as a restriction in or lack of ability to perform an activity, because of 
impairment in physical performance12 and it is generally assessed by quantitative instruments
that measure level of functioning, also called functional status. 
Medical comorbidity is defi ned as the presence of one or more somatic comorbid 
diseases. It can be assessed by quantitative instruments that measure cumulative disease 
burden, or quantitatively by adding up of the number of chronic and acute medical illnesses, 
and/or as a qualitative description of co-occurrence of chronic and acute medical illnesses.
Malnutrition is defi ned as inappropriate intake of nutrients. Nutritional intake can be 
assessed with instruments, such as the Mini-Nutritional Assessment tool30 and laboratory 
tests. Furthermore, as malnutrition can be accompanied by inappropriate weight loss, 
measures of weight loss or Body Mass Index were extracted as relevant.31
Cognitive (dys)function is a heterogeneous concept as there are many domains in 
cognitive functioning. Data on global measures of cognitive functioning were extracted 
(usually screening instruments covering more than one domain), as well as domain-specifi c 
instruments. 
Frailty is a state of vulnerability to poor resolution of homeostasis after a stressor. 
Operational defi nitions are generally validated by identifying patients at high risk for poor 
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health outcomes as falls, disability, institutionalisation and death. Operational defi nitions 
nonetheless vary widely, with the main difference whether parameters are restricted to 
biomedical parameters (i.e. physical frailty), or whether also psychosocial parameters are 
included.32 
Quality Assessment 
According to the Cochrane methodology to assess the risk on bias, random sequence 
generation and allocation concealment, blinding of patients and personnel, blinding of 
outcome assessment, handling incomplete outcome data, and completeness of reporting 
were evaluated, based on the information reported in the manuscripts.33
 RESULTS
 Study Selection
The study selection process is described in Figure 1. We extracted 2733 articles, of which 
2653 were excluded on title and abstract. After full review of 80 possibly eligible articles, 27 
were included.34-60 Manual search of the references of included articles, systematic reviews 
and meta-analyses published after 20103,6,7 did not yield extra studies. An overall number 
of 6356 patients were randomized in the 27 studies that were included.
Study Characteristics
The main characteristics of the studies included are described in Table 1. Of 27 studies, 
14 studies were placebo-controlled and 13 studies were head-to-head comparisons of 
different antidepressants. No studies compared an antidepressant with a non-pharmaco-
logical intervention. 
 The sample size at randomisation ranged from 3740 through 752 patients,58 with a 
median of 210 patients. Studies were mostly conducted at inpatient or outpatient mental 
health or primary care settings. One study recruited patients in a long term care facility.54
 Severity of depression was predominantly measured with the Montgomery Åsberg 
Depression Rating Scale (MADRS),61 and the Hamilton Rating Scale for Depression:62 17-, 
24- and 31-item versions. Primary outcome parameters were either a change in depression 
severity, response (defi ned as a 50% decrease of depression severity) or remission (defi ned
as a score below a pre-defi ned cut-off point). Seven of the 14 placebo-controlled studies 
favored the antidepressant. Of the 13 studies comparing two different antidepressants, 
only one study showed a favourable outcome for either one: nortriptyline 50-100 mg showed 
better outcomes than citalopram 30-40 mg.49
 The median of the mean age of the study population was 71 years. Only two studies 
had included a study population with a mean age of 75 years or higher44,55 and none with a 
mean age above 80 years. Two studies separately reported on patients older than 75 years,42,55
one showing no difference in outcome for citalopram versus placebo,55 the other showing no 





In general, the geriatric characteristics were taken into account in the research methods 
only at very specifi c points (see Tables 1 and 2). Malnutrition and physical frailty were not 
regarded as methodological variables in any trial. These two characteristics were, therefore, 
omitted from Table 2. 
 Disability
Disability was included as primary outcome measure in one study and as secondary 
outcome measure in four studies. Two studies used the Sheehan Disability Scale (SDS)63
and three the Medical Outcomes Study short-form Health Survey (SF-36).64 Overall two 
studies found functional outcomes that were in line with the outcomes of depression42,58
and three did not.43,55,59
                                                                      
 Pubmed: 1243 ti tles EmBASE: 1709 ti tles PsychInfo: 504 ti tles
  Total: 3456 arti cles
    
    Exclusion of 723 duplicate
    arti cles
  Total: 2733  arti cles
    Excluded on ti tle and  abstract:
    2653 arti cles
  Eligible: 80 arti cles
    53  arti cles excluded:
    -  Inclusion minor depression: 10
    -  Relapse preventi on: 16
    -  Treatment resistance: 4
    -  Augmentati on therapy: 6
    -  Second publicati ons: 9
  Finally included: 27  -  Study durati on too short: 3
  original arti cles  -  Other 5
Figure 1: 
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 Medical Comorbidity 
Twenty studies excluded patients with ‘unstable or acute medical comorbidity’. These 
descriptions were not specifi ed. Only one study (amongst inpatients) had no restrictions
with regard to medical comorbidity at inclusion.46 Another study specifi cally focused on 
a depressed population with specifi c comorbidity: heart failure with an ejection fraction 
below 50%.40 Twelve studies excluded two or more conditions that were specifi c contra-
indications for treatment, e.g. epilepsy or narrow angle glaucoma, signifi cant (cardio- or 
cerebro) vascular disorders and/or use of specifi c medications, such as anti-epileptics or 
Class 1 antiarrythmics. 
 Seven studies reported on medical comorbidities as baseline characteristic. Two studies 
reported the number of comorbidities,46,58 while another three studied the specifi c medical 
conditions without reporting cumulative quantifi ed data.39,51,60 Two studies used a quanti-
tative and validated measure, the Cumulative Illness Rating Scale - Geriatrics (CIRS-G)65, 
which assesses cumulative disease burden and is validated for older persons in somatic 
and psychiatric settings.48,55 The mean sum score of the CIRS-G was 9.3 ± 4.148 and 7.2 ± 
3.955 respectively. 
 Cognitive (dys)function
Of all studies included, 21 studies (77%) excluded patients with a diagnosis of dementia 
and/or patients with a Mini Mental State Examination (MMSE) score of ≤ 24. Six studies 
described the MMSE at baseline. The mean (± standard deviation) MMSE scores ranged 
from 25.5 ± 3.346 through 29.2 ± 0.9.42
 The three studies that included a cognitive measure as covariate did not fi nd an asso-
ciation between depression outcome and baseline cognitive function.48,53,55 
 In the seven studies with cognitive functioning as a primary or secondary outcome 
measure, 11 different cognitive tests were used (see Table 1). Of the three placebo controlled 
studies that reported on cognitive tests as outcome measure, two studies found improved 
memory function in the treatment arm, whereas results on the tests for attention and 
executive function were similar.45,53 The third study neither found a treatment effect on 
separate test scores, nor on the composite score of four cognitive tests.54
Adverse Events
All studies reported on adverse events and measured either symptoms spontaneously 
reported by patients or used assessment instruments, such as the Side Effect Scale 
(SES),66 the Systematic Assessment for Treatment Emergency Evens (SAFTEE)67 or the 
UKU Side Effect Rating Scale,68 or used combined methods. Although these scales included
side effects of antidepressants that are also relevant for older people, relevant and serious 
adverse events, such as falls, were mostly not specifi cally covered. Only one study 




Legenda: risk of bias:         
 = low risk;     
 = unclear risk        
 = high risk    
Figure 2: 
Quality Assessment: risk of bias of included studies
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The quality assessment is reported in Figure 2. In summary, fi ve studies42,45,46,56,57 had a low 
risk of bias on all items. Another 11 studies scored a low risk of bias on either four or fi ve 
items, combined with an unclear risk on two or one items. This could still be classifi ed as 
‘good’. The main methodological shortcomings lie in insuffi cient reporting on the rando-
mization procedure (n = 16) or allocation concealment (n = 20). 
 Only fi ve studies were judged as having a high risk of bias on two or more items35,37,38,41,49. 
Two of them were single blind studies41,49, whereas a third study was also judged as being 
single blind, although this was not explicitly mentioned.37
 Only seven articles reported on the number of persons screened; the response rate 
in these studies was 42% (1624 out of 3829 persons). The attrition rate of the 27 studies 
ranged from 7%60 to 45%.48 The mean attrition rate was 22.1%. Eight studies had an 
attrition rate above 30% 35,39,46,48,50,54,56,59. Follow up methods and reporting of reasons for 
lack of follow up were adequately described in 20 of the respective 24 studies. All studies 
reported adequately on drop-out because of adverse events.
 DISCUSSION
In summary, this systematic review shows that except for cognitive (dys)function, all 
other geriatric characteristics are rarely, or not at all, taken into account in antidepressant 
treatment trials for late-life major depression: neither as possible relevant effect modifi ers, 
outcome measures, nor in assessing adverse effects. Serious medical comorbidity was 
excluded in 20 studies and medical comorbidity was only considered as a descriptive 
variable at baseline in seven studies. Disability and cognitive (dys)function were included 
as outcome measures in fi ve and seven of the 27 included studies respectively. Moreover, 
cognitive (dys)function was the only geriatric characteristic that was used as co-variable, 
in no more than three studies. Malnutrition and frailty were not taken into account at all. 
Finally, only two studies separately analysed the older age group of 75 years or above, 
although the prevalence of depression is found to increase in this higher age group. 
 This summary enables three conclusions. First, the exclusion of older people with serious 
medical comorbidity and the lack of attention for four of the fi ve geriatric characteristics as 
an inclusion or baseline variable, suggests that older people with these characteristics are 
possibly underrepresented and/or understudied in RCTs on treatment of major depression. 
This may mean that evidence on treatment results of major depression has insuffi cient 
external validity for the heterogenic population of older adults. Second, because of the lack 
of including geriatric characteristics as covariable, the possible effect these characteristics 
might have on the outcomes of RCTs on treatment of major depression in older persons 
cannot be quantifi ed. Finally, disability, nutritional status and cognitive function are rarely 
used as outcome measures, nor as adverse effects, although these characteristics are 
considered to be relevant outcome measures for older persons with depression, both for 
the positive and the potentially negative effects of antidepressant drugs.17, 22, 23
84
CHAPTER 5
Methodological Shortcomings in Measurement of Geriatric Characteristics
The RCTs studied lack methodological rigor in assessing geriatric characteristics. Functional
status was assessed by scales not specifi cally developed for older persons. Medical comor-
bidity was predominantly used as exclusion criterion, but the lack of operationalization of 
vague terms, such as ‘unstable/serious/acute medical condition’ or ‘condition possibly
interfering with study medication’, was a handicap to knowledge of precisely which 
comorbidity was excluded. Currently, there is no consensus on how to assess medical 
comorbidity as a baseline variable in antidepressant drug trials in older patients, which leads 
to different measurements, and does not enable comparison between study populations. 
The two studies using the CIRS-G showed substantially higher sum scores than reported in a 
community-dwelling older population,65 but a comparable sum score to an older outpatient 
population with somatoform disorders.68
 Cognitive status was assessed by 11 different tests as outcome measures, similarly 
precluding pooling or comparison of data.
 Frailty measures were not used as variable in any study, which is probably explained by 
the relatively recent attention for the possible relation between frailty and depression.18
Strengths and Limitations
Our review has several strengths. We used an extensive search strategy that enabled 
inclusion of more studies on major depression treatment from 2000 onward than other 
systematic reviews and meta-analyses.3,6,7,69-71 Another strong point of this systematic review 
was the overall good quality of the included RCTs. The main problem in risk of bias was 
unclear reporting on randomisation procedure and allocation concealment. Only fi ve studies 
had a high risk of bias on two or more items, including probably three single blind studies. 
The overall attrition rate of 22.1% is in agreement with this quality judgement, though 
eight studies had an attrition rate higher than 30%. The attrition rate in our systematic 
review is somewhat lower than the 27% in an earlier meta-analysis on antidepressant trials 
in older adults including studies from 1975 onward.72  Studies that included more patients 
with geriatric characteristics would probably have led to a higher attrition rate.73  
 As this systematic review is the fi rst to focus on geriatric characteristics in studies on 
antidepressant treatment in older adults, it is complementary to other systematic reviews 
and meta-analyses on treatment outcomes of depression in older age.3,6,7 These focus 
mainly on co-variables that are known to be directly related to depression, like severity or 
duration of the depressive episode. One meta-analysis confi rms the sparse reporting of 
potentially relevant adverse events in older adults.71
 For proper interpretation, however, limitations should be acknowledged. As the investi-
gated geriatric characteristics were rarely taken into account as variables in the included 
studies, a quantitative meta-analysis on the effect of these characteristics on treatment 
outcome could not be conducted. Analysis of geriatric characteristics may also have been 
missed, because of the exclusion of secondary publications. Three out of the nine articles 




articles (two of the same trials) did not fi nd any impact of general comorbidity or arthritis 
on depression treatment outcome.74-76 
Future Clinical Trials
We realise that often the argument of insuffi cient time or funding is mentioned as reason for 
not taking geriatric characteristics into account. However, this points at debatable priori-
ties as it results in conducting RCTs of which it is unclear whether the results are applica-
ble to older adults seen in regular practice.24 The underrepresentation of older populations 
in clinical pharmacological research is rightly brought under attention,77,78 so are strategies 
improving recruitment of older people in research.79 We strongly recommend not only 
improving recruitment for older persons, but also to adopt a more geriatric focus with 
methodological adaptations in future studies on antidepressant treatment in older adults, 
and offer some suggestions. 
 A fi rst step might be to take the fi ve geriatric characteristics, which were focused on in 
this study, into account in future RCT designs. Geriatric characteristics can best be well 
defi ned and used as descriptive variables. More relevant outcome measures on functional 
status, cognitive function and nutritional status should be used, with these well validated 
as responsive measures for older populations. Potential effect modifi ers, such as medical 
comorbidity and frailty, should be used as covariables and not as exclusion criteria, because
with the latter, the study loses external validity. RCTs in old-age psychiatry should preferably 
be powered to analyse subgroups of older patients or test interaction effects with geriatric 
conditions like frailty. Finally, treatment focusing on both psychiatric and geriatric characte-
ristics, for example as ‘collaborative care treatment’,80 might be of benefi t for older adults 
with depression and comorbid geriatric conditions, and urgently requires well designed 
trials dedicated to the study of these complex interventions.
 CONCLUSION
Although geriatric characteristics are probably effect modifi ers or relevant outcome measures
in late-life depression, these are rarely taken into account in RCTs on antidepressant drugs. 
Therefore, these characteristics require more attention in future studies. Studies including 
the oldest adults, are underrepresented. We recommend not only improving recruitment 
for older persons, but also adopting a more geriatric focus with methodological adaptations 
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 Supplementary: Search Strategies
 Search strategies
To identify  studies on older adults, we used the validated strategy of Wilson: elder* [tiab] 
OR older* [tiab] OR late-life [tiab] OR geriatri* [tiab] OR senil* [tiab] OR old age [tiab], 
added with OR aged [Mesh].1 
To identify RCTs  in PubMEd we used the specifi c search strategy of Haynes: randomized
controlled trial[Publication Type] OR (randomized [tiab] AND controlled [tiab] AND trial 
[tiab].2
 PubMed 
Diagnosis: Depression[Mesh] OR Depressive Disorder[Mesh] OR Depressi* [tiab]
Treatment: [Antidepressive Agents [Mesh] OR Antidepressive Agents [Pharmacological 
Action] OR Monoamine Oxidase Inhibitors [Mesh] ] OR [Antidepressive agent* OR Anti-
depressant* OR tricyclic* OR Uptake Inhibitor* OR selective serotonin reuptake Inhibitor* 
OR Monoamine Oxidase Inhibitor* OR MAO Inhibitor* OR SSRI*]
Age selection: Aged [Mesh] OR [elder* [tiab] OR older* [tiab] OR late-life [tiab] OR geriatr* 
[tiab] OR senil* [tiab] OR old age [tiab]]
Randomized controlled trial: (randomized controlled trial [Publication Type] OR (randomized 
[tiab] AND controlled [tiab] AND trial [tiab])) 
 PsychInfo  
Diagnosis: exp Recurrent Depression/ or exp Endogenous Depression/ or exp Reactive 
Depression/ or exp Treatment Resistant Depression/ or exp Major Depression/ or Depressi*.
ti,ab
Treatment: antidepressant drugs/ or bupropion/ or citalopram/ or fl uoxetine/ or fl uvoxa-
mine/ or iproniazid/ or isocarboxazid/ or lithium carbonate/ or methylphenidate/ or mian-
serin/ or moclobemide/ or molindone/ or nefazodone/ or nialamide/ or nomifensine/ 
or paroxetine/ or phenelzine/ or pheniprazine/ or pipradrol/ or serotonin norepinephrine 
reuptake inhibitors/ or sertraline/ or sulpiride/ or tranylcypromine/ or trazodone/ or 
tricyclic antidepressant drugs/ or venlafaxine/ or zimeldine/ or lithium/ or monoamine 
oxidase inhibitors/ or serotonin reuptake inhibitors/ or ((Antidepressive agent* or Anti-
depressant* or tricyclic* or Uptake Inhibitor* or selective serotonin reuptake Inhibitor* 
or Monoamine Oxidase Inhibitor or MAO Inhibitor* or SSRI or serotonin norepinephrine 
reuptake inhibitor*).mp )
Age selection: (Elder* or older* or late-life or geriatr* or senil* or old age or aged).ti,ab.
Randomized controlled trial: limit to “therapy (best balance of sensitivity and specifi city)”
 EMBASE 
Diagnosis: (depression/ or agitated depression/ or atypical depression/ or depressive 
psychosis/ or endogenous depression/ or involutional depression/ or late life depression/
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or major depression/ or masked depression/ or melancholia/ or “mixed anxiety and depres-
sion”/ or “mixed depression and dementia”/ or reactive depression/ or seasonal affective 
disorder/ or treatment resistant depression) or (depressi*.ti,ab.)
Treatment: (exp antidepressant agent) or ((Antidepressive agent* or Antidepressant* or 
tricyclic* or Uptake Inhibitor* or selective serotonin reuptake Inhibitor* or Monoamine
Oxidase Inhibitor or MAO Inhibitor* or SSRI or serotonin norepinephrine reuptake 
inhibitor*).mp.)
Age selection: (Elder* or older* or late-life or geriatr* or senil* or old age or aged).ti,ab.
Randomized controlled trial: limit to “therapy (best balance of sensitivity and specifi city)”
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Frailty, multimorbidity and functional decline predict adverse health outcomes in community 
dwelling older people and older patients in general hospitals. This study investigates whether 
these characteristics separately are independent predictors of  health outcomes of acute 
psychiatric hospitalization. 
 Methods
Observational study in a prospectively sampled cohort of older patients, consecutively 
admitted to a psychiatric hospital.  
On admission we assessed frailty (Frailty Index and walking speed); multimorbidity 
(Cumulative Index Rating Scale Geriatrics (CIRS-G)) and functional status (Barthel Index). 
We used the Clinical Global Impressions of  Improvement scale (CGI-I) as the psychiatric 
outcome measure, and dichotomized discharge destination as overall outcome measure: 
favourable (able to return home or previous care level) or adverse (death, or move to 
higher level of residential care).  
 Results 
We included 120 patients, 74.6 years (±7.8). 52.5% Of the patients were frail  (FI ≥ 0.25). 
The mean level of the CIRS-G was 13.5 (5.4). Mean CGI-I at discharge was 2.8 (± 1.0), 
indicating moderate improvement in the psychiatric outcome. Neither FI, CIRS-G, nor 
Barthel scores were, independent of age, sex and diagnosis, associated with the CGI-I. FI 
was predictive for adverse discharge destination (OR 1.91 [95% CI 1.09 – 3.37] per 0.1), 
as were higher CIRS-G (OR 1.19 95% CI 1.06 – 1.34, per point) and lower walking speed 
(OR 1.35 [95% CI 1.06 – 1.72] per 0.1 m/s).  
 Conclusions 
Half of our patients were frail and had a high level of multimorbidity. The FI, walking speed 
and multimorbidity did not predict improvement of psychiatric symptoms at discharge, 




Geriatric syndromes acute admissions: discharge
 INTRODUCTION
Frailty, multimorbidity and functional impairment are associated with negative health 
outcomes in older adults.1-3 These so called geriatric syndromes, defi ned as multi-causal 
health problems with high prevalence in old age,3 may co-occur independently, but often 
overlap and occur together.4,5  
 Frailty is an age related state of increased vulnerability to poor resolution of homeostasis 
after a stressor event, which increases the risk of adverse outcomes.1,6
 Frailty is operationalised and validated in two different models: fi rst in the accumulation 
of defi cits model: a Frailty Index (FI) is constructed based on the concept that the more 
defi cits individuals have, the more frail they are. Symptoms, signs, disabilities and diseases 
are termed as defi cits and contain the following domains: cognition, mood, mobility and 
balance, nutritional status, vision and hearing, (Instrumental) Activities of Daily Living, 
medical history, selected items of physical examination, or laboratory results.7 The sum 
score of the defi cits that are ‘wrong’ is divided by the number of defi cits that are scored, 
resulting in a score between 0 and 1: the higher the FI, the more frail an individual is. 
 The other concept model of frailty is the ‘physical phenotype’ model. It consists of fi ve 
items: slow gait speed, weak hand grip strength, unintentional weight loss, self-reported 
exhaustion and low energy expenditure. Every item is scored positive when an individual 
has a score that is in the lowest quintile score compared to a population based cohort, 
resulting in a score robust (0), pre-frail (1 or 2) and frail (≥ 3).4 Frailty has mainly been 
studied in community dwelling older adults4,8,9 and in hospital patients.10
 There are indications that frailty is also associated with psychiatric disorders in older 
persons.11 It is investigated in longitudinal and cross sectional studies in older patients with 
depression, where it is found to be associated with severity of depressive symptoms.12-16
 Functional impairment is defi ned as restriction in or lack of ability to perform an activity, 
because of impairment in physical performance.17 It is known as a risk factor as well as 
a consequence of depression in older adults17,18 and inpatients with psychotic or bipolar 
disorder.19-22
 Multimorbidity, resulting in complex interactions of several co-existing diseases, is 
associated with psychiatric disorders like psychosis, bipolar disorder or depression.23-25
In older adults with cognitive disorders or dementia associations with frailty, functional 
impairment and multimorbidity are found as well.26-28
 Up to now frailty, multimorbidity and functional status have not been studied for their 
impact in clinical studies in geriatric psychiatry, although they might be as relevant in 
older psychiatric populations as in older adults in primary care or general hospitals.29 This 
underlines the need to study the impact these geriatric syndromes have on outcomes of 
treatment in older adults with psychiatric disorders. 
 We conducted an observational follow up study in older patients with severe mental 
disorders who were admitted to acute wards for geriatric psychiatry. First, we investigated 
the prevalence and correlations of geriatric and psychiatric characteristics in patients with 
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different psychiatric disorders at admission. Second, we studied whether frailty (measured
with an FI or walking speed), multimorbidity (measured with the Cumulative Illness 
Rating Scale Geriatrics (CIRS-G))30 and functional impairment, (measured with the Barthel 
index)31, separately and independent of age, sex and diagnosis, were predictors of the 
outcome measures at discharge: the score on the Clinical Global Impressions Scale of 
Improvement (CGI-I)32 and discharge destination. 
METHODS
We conducted an observational follow up study in a prospectively sampled clinical cohort 
of older adults who were admitted to an acute department for geriatric psychiatry between 
1th February 2009 and 1th August 2010. 
Setting
The study was carried out in two acute geriatric psychiatry wards of Pro Persona Mental 
Health Care, which is a large psychiatric teaching hospital in Nijmegen, the Netherlands.
One ward was specialised in older patients with mood disorders, anxiety disorders 
and psychotic disorders, and the second in patients with Behavioural and Psychological 
Symptoms of Dementia (BPSD). Patients with multimorbidity could be referred to these
geriatric psychiatry wards, as treatment for somatic diseases is included in medical care, 
but patients needing treatment for severe acute somatic problems, (i.e. intravenous 
therapy or intensive somatic diagnostic procedures) could not be admitted. Geriatric 
psychiatrists and  geriatricians were involved in multidisciplinary treatment.  
Subjects 
Included were all consecutively referred patients. Excluded were patients in whom no 
informed consent was given, who stayed less than fi ve days or were not able to understand 
Dutch. As some patients were readmitted, only the data of the fi rst included admission 
was analysed in our study. If patients could not give informed consent themselves, we asked 
their proxies. There were 172 consecutive admissions of 142 different patients in the study 
period. 120 patients could be included in the study sample (Figure 1).  
 As we conducted an observational study with limited extra data collection compared to 
our usual care, the medical ethical committee approved informed consent as ‘written or 
oral consent of the patient or proxy’.  
 Baseline measures
On admission we collected the following demographic data: age, gender, marital status, 
level of education and living situation. Within the fi rst week after admission all other 
measures were assessed. Psychiatric diagnoses were made according to the DSM-IVTR
classifi cation.33 Although patients have usually more than one diagnosis, we used the 
main diagnosis on Axis 1 or Axis 2 for our study. We categorised all patients in four main 
6
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   172 Pati ents admitt ed 
 Excluded as re-admissions: 30
    
   142 Eligible pati ents
 Excluded total of 22:
 No informed consent:   10
 In-hospital stay < 7 days:        4
 Other  8
   
   120 Pati ents included
Figure 1: 
Flow diagram of selecti on process of Randomized Controlled Trials    
diagnosis groups: ‘depressive disorder’, n = 41 (39 major depressive disorder, 2 dysthymia); 
cognitive disorder and dementia, admitted for ‘BPSD’, n = 41 (9 cognitive disorder not 
otherwise specifi ed, 30 dementia, 2 delirium);  ‘psychosis and bipolar disorder’, n = 17 (12 
bipolar disorder, 5 psychotic disorder) and ‘other psychiatric diagnoses’, n = 21 (5 anxiety 
disorder, 4 somatoform disorder, 5 substance abuse disorder and 5 adjustment disorder, 
2 personality disorder). 
 Frailty
Frailty was measured in different ways: fi rst, we used the accumulation of defi cits model 
and we constructed a Frailty Index (FI) of 39 items, containing: cognition, measured with 
MMSE;34 mobility, measured with the Timed Up and go Test (TUG);35 balance, measured 
by the Performance-Oriented Mobility Assessment (POMA);36 nutritional status, measured
with the Body Mass Index score. Additionally vision, hearing, Instrumental Activities 
of Daily Living (IADL), number of medications, medical history according to the family 
practitioner, selected items of physical examination, and laboratory results at admission 
were included. All items are scored according to the procedure recommended for FI 
construction.37 See supplementary table 1 for included items and scoring options of each 
individual item of the FI. 
 To prevent overlap, we have excluded psychiatric and ADL items. The FI contained 
only one global item on IADL. Former research has shown that FI scores < 0.08 indicate 
being robust, a score between 0.08 and 0.25 indicates pre-frailty state, and a score of > 0.25 
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indicates being frail, whereas a score above  approximately 0.6 is considered as the maximum
observable score for people alive.38
 Second, because of its predictive validity for mortality and its ease of use, we have 
used walking speed as a separate measure of frailty.39 We used the average walking speed 
in metres per second over 6 metres. Generally, a walking speed of  > 1.0 m/s is judged as 
good and < 0.8 indicates probable frailty. 
 However, walking speed is also part of the ‘physical frailty’ phenotype.4 As self-reported 
exhaustion and low energy expenditure overlap with symptoms of several severe mental 
disorders, we have measured hand grip strength and nutritional status besides walking 
speed and chosen not to take the full physical frailty phenotype into account in our study. 
Hand grip strength (HGS) was measured in kilograms with the Jamar Dynamometer, 
using the dominant hand, taking the best score of three consecutive attempts.40 Overall, 
a hand grip strength of women > 18 kg and of men > 30 kg is considered to be adequate. 
We used the Mini Nutritional Assessment (MNA) (range 0 - 30: score < 17 indicating 
undernutrition, 17 - 23,5: risk for undernutrition, and 24 - 30: well nourished) as measure 
for nutritional status.41 
 Multimorbidity
Multimorbidity was measured with the sum score of the Cumulative Illness Rating Scale 
Geriatrics (CIRS-G).30  It measures the lifelong cumulative burden of diagnosed diseases in 
14 domains: 13 domains of different somatic organ systems and the psychiatric domain. 
Each item can be scored from 0 - 4 (range 0 - 56, higher score: more multimorbidity). 
Besides the sum score, we used the Comorbidity Index: the number of items scoring equal 
or greater than 2, indicating burden of at least two relevant diseases. As all patients scored 
3 or 4 on the psychiatric domain, we were interested in a comorbidity index ≥ 3: having two 
relevant diseases besides the psychiatric disease. 
 Functional status
Functional status was measured with the Barthel index, a scale to measure activities of 
daily living, consisting of 10 items, two items can be scored 0 or 1, two items 0 to 3 and 6 
items 0 to 2 (range  0 - 20, higher score, more independent).31
 All prospective measurements were conducted by professionals who were involved in 
patient care: two residents in training for geriatrician and one in training for psychiatrist 
(for history taking, physical and psychiatric examination, psychosocial history, MMSE). 
They were trained in data acquisition by and under supervision of one psychiatrist and 
two geriatricians. The other involved disciplines were: nurses (Barthel), one dietician (BMI, 
MNA), and one physical therapist (6 metre walking test, Hand grip Strength, TUG, POMA).
Outcome Measures
We defi ned two different treatment outcome measures at discharge as dependent variables 
in our study: 1. the Clinical Global Impressions of Improvement scale (CGI-I) as psychiatric 
outcome measure and 2. dichotomized Discharge Destination as overall outcome measure:
6
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favourable (able to return home or previous care level) or adverse (death, or move to higher 
level of residential care).  
 Clinical Global Impressions Scales 
The severity of psychiatric disorders is usually measured by specifi c severity scales, making 
it diffi cult to compare the severity of different psychiatric disorders, or the level of impro-
vement after treatment. For this reason, we have assessed the severity of the different 
psychiatric disorders by Clinical Global Impressions Scales. We used an expert panel of 
three professionals, who were not involved in the treatment of the included patients, to assess 
CGI scales: a psychiatrist (PH), a geriatrician (CB) and a senior resident in geriatrics (NL). 
They assessed the scales independently and retrospectively.  
 To assess the severity of the mental disorders at admission we used the Clinical Global 
Impressions Severity Scale at Admission (CGI-SA), and at discharge the Clinical Global 
Impressions Severity Scale at Discharge (CGI-SD).32 We used the Clinical Global Impressions 
Scale of Improvement (CGI-I) to assess the extent of improvement or worsening of the 
psychiatric symptoms at discharge.32 The CGI scales provide an overall clinician-determined 
summary measure that takes into account all available information, including knowledge 
of the patient’s history, psychosocial circumstances, symptoms, behaviour, and the impact 
of the symptoms on the patient’s ability to function.42 The CGI Severity scales are seven 
point scales scoring from 1 (normal, no symptoms) to 7 (very severely ill). The CGI-I is 
a seven point scale scoring from 1 (very much improved) to 7 (very much worse), with 
a score of 4 indicating no change. The CGI scales are validated for different psychiatric 
disorders,43-45 but not specifi cally in older adults, although older populations are taken 
into account in one large study that adequately validated the CGI scales in an inpatient 
clinic, which showed good overall validity.43 We used a scoring guideline and a matrix 
with examples how to score outcomes in different disorders.42,46-48 The CGI-SA was scored 
using the admission report, which includes both the patient’s and proxy’s psychiatric and 
medical history, psychiatric and physical examination, social circumstances and level of 
functioning. At discharge the CGI-SD and CGI-I were scored using the discharge letter. If 
the discharge letter was unavailable, the last treatment plan before discharge was used. 
 The CG-I scales are not meant to take the infl uence of somatic morbidity into account. 
This was stressed in the scoring guideline. To improve our score reliability, we conducted 
a pilot assessment procedure in which we independently scored 10 patients, who were 
admitted to the geriatric psychiatry department before the study period.49,50
To compose one score for the CGI-SA, the GCI-SD and the CGI-I for each patient, we took 
the mean of the scores by the three panel members. To establish the interrater reliability of 
the average CGI scores (CGI-SA, CGI-SD and the CGI-I) of the three raters we calculated an 
intra class correlation coeffi cient (ICC). The ICC for the CGI measurements were ‘good’ to 





We used ‘Discharge Destination’ as a dichotomised overall health outcome measure: 
favourable (able to return home or previous care level) or adverse (death or move to a 
higher level of residential care compared to the situation before admission). 
 Analysis
To analyse differences in demographic variables as well as outcomes between the diag-
nosis groups, we used an one way ANOVA for continuous and χ2 tests for categorical
variables, with a p value signifi cance of 0.005, as Bonferroni correction for multiple
comparisons.
 The Pearson’s Correlation Coeffcient (CC = r) was used to analyse correlations between 
age, FI, walking speed, Barthel, CIRS-G, Hand Grip Strength, MMSE and MNA as well as 
their correlations with the CGI-SA, CGI-SD and the CGI-I.  
 We performed four linear regression analyses to investigate whether the FI, CIRS-G, the 
Barthel, and walking speed, separately are predictors for the CGI-I as dependent variable. 
We used age, gender, level of education, marital status, living independent or not before
admission, psychiatric diagnosis group and the CGI-SA as covariates to correct for 
independency towards these prediction measures, which are already used in psychiatric 
studies.    
 We performed four logistic regression analyses with the FI, CIRS-G, Barthel and walking
speed, each as separate independent variable and Discharge Destination as dependent 
variable. Again, we included age, gender, level of education, marital status, living independent
or not before admission, psychiatric diagnosis group and the CGI-SA as covariates.
 RESULTS
Demographic, psychiatric and geriatric measures at baseline: 
 prevalence and correlations 
Table 1 shows that 63 (52.5%) patients had an FI ≥ 0.25; 55 (49.1%) a walking speed < 0.8 
m/s or were unable to walk. Fifty-two (46.4%) patients had a Hand Grip Strength below the 
Fried cut of score and 105 (92.1%) were undernourished or were at risk for undernutrition. 
 Forty-four patients (37.9%) scored as frail (FI ≥ 0.25), had at least one problem in ADL 
(Barthel < 19), and had at least two or more relevant diseases besides the psychiatric disease 
(CI score ≥ 3). Fourteen patients (12.1%)  were robust, functionally independent and had a low 
CI score of ≤ 3.  
Table 2 shows these measures at admission and outcomes of treatment in the four 
different diagnosis groups. Neither the FI, CIRS-G, Barthel nor walking speed differed 
signifi cantly between diagnosis groups, nor was the CGI-SA.
 Besides differences in mean age and the fi nding that patients with ‘psychosis or bipolar 
disorder’ were less frequently married (p < 0.05), there were no differences in demographics 
between the four diagnosis groups (data not shown). 
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Table 1 
Demographics, psychiatric and geriatric characteristi cs on admission.
Total sample N=120




  Never married or divorced
  Widowhood




  Not specifi ed
Living situati on 
      Independent (alone or with spouse)
      Not independent
  Nursing home
  Residenti al home
  Sheltered Care Mental Care
Diagnosis DSM IV 
  Depressive disorders
  Cogniti ve disorders
  Psychosis and Bipolar disorders
  Other diagnoses
Clinical Global Impressions 
  CGI Severity admission 
Frailty Index 
  < 0.08 
     0.08 ≤ FI < 0.25
     0.25 ≤ FI ≤ 0.45
  > 0.45
Walking speed 6 meter (m/sec)  (n = 112)
  > 1.0 
  0.8 – 1.0 
  < 0.8
  Mobility too impaired  to perform test
  Not able for other reasons. 
   N   (%)
 74.6 (7.8)
   74 (61.7)
   49 (40.8)
   34 (28.3)
   37 (30.8)
   62 (51.7)
   24 (20.0)
   24 (20.0)
   10 (8.3)
   94 (78.3)
   26 (21.6)
        10 (8.3)
         13 (10.8)
             3 (2.5)
   41 (34.2)
   41 (34.2)
   17  (14.2)
   21  (17.5)
 5.17 (0.76)
 0.27 (0.10)
       5    (4.2)
     52  (43.3)
     56  (46.7)
       7     (5.8)
 0.85 (0.33) 
   31  (27.7)
   21  (18.8)
   50  (44.6) 
      5    (4.5)
      5    (4.5)
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Total sample N=120 
Hand Grip Strenght (kg) (n = 112)
  Women (n = 72)
  Men (n = 40)
Nutriti onal status (n = 114)
Mini Nutriti onal Assessment (MNA) (0 -30)
  < 17 
  17 – 23.5
  24 - 30
Fried criteria
 Walking speed < cut-off  
 HGS < cut-off  
 MNA < 17 
Multi morbidity
Cumulati ve Index Rati ng Scale Geriatrics (CIRS-G) 
(0-56)
 CIRS-G Sumscore
 CIRS-G Comorbidity Index
Functi onal status (n = 116)
 ADL Barthel index (0 - 20)
  ADL Barthel 1 – 18 (n)
  ADL Barthel 19 – 20 (n)
Cogniti on (n = 114)
 MMSE
Number of medicati ons
   N   (%)
 19.6 (7.7)
 30.7 (8.7)
 18.1 (4.4) 
   39 (34.2)
   66 (57.9)
   9 (7.9)
   36 (33.6)
   52 (46.4)
   39 (34.2)
 13.5 (5.4) 
   4.6 (2.1)
 15.4 (5.3)
   64 (55.2)
   52 (44.8)
 22.9 (6.5) 
   7.3 (3.7)
Note: between brackets: % for number of pati ents, and SD for conti nuous measures
 Higher age was correlated with higher scores on the Frailty Index (r = 0.36, p = 0.000), 
CIRS-G (r = 0.24, p = 0.008), lower scores on the Barthel (r = 0.32, p = 0.001) and lower 
walking speed (r = 0.35, p = 0.000). Neither gender, level of education nor marital status 
were correlated with geriatric syndromes. 
 Supplementary table 2  shows that most geriatric measures were intercorrelated, but 
did not correlate with CGI-SA, CGI-SD and the CGI-I. 
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 Clinical Global Impressions of Improvement: CGI-I
The results of the linear regression analyses for the four different predictors are shown in 
table 3. 
Neither the FI, CIRS-G, Barthel, nor walking speed were independent predictors of CGI-I in 
the whole sample. Patients with ‘BPSD’ had the highest CGI-I and patients with a ‘depressive
disorder’ the lowest CGI-I, as analysed with ANOVA. In the linear regression analyses, 
the group of patients with ‘BPSD’ showed signifi cantly worse improvement in all four 
multivariable models, compared to patients with ‘depressive disorders’. The subgroups 
were too small to investigate interactions between diagnoses, geriatric variables and the 
CGI-I. None of the other co-variates were associated with the CGI. 
 Discharge destination
Seventy-seven patients (64%) had a favourable discharge outcome and were able to return 
to their own living situation. Forty-three patients (36%) had an adverse discharge outcome, 
of whom six patients died (see table 2).
 The FI was a signifi cant predictor for this adverse outcome (table 4): OR 1.91, [95% CI 
1.09 - 3.37]  (per 0.10 point increase), as were the CIRS-G: OR 1.19 [95% CI 1.06 - 1.34] 
(per 1 point increase), and walking speed: OR 1.35 [95% 1.06 - 1.72] (per 0,10 metre per 
second slower). 
 Patients admitted with ‘BPSD’ had a high odds on adverse discharge destination 
compared to patients with depressive disorders. Being unmarried or widowed gave higher 
odds on adverse outcome than being married. Patients who lived independently had a higher 
odds on an adverse discharge destination than patients who already lived in residential or 
nursing home care, which seems logical.
 DISCUSSION
This observational follow up study is the fi rst, as far as we know, to assess prevalence of 
geriatric characteristics at geriatric psychiatry admission and their value as predictor for 
outcomes at discharge. None of the four independent geriatric variables were independent 
predictors for the CGI-I scores. Nevertheless, frailty, multimorbidity and lower walking 
speed had predictive power for less favourable discharge destination.
 Due to the observational design, with a participation grade of 84.5% by broad inclusion 
criteria, these results are likely to have high extern validity for similar psychiatric populations.
On the other hand, we studied only one psychiatric hospital, and patients therefore may 
not be representative for all Dutch departments of geriatric psychiatry, where patients with 
dementia, serious comorbidity or frailty might not be admitted. 
6
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Geriatric measures at admission
We found that half of the patients were frail, as evaluated with an FI constructed according 
to accumulation of defi cits model, and as measured with walking speed; there was a high 
level of multimorbidity. Most patients had at least functional impairments in one domain, 
and were at risk for undernutrition or undernourished at admission. 
Frailty, multimorbidity and functional impairment were found to be signifi cantly 
correlated, resulting in a high percentage of overlap (37.9%), in concordance with larger 
population based studies.4,5,51 Our FI did hardly contain items of functional status, but we 
included somatic items. Nevertheless, the correlations between FI and the CIRS-G and the 
Barthel were both high. Although somatic items are incorporated in the FI, this does not 
mean that CIRS-G is a part of the FI. In the FI the somatic items are dichotomised and are 
incorporated in a model of accumulation of defi cits. The CIRG-G is, like the FI, a model of 
defi cit accumulation, but only of diseases, and also expresses disease severity. Together an 
FI, Barthel and CIRS-G result in a comprehensive overview of  older psychiatric patients. If 
persons have problems in one or more of these geriatric domains, they could benefi t from 
a multidisciplinary Comprehensive Geriatric Assessment (CGA)52 in order to assess more 
geriatric syndromes as risk for falls, cognitive decline or urinary incontinence as well as 
life style, quality of life and advanced care planning. Subsequently, a CGA should be used 
to develop a coordinated care plan to focus interventions on all the relevant problems for 
individual persons.
 When focussing on the FI, we found that higher age was correlated with the FI, although 
the association seems not as strong as in population based studies53,54 and notably, female 
sex was not associated with frailty in this population, in contrast with community based 
studies.55  
 In our study the prevalence of frailty as measured with an FI (52.5%) is much higher 
than in community dwelling older adults (13.6%).8 The mean of our FI was somewhat 
lower compared to studies in general hospitals,56-58 and in one other geriatric psychiatric 
ward.59 These FIs contained more ADL items than our FI. 
 Depression is the only mental disorder in older adults that has been investigated in 
relation to frailty in cross sectional and longitudinal studies. In almost all these studies, 
the Fried criteria were used to measure frailty, showing a prevalence of frailty of 40.4% 
in mainly outpatient populations with depression.15 We could not compare the FI with 
the full fi ve item physical frailty phenotype criteria. The three Fried items we have taken 
into account, gait speed, grip strength and nutritional status, had a higher prevalence 
of limitations compared to older community populations4 and to an older outpatient 
population with depression.14 
 The mean CIRS-G score (13,5, SD 5,4) was comparable to scores in patients admitted 
to geriatric wards in medical hospitals.30,58,60 
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Clinical Global Impressions Scales
The application of the CGI scales as a single measurement for clinical impression of severity 
and improvement across psychiatric diagnoses proved to be feasible and reliable with a 
good to very good ICC. The scores at baseline and admission are in line with one validation 
study of CGI scales in an inpatient psychiatric setting, including older patients.43 As it was 
scored by an independent consensus panel, it had to be scored retrospectively.  
 The geriatric predictors and the CGI measures were not mutually associated, suggesting 
the severity of psychiatric disorders to be independent of geriatric syndromes and the CGI 
scales to be valid instruments to score severity or improvement of psychiatric symptoms 
separate from the presence of geriatric syndromes. 
Outcome: the CGI-I
This lack of correlation foreboded the lack of predictive value in predicting the CGI-I 
scores: the improvement in CGI-I scores at discharge, which was overall ‘moderate’, was inde-
pendent of the presence of geriatric syndromes, nor was it associated with any of the covariates. 
 The diagnosis group of ’BPSD’ showed signifi cant less improvement in all four analyses 
compared to patients with depressive disorders. This confi rms former studies, which have 
shown that severe BPSD are diffi cult to treat.61,62 
 The diagnosis groups were too small to analyse possible interactions between 
diagnoses, predictors and CGI-I scores, as we would possibly expect: in depressive disorders,
cross-sectional and longitudinal studies show bidirectional associations between frailty and 
depression,13-16 although there are yet no treatment studies taking frailty as predictor into 
account.29 The same accounts for studies for other psychiatric disorders and multimorbi-
dity23,25,63,64 and studies on BPSD.65,66 
 In the whole sample, only few patients were robust or without multimorbidity, which 
also may have covered  possible associations with geriatric syndromes.
 Notable is the fact that we did not fi nd covariates known from studies on depression in 
older adults, such as age, male gender or severity of the psychiatric symptoms at admission, 
to be associated with the CGI-I.67,68
Outcome: Discharge Destination
One third of the patients could not return to their former living situation, 6 persons 
even died in their hospitalisation period. FI, CIRS-G and walking speed were separate, 
independent predictors of this adverse outcome of discharge destination (death, or move 
to higher level of residential care). This fi nding is in line with data on predictive power of 
frailty in general hospitals56,57 and with the overall predictive value of multimorbidity, but 
not that of functional status.69 As patients with BPSD were found to improve less on the 
CGI-I, they were also more prone to adverse discharge destination: ‘BPSD’ is one of the 
predictors of nursing home admission.70,71 Demographic covariates such as low level of 
education and being single or divorced or living independently before admission also gave 
a higher odds ratio on adverse discharge destination. These fi ndings confi rm the reliability 
of our predictive model. 
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 According to our research question, we focussed on the separate predictive value of the 
geriatric variables and not on the complete multivariate model in this small population. The 
high correlations between the predictors  would probably also have led to multicollinearity, 
which would have hampered the interpretation of the outcomes.
Implications and further research
Our fi ndings mean that geriatric syndromes should not only be taken into account in 
discharge planning, but may also add in the overall treatment perspective of older patients 
with severe mental disorders.  
 We recommend screening for frailty, though our research was not aimed at fi nding 
the best screening tool. In line with our data, and for reasons of applicability, walking 
speed can be used, for example combined with the Clinical Frailty Scale, which is validated 
against the FI.72 Alternatively, multimorbidity may also be assessed by the CIRS-G. Such 
measures can be used in geriatric psychiatry populations to identify patients who can 
benefi t from a Comprehensive Geriatric Assessment (CGA). Future studies should compare 
screening methods for effectiveness, effi ciency and feasibility.
 These CGAs should best be followed by complex care interventions in collaborative, 
interdisciplinary care models for older patients who have severe psychiatric disorders.   
 Collaborative care of psychiatric disorders and multimorbidity has been investigated 
in younger outpatients with depression, in which the depression as well as the somatic 
conditions and functional status improve signifi cantly better in treatment than in control 
groups.73-75 The usefulness of a collaborative care model might be even more benefi cial in 
older adults with severe mental disorders. However, in practice it both can be ‘too little 
and too late’, if it starts up only after admission to acute geriatric psychiatry wards, taking 
into account the high prevalence of geriatric syndromes at admission and the impact of 
frailty and multimorbidity on discharge destination 
 Further research on complex care interventions with interdisciplinary, collaborative 
care models should include larger sample sizes, frailty or multimorbidity measures as 
targeting criteria, and best include quality of life or wellbeing as generally preferred outcomes
by older people themselves.
 CONCLUSION
The level of frailty and multimorbidity of the older patients admitted to acute geriatric 
psychiatric wards in our study is comparable to older patients admitted to general hospitals. 
Frailty, together with walking speed and multimorbidity may help to identify patients at risk 
for in hospital mortality, or move to higher level of residential care. Together these fi ndings 
underline that geriatric syndromes, complementary to psychiatric diagnoses, matter in 
understanding the outcomes in geriatric psychiatry. Well-designed studies on complex care 
interventions, taking these geriatric syndromes into account, are urgently needed in older 
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Operati onalisati on of 39-item Frailty Index 
                                                                             
Items Scores
Functi onal status
 Transfer 0 = independent; 0.5 = some help; 1 = much help or dependent
 Global Impression Mobility 0 = independent; 0.5 = walking aid; 1 = wheelchair or bedridden
IADL   0 = Independent; 0.5 = some help; 1 = much help or dependent 
 Impaired vision 0 = No; 1 = Yes
 Impaired hearing 0 = No; 1 = Yes
Cogniti on
 MMSE (0 – 30) 0 = 25 – 30; 0.25 = 21 – 24; 0.50 = 18 – 20; 0.75 = 10 – 17; 1 = 10 
 Diffi  culty in practi cal skills 0 = No; 1 = Yes 
 Diffi  culty in understanding 0 = No; 1 = Yes
 Diffi  culty in speaking 0 = No; 1 = Yes
Medical history according to own 
general practi ti oner
 Hypertension 0 = No; 1 = Yes
 Acute coronary syndrome  0 = No; 1 = Yes
 Congesti ve heart failure 0 = No; 1 = Yes
 Chronic Pulmonary Disease 0 = No; 1 = Yes
 Cancer 0 = No; 1 = Yes
 Stroke  0 = No; 1 = Yes
 Parkinsonism 0 = No; 1 = Yes
 Thyroid disease 0 = No; 1 = Yes
 Diabetes Mellitus 0 = No; 1 = Yes 
 Artriti s/osteoporosis 0 = No; 1 = Yes
 Kidney disease 0 = No; 1 = Yes
Physical examinati on
 Tremor 0 = No; 1 = Yes
 Impression of illness; 0 = No; 1 = Yes
 deconditi oning; undernutrti on etc
 Abnormal auscultati on lungs 0 = No; 1 = Yes
 Abnormal auscultati on heart 0 = No; 1 = Yes
 RR systolic 0 = 101 – 160; 1 = < 101 or >160
Lab hematology and chemistry
 Hemoglobin (mmol/l) Female = 0 = 7.5 – 10.0;   0.5 = 7;0 – 7;5; 1 = < 7.0 OR > 10.0 
  Male = 0 = 8.5 – 11.0; 0.5 = 8.0 – 8.5; 1 = < 8.5 OR > 11.0
 CRP (mg/l) 0 = ≤ 3; 0.5 = 3 – 10; 1 = > 10 
 MDRD (ml/min) 0 = > 60; 0.5 = 50 – 60; 1 = < 50 
 Glucose (mmol/l) Fasti ng 0 = 4.0 – 6.1; 0.5 = > 6.1 OR  ≤ 7.1;  1 = > 7.1 
  Non fasti ng 0 = 4.0 – 7.8; 0.5 = > 7.8 OR ≤ 11.1; 1 = < 4.0 OR > 11.1
 Natrium (mmol/l) 0 = 135 – 145; 0.5 = 130 – 134 OR 146 – 150; 1 = < 130 OR > 150
 Kalium (mmol/l) 0 = 3.5 – 5.0; 0.5 = 3.0 – 3.4 OR 5.1 – 5.5; 1 = < 3.0 OR > 5.5
 TSH (mU/l) 0 = 0.27 – 4.2; 0.5 = 4.3 – 10.0; 1 = < 0.27 OR > 10.0
Number of medicati ons at admission ≥ 4 0 = ≤ 4; 1 = > 4 
Nutriti on
 BMI (kg/m2) 0 = 23 ≥ x ≤ 33; 0.5 = 19 – 23 OR > 33; 1 = < 19 OR > 35
 Involuntary weight loss last three 0 = No weight loss; 0.25 = don’t know; 0.5 = 1 – 3; 1 = ≥ 3 
 months (kg)
Mobility and muscle strength
 Fall last half year 0 = No; 1 = Yes
 TUG* (sec) 0 = < 10; 0.5 = 10 – 20; 1 = > 20 
 POMA** (0 - 28) 0 = > 24; 0.5 = 19 – 24; 1 = < 19
 Fear of falling 0 = No; 1 = Yes
* Timed Up and Go Test; ** Performance Oriented Mobility Assesssment
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Older adults with psychiatric disorders have a substantially lower life expectancy than 
age matched controls. Knowledge of risk factors may lead to targeting treatment and 
interventions to reduce this gap in life expectancy. In this study we investigated whether 
frailty independently predicts mortality in older patients following an acute admission to a 
geriatric psychiatry hospital. 
 Methods
Clinical cohort study with a 5-year follow up of 120 older patients admitted to a psychiatric 
hospital between February 2009 and September 2010. 
On admission we assessed frailty with a Frailty Index (FI). We applied Cox-regression 
analyses with time to death as the dependent variable, to examine whether the FI was a 
predictor for mortality, adjusted for age, sex, level of education, multimorbidity (Cumulative 
Illness Rating Scale for Geriatrics, CIRS-G scores), functional status (Barthel Index), 
neuropsychiatric symptoms (NPS) and severity of psychiatric symptoms at admission 
(Clinical Global Impressions Scale of Severity, (CGI-SA)).
 Results
Of the 120 patients, 63 (53%) patients were frail (FI ≥ 0.25) and 59 (49%) had died within 
5 years. The FI predicted mortality with a hazard ratio (HR) of 1.78 [95% CI 1.06 - 2.98] per 
0.1 point increase, independent of the covariates. Multimorbidity measured by the CIRS-G 
and functional status measured by the Barthel Index were not significantly associated. 
 Conclusions
Frailty was a strong predictor of mortality, independent of age, gender, multimorbidity and 
functional status. This implies that frailty may be helpful in targeting inpatient psychiatric 
treatment and aftercare according to patients’ life expectancy. 
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 INTRODUCTION
It is well recognised that adults with severe psychiatric disorders have on average a 
life expectancy of about 10 years less and a mortality rate two times higher than age 
matched controls.1-3 The excess mortality is mostly due to somatic comorbidity: especially 
cardiovascular, but also infectious, endocrine, pulmonary and oncologic diseases.1,2,4,5
 A substantial loss in life expectancy persists in older adults with psychiatric disorders,6,7
but risk factors may be different from those at younger age. Insight into risk factors may 
lead to specifi c interventions to reduce the gap in life expectancy between older adults with 
psychiatric disorders and the general population. 
 First, multimorbidity (having two or more chronic diseases), which includes mental 
disorders,8-10 rather than one specifi c disease, may be a predictor of mortality in older 
psychiatric patients. It is highly prevalent in older age,11 with a prevalence of 55% - 98% 
in persons 65 years or older,12 and is strongly associated with mortality.13 Secondly, functional
impairment is known to be a risk factor for mortality in older general and in hospital 
populations and may also be a risk factor in older psychiatric patients.14,15
 Possibly most important, frailty may be a strong predictor of mortality in older patients 
with psychiatric disorders. This state of increased vulnerability to poor resolution of 
homeostasis after a stressor is known to increase the risk of adverse outcomes such as 
mortality,16-18 independently of multimorbidity and functional status in community dwelling 
older populations,17,19 as well as in older adults admitted to general or academic hospitals.20,21
Nonetheless, to our knowledge, this has not yet been studied in depth in geriatric psychiatric 
patients. 
 The concept of frailty can be operationalized in many ways, of which two models of 
biomedical frailty are best validated and most widely used. The fi rst model is the accumulation 
of defi cits model, which uses a set of symptoms, signs, disabilities and diseases to obtain 
a Frailty Index (FI). A higher FI implies that a person is more frail.22 One item increase 
in 40-item FIs resulted in 4% increase in 5-year mortality in seven studies in community 
dwelling older populations.23 
The second model is the ‘physical frailty phenotype’ model. It consists of fi ve items: slow
gait speed, weak hand grip strength, unintentional weight loss, self-reported exhaustion and 
low energy expenditure.17 Of these items, the last two overlap with symptoms in different 
psychiatric disorders. Walking speed,24 hand grip strength25 and nutritional status26 have 
previously been investigated as sole indicators of frailty and were found to be signifi cant 
predictors of mortality in older community dwelling populations: 0.1 metre per second 
reduction in walking speed was associated with a 12% increase in 5-year mortality;27
5 kg reduction in hand grip strength was associated with a 16% higher 4-year mortality.28
Undernutrition was predictive for 5- and 10-year mortality in older adults in the community26,29
and in hospitalised populations.26,30 
 We already reported that an higher FI, lower walking speed and multimorbidity were 
found to be predictors of discharge destinations with lower autonomy in patients admitted 
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to acute wards for geriatric psychiatry.31 In this follow up study, we investigated mortality 
within fi ve years after admission in the same study population. We primarily focused on 
the question whether frailty, measured with an FI, is a predictor of mortality, independent 
of age, sex, level of education, multimorbidity, functional status, severity of the psychiatric 
symptoms at admission and a diagnosis of cognitive disorders with neuropsychiatric
symptoms (NPS). Secondly, we investigated three other frailty measures as possible 
predictors for mortality: walking speed, hand grip strength and nutritional status.
METHODS
We conducted a 5-year follow up study in a prospectively sampled clinical cohort of 120 
older adults, admitted to acute wards for geriatric psychiatry between 1st February 2009 
and 1st August 2010. The methods have been described previously and are summarised 
here.31
Setting and Participants
The study was carried out in two acute geriatric psychiatry wards of Pro Persona Mental 
Health Care, a large psychiatric teaching hospital in Nijmegen, the Netherlands. Eligible 
were all consecutively referred patients. Excluded were patients who declined informed
consent, were admitted less than fi ve days, or were not able to understand Dutch. If 
patients were judged incapable to consent themselves, we asked their proxies. As we 
conducted an observational study with only limited extra data collection compared to our 
usual care, the medical ethical committee approved informed consent as ‘written or oral 
consent of the patient or proxy’. In patients who were readmitted (n = 30), only the data of 
the fi rst included admission were analysed in our study. The 172 consecutive admissions 
pertained to 142 unique patients in the study period. As 10 patients refused consent and 
12 were excluded according to our exclusion criteria, the fi nal study sample consisted of 
120 patients.31
Demographics and psychiatric diagnoses
On admission we collected data on age, sex, marital status, level of education and living 
situation. All patients were clinically diagnosed according to the DSM-IVTR classifi cation.32
We used the main diagnosis for our study. We categorised all patients in four main diagnosis
groups: depressive disorder (n = 41); cognitive disorder and dementia, admitted with 
NPS (n = 41); psychosis and bipolar disorder (n = 17) and other psychiatric diagnoses 
(n = 21; anxiety disorder: n = 5, somatoform disorder: n = 4, substance abuse disorder: n = 5,
adjustment disorder: n = 5, and personality disorder: n = 2). 
Frailty
We constructed a Frailty Index (FI) of 39 items31 following the procedure described by 
Searle et al. (see chapter 6, p. 118).33 The FI ranges between 0 and 1, as the sum score 
7
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of the defi cits that are present is divided by the number of defi cits that can be scored. FI 
scores smaller than 0.08 indicate being robust, a score between 0.08 and 0.25 indicates a 
pre-frailty state, and a score greater than 0.25 indicates being frail.34,35
 Walking speed was measured as the average speed in metres per second over 6 metres 
walking.24 Generally, a walking speed of > 1.0 m/s is judged as good and < 0.8 indicates 
probable frailty.17 Hand grip strength was measured in kilogram force (kg), with the Jamar 
Dynamometer, using the dominant hand. Overall, a hand grip strength of > 18 kg and > 
30 kg are considered to be adequate for women and men, respectively.17 We used the Mini 
Nutritional Assessment (MNA) as measure of nutritional status (range 0 - 30: score < 17 
indicating undernutrition, 17 - 23,5: risk for undernutrition, and 24 - 30: well nourished).36 
Multimorbidity and functional status
Multimorbidity was measured with the Cumulative Illness Rating Scale for Geriatrics 
(CIRS-G).37 It measures the cumulative burden of diagnosed diseases in 14 domains: 13 
domains of different somatic organ systems and the psychiatric domain. Each item can be 
scored from 0 - 4 (range 0 - 56, higher score: more multimorbidity). Functional status was 
measured by assessing the performance on activities of daily living with the Barthel Index 
(range 0 - 20, higher score: more independent).38 
Severity of the psychiatric disorder
To assess the severity of the mental disorders we used the Clinical Global Impressions 
Scale of Severity at Admission (CGI-SA).39 The CGI-SA provides an overall clinician-
determined summary measure that takes into account all available information, including 
knowledge of the patient’s history, psychosocial circumstances, symptoms, behaviour, 
and the impact of the symptoms on the patient’s ability to function.40 The CGI-SA is a 
seven-point scale scoring from 1 (normal, no symptoms) to 7 (very severely ill). We asked 
an expert panel of three professionals, who were not involved in the treatment of the included
patients, to independently score the CGI-SA for each patient retrospectively. The ICC for 
the CGI-SA was good with a score of 0.77.31
Data collection
All measurements, including the items incorporated in the FI, were conducted by profes-
sionals who were involved in patient care of the participants: two residents in training for 
geriatrician and one in training for psychiatrist, under supervision of one psychiatrist and 
two geriatricians. Nurses scored the Barthel Index, a physiotherapist the mobility measures 
and a dietician the BMI and MNA. 
Outcome measure: mortality
We analysed survival over one and fi ve years after admission. Mortality was checked in the 
national mortality registry of the Netherlands for date of death until fi ve years after the last 




Univariable associations with survival times were graphically assessed with Kaplan Meier 
curves and tested with a log rank test. Multicollinearity was checked using the Variance 
Infl ation Factor (VIF).
 We used Cox proportional hazards regression models to analyse the predictors’ association
with survival times, fi rst in a univariable and next in a multivariable manner.
As predictors of survival in our primary analyses we considered: age, sex, level of 
education (low versus middle/high), diagnosis (patients with NPS versus patients with 
other diagnoses), CGI-SA, FI, CIRS-G, and the Barthel Index. 
 In our secondary multivariable models, we considered: age, sex, level of education, 
NPS, and CGI-SA, combined with either walking speed, hand grip strength or the MNA 
score. Statistical analyses were conducted using SPSS version 25, with a signifi cance level 
of 0.05.  
RESULTS
Baseline characteristics
Demographics, psychiatric and geriatric measures of the 120 participants at admission 
are presented in table 1. Mean age of the whole sample was 74.6 (SD = 7.8) years and 62% 
were female. A total of 63 (53%) patients had an FI ≥ 0.25, 55 (49%) had a walking speed 
< 0.8 m/s or were unable to walk, 52 (47%) patients had a low hand grip strength, 39 (34 %) 
were undernourished, and 66 (58%) patients were at risk for undernutrition.
 Mortality
One year after admission 20 (16%) of patients had died. All had an FI ≥ 0.25. 
Five years after admission 59 patients (49%) had died: 65% of the men and 39% of the 
women. There was a signifi cant higher mortality rate among men compared to women 
(P log-rank = 0.002), with a median survival time of 2.9 years for men. 
 The mortality rate of patients with an FI > 0.25 was 63% with a median survival time 
of 2.4 years, whereas 33% of patients with an FI ≤ 0.25 died within the fi rst 5 years after 
admission (P log-rank < 0.001), see fi gure 1. 
FI and mortality within one year after admission
We analysed the predictive value of the FI per 0.1 point increase in multivariable analysis 
with only age and sex as covariates. The HR was 2.73 [95% CI 1,80 - 4.15] per 0.1 point 
increase, in which age lost its predictive value. The group of patients that died within one 
year was too small for a complete multivariable analysis.
7
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   Total sample  Survivor Deceased
    aft er 5 years within 5 years
   N = 120 n = 61 n = 59
Age  74.6  (7.8) 71.3  (7.2) 78.0  (6.9)
Sex  
 women 74  (62) 45  (74) 29  (49)
 men 46  (38) 16  (26) 30  (51)
Marital status   
 Married or with spouse 49  (41) 28  (46) 21  (36)
 Never married or widowed 71  (59) 33  (54) 38  (64)
Level of Educati on (n =110)   
 Middle and High 48  (44) 29  (51) 19  (36)
 Low 62  (56) 28  (49) 34  (64)
Living situati on    
       Independent (alone or with spouse) 94  (78) 51  (84) 43  (73)
 Not independent 26  (22) 10  (16) 16  (27)
  Nursing home   10  (8) 3  (5)   7  (12)
  Residenti al home   13  (11) 5  (8)    8  (14)
  Sheltered Care Mental Care     3  (3) 2  (3) 1  (2)
Diagnosis DSM IVTR    
 Depressive disorders 41  (34) 22  (36) 19  (32)
 Cogniti ve disorders (NPS) 41  (34) 13  (21) 28  (48)
 Psychosis and Bipolar disorders 17  (14) 11  (18)   6  (10)
 Other diagnoses 21  (18) 15  (25)    6  (10)
Frailty Index (FI) 0.27  (0.10) 0.23  (1.0) 0.31  (0.10)
 < 0.08  5  (4) 5  (8) 0  (0)
 0.08 ≤ FI < 0.25 52  (43) 33  (54) 19  (32)
 0.25 ≤ FI ≤ 0.45 56  (47) 22  (36) 34  (58)
       > 0.45 7  (6) 1  (2) 6  (10)
Walking speed 6 metre (m/sec) (n = 112) 0.85  (0.33) 0.92  (0.36) 0.76  (0.28)
 > 1.0  31  (28) 21  (35) 10  (19)
 0.8 - 1.0  21  (19) 14  (23)   7  (14)
 < 0.8 50  (45) 19  (32) 31 (60)
 Mobility too impaired to test    5  (5)   3  (5)   2 (4)
 Not able for other reasons    5  (5)   3  (5) 2 (4)
Table 1 























FI ≤ 0.25 versus > 0.25 and 5-year Survival  
   Total sample  Survivor Deceased
    aft er 5 years within 5 years
   N = 120 n = 61 n = 59
Hand Grip Strength (kg) (n = 112)   
 Women (n = 72) 19.6  (7.7) 21.5  (6.9) 16.4  (8.0)
 Men (n = 40) 30.7  (8.7) 37.3  (8.4) 26.8  (6.4)
Nutriti onal status (n = 114)   
Mini Nutriti onal Assessment (MNA) (0 - 30) 18.1  (4.4) 18.4  (4.4) 17.8  (4.6)
 24 - 30  9  (8)   6  (10)  3  (5)
 17 - 23.5 66  (58) 32  (55) 34  (61)
 < 17  39  (34) 20  (35) 19  (34)
Multi morbidity    
Cumulati ve Index Rati ng Scale Geriatrics (CIRS-G)  13.5  (5.4) 11.7  (5.0) 15.4  (5.1)
(0 - 56)
Functi onal status (n = 116)   
 ADL Barthel index (0 - 20) 15.4  (5.3) 16.8  (4.9) 14.0  (5.3)
  ADL Barthel 19 - 20 52  (45) 35  (59) 17  (30)
  ADL Barthel 1 - 18 64  (55) 24  (41) 40  (70)
Cogniti on (n = 114)   
MMSE (0-30) 22.9  (6.5) 23.9  (6.1) 21.7  (6.7)
CGI Severity Admission (CGI-SA) 5.2  (0.76) 5.1  (0.73) 5.3  (0.77)
Note: Conti nuous variables: mean and standard deviati on (SD); categorical variables: N = number and (%). NPS: 
NeuroPsychiatric Symptoms; MMSE: Mini Mental Status Examinati on; N=120 unless stated otherwise.
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FI, CIRS-G, Barthel, and mortality within 5 years after admission
We found no signifi cant multicollinearity between the variables, as the VIF was between 
1.00 and 2.43.  
 The FI, CIRS-G as well as the Barthel Index were each predictive for mortality within fi ve 
years after admission in both the univariable Cox-regression analyses as well as in models 
adjusted for age and sex, (see table 2).
 In our fully adjusted model including NPS versus other diagnoses and severity of 
psychiatric disorder (CGI-SA), and entering the FI, CIRS-G and Barthel simultaneously, the 
FI (HR 1.78 [95% CI 1.06 - 2.98] per 0.1 point increase) remained predictive for mortality 
besides age and sex, but not the CIRS-G or Barthel Index. 
Walking speed, hand grip strength, MNA scores, and mortality 
 within 5 years after admission
In our secondary analyses we found walking speed and hand grip strength to have predictive 
value for mortality within fi ve years after admission when adjusted for age and sex. For lower 
walking speed we found a HR 1.11 [95% CI 1.01 - 1.21] per 0.1 metre per second, and for hand 
grip strength a HR of 1.43 [95% CI 1.06 - 1-92] per 1 kg less strength. Nutritional status was not 
signifi cantly associated with mortality, with a HR of 0.97 [95% CI 0.91 - 1.03] per point increase 
in MNA score. In the fully adjusted models neither walking speed (HR 1.06 [95% CI 0.96 - 1.17]) 
nor hand grip strength (HR 1.28 [95% CI 0.91 - 1.80]) remained predictive for mortality. 
 DISCUSSION
In this fi rst study examining the predictive value of frailty on mortality of older adults 
admitted to geriatric psychiatric wards, the 5-year mortality rate was 49%. After adjusting 
for age, sex, level of education, severity of psychiatric disorder and a diagnosis of NPS, 
frailty remained a signifi cant predictor of mortality independent of multimorbidity and 
functional status.
Survival time
The survival time of our population indicates a sharp reduction in life expectancy compared 
to the general population, especially for men. The mean life expectancy of men aged 75 
years in 2010 was 10.8 years in the general Dutch population with a mean 5-year survival
rate of 79% for men and 87% for women. This is substantially higher than the 35% survival 
in men and 61% in women we found.41
 Two population-based studies on persons aged 65 years and over with severe psychiatric 
disorders showed a decreased life expectancy of three years in men compared to age matched
controls across a follow up period of 12 - 14 years.6 Another study found a 10-year mortality 
rate of 66% for men and 56% for women with schizophrenia.7 The high level of frailty in 
our in-patient population, compared to older persons in population-based cohort studies, 
may explain the higher mortality rate in our population compared to these studies. 
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Frailty Index and mortality
A systematic review found that the effect of frailty on mortality may persist for fi ve years in 
community dwelling older populations.21 Our study confi rms this long term predictive value 
of frailty on mortality and underlines the excess loss of life expectancy in frail patients in 
our older psychiatric population. 
 Only one study in a recent systematic review reported a HR of an FI per 0.1 point 
increase, as we did, and found a HR of 1.25 [95% CI 1.20-1.30] on 5-year mortality, corrected 
for age and sex, in a community-dwelling population, where we found a HR of 1.81.42 The 
high HR of 1.78 in our fully adjusted model may be explained by the higher mean FI in our 
clinical population. Anyhow, we confi rm the association of frailty with mortality in the older 
psychiatric population. 
 Former studies have found frailty, functional impairment and multimorbidity to be three 
distinct, but associated concepts.17,42,43 Frailty was found to be a predictor of mortality 
independent of multimorbidity and functional impairment in community dwelling population
based studies.17,19,42 Our results are in line with these fi ndings. 
 The inclusion of the presence of somatic disease items in our FI probably explains 
why multimorbidity loses predictive value in our full model. This is supported by the 
aforementioned study, which showed that when multimorbidity and functional status 
items were excluded from the FI, both disability and multimorbidity contributed to prediction 
of mortality, but when these items were included in the FI, disability and multimorbidity 
were no longer predictive.42
 We found that functional impairment was not independently predictive for mortality. 
This might partly be explained by the fact that functional status is also included in the FI, 
although to a lower extent than multimorbidity. A second and probably important explana-
tion is the fact that functional impairment can be caused by psychiatric disorders and may 
improve when these disorders recuperate, hence losing their predictive power on the long 
term. This is in line with the results of our former study showing that functional status at 
admission was not predictive of outcomes at discharge.31
 The comparison of our fi ndings with studies with in-hospital patients is not merely 
hampered by differences in follow up duration (one year at most), but also by differences 
in the operationalisation of the FI, and our small sample size.44-47 One study on patients 
admitted to geriatric wards found a HR of 1.91 [95% CI 1.6 - 2.3] per 0.1 FI-point increase 
for mortality (corrected for age and sex), with a follow up period of one year, and an overall
mortality rate of 20%. The mortality rate of 16% and the HR for the FI per 0.1 point 
(corrected for age and sex) of 2.73 [95% CI 1,80 - 4.15] that we found for one year mortality, 
is at least comparable to these outcomes.
 Walking speed, hand grip strength, undernutrition and mortality
Half of the patients showed a low walking speed and hand grip strength, but our study
could not confi rm the predictive value of these factors for mortality found in meta-analyses
among community dwelling older persons.24,27,28,48,49 Our fi ndings indicate that walking 
speed and hand grip strength as sole measures of frailty do not have a similar predictive 
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value compared to an FI in a psychiatric sample. There are several possible explanations 
for the lack of predictive value. Particularly in a psychiatric sample, walking speed and 
hand grip strength might become less reliable due to a temporarily lowered level of 
motivation. Probably , due to the relatively small sample size there is a lack of power, as 
the trend of the HRs for both walking speed and hand grip were in the direction that was 
expected in our multivariable analysis, but did not reach signifi cance. The MNA was not 
predictive for mortality at all in our population, probably explained by the fact that the 
effect of malnutrition is (sub)acute and related to the psychiatric disorders. Patients often 
improve their nutritional status when recuperating and for that reason MNA may not be 
predictive in the long term in this population. 
 Strengths and limitations
Our study has strong points: it is the fi rst to take frailty, multimorbidity and functional 
status into account as predictors for mortality in older patients with severe psychiatric 
disorders. Moreover, it presents a well described clinical study population and has complete 
follow-up data. However, the small sample size is a limitation. It hampers the possibility 
of analysing differences between all four diagnosis groups, and probably limits the power 
to detect a predictive effect of not only walking speed or hand grip strength, but also of 
the psychiatric characteristics (e.g. the severity of the psychiatric disorder (CGI-SA) or 
a diagnosis of NPS). As we only studied patients in one psychiatric hospital, we realise 
that our patients may not be representative for other departments of geriatric psychiatry. 
However, the observed association between frailty and mortality is likely generalizable to 
other settings, as this association is consistent with previous studies in other populations. 
Practice implications and further research
We found a high level of frailty when patients are admitted to acute geriatric psychiatric 
wards and a high impact of frailty on mortality, extending over 5 years.
 This implies that frailty may be helpful in targeting patient psychiatric treatment and 
aftercare according to patients’ life expectancy. It is used as such in general hospitals, for 
instance, to support targeted end stage renal dysfunction treatment50 or interventions 
such as aortic valve replacement.51
 To realize more widespread use of frailty measures, an FI might be incorporated in 
digital medical records.52 Another option is using simpler frailty screening instruments, 
such as the Clinical Frailty Scale, which is validated against the FI,53 combined with a mul-
timorbidity measure. 
Our data support the added value of frailty assessment in geriatric psychiatry populations,
which in analogy to general medical populations may be used to identify patients who can 
benefi t from a Comprehensive Geriatric Assessment (CGA).54 A CGA can result in specifi c 
advices on prevention and treatment and thus may also help to reduce the high mortality 
fi gures present in these frail older psychiatric patients. 
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 Frailty should be the focus of further research to improve outcomes in older psychiatric
patients. Future studies should examine the effectiveness, effi ciency and feasibility of using 
frailty-based screening methods in clinical practice to improve treatment-related decision-
making and the effect of possible interventions on outcomes in older psychiatric patients. 
 CONCLUSION
Frailty is a strong predictor of mortality in older adults, who are acutely admitted to geria-
tric psychiatric wards, independent of age, gender, multimorbidity and functional status. 
This implies that frailty may be helpful in targeting inpatient psychiatric treatment and 
aftercare according to patients’ life expectancy. Frailty should be focus of further research 
to improve outcomes in older psychiatric patients.
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Summary and General Discussion
SUMMARY
The aim of our research was to investigate the occurrence, prevalence and associations 
of geriatric syndromes and multimorbidity in older adults with psychiatric disorders and 
their impact on treatment outcomes. 
 Our studies were initiated and conducted in clinical practice. We called it an explorative 
quest, as much of the occurrence and impact of geriatric syndromes and multimorbidity 
in geriatric psychiatry was still unknown. 
 Summary of the main fi ndings
 Part 1: Geriatric and psychiatric characteristics in patients with medically unexplained
  somatic symptoms and somatoform disorders
In chapter 2 we described frailty, somatic symptoms and multimorbidity in older persons,
who were admitted to our outpatient clinic for medically unexplained symptoms, after 
excluding the small fraction of patients who clearly had a medical disease that explained 
the main symptom. 
 We investigated whether the primary symptoms of the 32 included patients were indeed 
unexplained or were partly explained and whether this was associated with differences in 
frailty (handgrip strength and walking speed (Timed Up and Go test (TUG)), multimorbidity
(Cumulative Illness Rating Scale for Geriatrics, CIRS-G), functional status (Groningen 
Activity Rating Scale (GARS), or level of somatisation (Whitely Index). 
 We found that half of the patients had a medically unexplained main symptom, while 
the other half had a main symptom that could be partly medically explained. The patients 
with the partly explained symptoms were older, had a slower gait speed, a lower handgrip 
strength, a higher level of multimorbidity and were more functionally impaired, compared 
to patients without an explanation for their main somatic symptom. The patients without an 
explanation for their symptoms had a higher level of somatisation, although the difference 
did not reach statistical signifi cance. 
 We concluded that a geriatric assessment has an added value in diagnosing older persons
referred for medically unexplained symptoms even when symptoms exist for years; The 
presumed unexplained symptoms can (partly) be based on frailty and multimorbidity, and 
therefore are often not unexplained in the strict sense.    
In chapter 3 we examined the somatic symptom burden as a measure of somatisation 
(Physical Health Questionnaire, PHQ-15) and the overall impact of the somatic symptoms 
on different aspects of everyday activities (e.g. social, household, sleep: Sickness Impact 
Profi le, SIP)) as well as the psychiatric morbidity (DSM IVtr diagnoses) in the same 32 
patients as studied in chapter 2. 
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 The somatic symptom burden was of medium severity and the overall impact of the 
somatic symptoms on the level of activities was high. All patients were diagnosed with a 
somatoform disorder. More than half was also diagnosed with a depressive disorder and 
one third with an anxiety disorder. The persons with a depressive disorder had a higher 
level of somatic symptom burden and there was a higher impact on everyday activities 
than for patients without a depressive disorder.
 We concluded that identifying psychiatric morbidity in older persons with medically 
unexplained somatic symptoms is highly relevant, in addition to attention for the physical 
causes of the symptoms. 
 Based on the results in chapters 2 and 3, we advocated an interprofessional assessment 
by psychiatrist/psychologist and geriatrician in older persons with presumed unexplained 
somatic symptoms. 
In chapter 4 we compared frailty (the Physical Frailty Phenotype criteria) and somatic 
comorbidity (self-reported Charlton comorbidity Index and number of prescribed medica-
tions) in 118, broadly included, older persons with medically unexplained or insuffi ciently
explained somatic symptoms (MUS) and 154 older persons with medically explained 
somatic symptoms (MES) in general practices: the Older Persons with Unexplained 
Symptoms (OPUS) study. In this study we did not differentiate between persons with 
unexplained and partly explained symptoms, so both are represented in the MUS subpo-
pulation. Subsequently, we explored the association between the severity of somatisation 
(Brief Symptom Inventory, BSI-53) with frailty and somatic comorbidity in persons with 
MUS.
 The likelihood of being frail was three times higher for patients with MUS compared 
with those with MES. The patients with MES had a higher level of somatic comorbidity 
compared to patients with MUS, but were prescribed the same number of medications.
 The severity of somatisation (BSI-53) in patients with MUS was associated with the 
frailty sum score, the level of comorbidity, number of prescribed medications and adversely 
with handgrip strength. 
 We concluded MUS is a challenging problem; it seems to increase in older patients 
where MUS and MES can be mingled. Based on the results of chapters 2 and 4, we suggest
that frailty and multimorbidity should be considered as potential explanations for non-specifi c
symptoms before classifying them as MUS and therefore to ensure access to geriatric care 
for these patients. 
 Part 2: Geriatric characteristics in randomised controlled trials on antidepressants
In Chapter 5 we performed a systematic review, in which we examined whether and how 
frailty, medical comorbidity, disability, cognitive (dys)function and malnutrition are taken 
into account in randomised controlled trials (RCTs) with antidepressant drugs for major 
depressive disorder in patients aged 60 years or above. We included 27 studies. 
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 Frailty and malnutrition were not taken into account in any study. Disability was used 
as an outcome measure in fi ve studies. ‘Serious’ medical co-morbidity was excluded in 20 
studies and only two studies explicitly included a population with possibly serious medical 
comorbidity. Six studies described a score of the Mini Mental State Examination (MMSE) 
at baseline. Cognitive function was the only condition taken into account as co-variable 
(n = 3) or stratifying variable (n = 1), and was used as an outcome measure in seven studies. 
 We concluded that geriatric characteristics are rarely taken into account in RCTs on 
antidepressant drugs in late-life depression and studies including the oldest adults are 
underrepresented. This warrants recruitment of the oldest adults and measurement of 
geriatric characteristics as determinant and outcomes in future studies.
 Part 3: Frailty, multimorbidity and functional status in older adults admitted to acute 
 psychiatric wards
We conducted a clinical cohort study with a 5-year follow-up of 120 older patients, mean 
age 75 years, admitted to acute geriatric psychiatric wards, described in chapters 6 and 7.
A total of 41 patients had a depressive disorder, 41 patients had cognitive disorders with 
neuropsychiatric symptoms, 17 patients had psychotic disorders or bipolar disorders 
and 21 patients had other diagnoses (anxiety, substance use or personality disorder). 
On admission, we assessed frailty (Frailty Index (FI), walking speed (6-metre walking) 
and handgrip strength), multimorbidity (CIRS-G), functional status (Barthel Index) and 
undernutrition (Mini Nutritional Assessment (MNA)). As psychiatric measure we used the 
Clinical Global Impressions Scale at Admission (CGI-SA).
Chapter 6 describes these geriatric measures on admission and considers whether separately
they were independent predictors of:
1. the psychiatric outcome at discharge, measured with the Clinical Global Impressions 
 Improvement Scale (CGI-I) and 
2. discharge destination: favourable (able to return home or to previous care level) or 
 adverse (death or move to a higher level of residential care compared to the situation 
 before admission). 
We found that half of our patients were frail as measured with the FI, walking speed and 
handgrip strength and had at least one problem on the Barthel index. The level of the 
CIRS-G was comparable to patients who are admitted to acute geriatric wards in general
hospitals. More than 90% of the population was undernourished or was at risk of 
undernutrition. Geriatric measures were mutually correlated, but did not correlate with the 
CGI-SA. Geriatric measures did not differ between patients with different diagnoses, with 
the exception of the MNA, which was worst in patients with a depression. 
 Neither the FI, CIRS-G nor Barthel scores were separately, independent of age, sex and 
diagnosis, associated with the CGI-I. However, the FI was a strong predictor of the defi ned 
adverse discharge destination, together with walking speed and the CIRS-G. The Barthel 
Index was not predictive of either of the two health outcomes. 
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 We concluded that geriatric syndromes, complementary to psychiatric diagnoses, are 
important in understanding the – especially non-psychiatric - outcomes in geriatric psychiatry
and may help to identify patients at risk of adverse discharge destination. 
In chapter 7 we primarily investigated whether the FI independently predicts mortality within
fi ve years after admission, independent of covariates including the CIRS-G, Barthel Index, 
age, sex, level of education, diagnosis of neuropsychiatric symptoms and CGI-I. 
 We found that the FI strongly predicted mortality (HR 1.78 [95% CI 1.06 – 2.98]), indepen-
dent of covariates. 
 In secondary analysis, we found neither walking speed, handgrip strength nor the 
MNA separately to be predictive of mortality, when adjusted for the same covariates. 
 We concluded frailty may be helpful in targeting inpatient psychiatric treatment and 
aftercare according to patients’ life expectancy.
8
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GENERAL DISCUSSION
This general discussion starts with an epilogue on our case history and the outlines of our 
hypotheses. Secondly, I will evaluate the methodological issues of this thesis. I will then 
refl ect further on the outcomes we have found, and fi nally I will consider the implications 
of our results for clinical practice and future research. 
 1. Our case history: starting point of our hypotheses
 Epilogue
Mrs A improved within 2 months after initiating treatment: her depressive mood, anxiousness, 
suspicion, weight, ADL and mobility improved considerably. She took up enjoyable activities, 
with the help of her lady companion. 
  Nevertheless, her treatment trajectory was complicated by polymyalgia rheumatica 
(PMR), which at first sight was mistaken for a relapse of her depressive disorder, but was 
recognised in an extra visit to our outpatient clinic and treated immediately, resulting in 
fast remittance of the PMR and further improvement in her general condition and quality 
of life. 
  However, six months later, it became clear that, although the depressive disorder was 
still in remission, the memory complaints were deteriorating slowly, as well as the capability 
to perform household tasks, confirmed by cognitive tests and a second visit by our occupational
therapist. Mrs A was then diagnosed with dementia, probably of vascular or combined 
vascular/Alzheimer’s origin.
We presented Mrs A as an example of a frail person with associations of geriatric syndromes 
and multimorbidity with psychiatric symptoms. I will refl ect on her more extensively in 
3.2. As much of the occurrence and impact of geriatric syndromes and multimorbidity in 
patients like Mrs A was found to be still unknown, this inspired us to start our research in 
clinical practice. 
 Overall, our hypothesis that multimorbidity and geriatric syndromes frequently occur in 
association with psychiatric disorders in older adults was confi rmed. We were also able to 
confi rm the hypothesis that these characteristics are predictive of negative health outcomes 
at discharge (multimorbidity and frailty) and mortality within fi ve years after admission 
(frailty). Our systematic review could neither confi rm nor reject that multimorbidity or geriatric 
syndromes predict outcomes in RCTs on antidepressants, as these variables where hardly 
taken into account. 
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 2. Refl ections on methodology
Observational studies, both cross-sectional and cohort studies, exploring patient charac-
teristics and possible predicting variables for outcomes, necessarily precede intervention 
studies. As there were as yet few studies on multimorbidity and geriatric syndromes in 
older persons with psychiatric disorders, we had to restrict ourselves to these two study 
designs. We added a systematic review to check whether and how geriatric characteristics 
are taken into account in RCTs on anti-depressant drug treatment. These studies are all 
complementary to one another and provide a broad picture of the relevance of multimor-
bidity and geriatric syndromes in geriatric psychiatry, but also the lack of attention for 
these characteristics. 
 2.1 Time perspective
During our quest, we carried out four different studies over a 10-year period: two cross-
sectional studies: the pilot study on MUS (2006), followed by the OPUS study (2010-
2014); a Systematic Review (2012-2013) and a prospective cohort study, with a fi ve-year 
follow-up (2010-2016). 
 This implicated a lengthy trajectory of my research and time to publication. This would 
make it likely that results are no longer relevant or outdated, but this is not the case.
 MUS in older adults has only been studied by our own research group. Of the geriatric 
syndromes we studied, especially frailty has been studied, but almost exclusively in relation 
to depression. Multimorbidity is defi ned as a challenge, but is not yet a generally investi-
gated subject in psychiatry.1
 2.2 Research in clinical practice: strengths and limitations
The fi rst strength of our research lies in answering questions that are relevant in the 
clinical practice of older patients. Secondly, we were the fi rst to perform studies on multi-
morbidity and geriatric syndromes in older patients with MUS and different psychiatric 
disorders. We have therefore added substantial, clinical knowledge to the fi eld of geriatric 
psychiatry, offering a novel perspective on older patients with psychiatric disorders. Thirdly, 
we included patients with different psychiatric disorders, which broadens the relevance of 
our fi ndings to many patients with psychiatric disorders. Finally, the data collection was 
duly complete in all the studies.
 But of course, our cross-sectional and follow-up cohort studies, performed in clinical 
practice, also have limitations, which we covered in our articles. In short, data collection 
was conducted by clinicians, with the risk of data collection bias; in both studies there was 
patient selection bias. In our pilot study, the number of patients was small, consequently 
the statistical power was limited and we were unable to take covariables into account in 
the comparison of patients. In our cohort study, with a larger patient sample, the broad 
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range of psychiatric disorders hampered the possibility to analyse the predictive value of 
variables for patients with different diagnoses and the study had limited power to analyse 
the predictive value of all our possible predictors. 
 These limitations are not all applicable to the OPUS study. Data collection was 
performed by well-trained and supervised researchers. Moreover, we were able to include 
a suffi cient number of patients for multivariate analysis. We included persons with mild as 
well as severe conditions of MUS, but we were unable to preclude patient selection bias 
as the recruitment process differed between settings (population, primary care, secondary 
mental & geriatric care). 
 The systematic review has its own strengths as it was conducted according to the 
PRISMA quality standards,2 including assessment of the quality of the included RCTs 
based on the Cochrane criteria.3 The review design was registered in PROSPERO (number 
CRD42014007300). 
Specifi c considerations are necessary with regard to our cohort study. This study was 
originally designed as an observational study to measure prevalence of undernutrition and 
mobility problems in patients who were admitted to our acute wards. 
 We broadened the research questions after data collection to a prospective cohort 
study with outcome measures at discharge and mortality within fi ve years after admission. 
As we had not foreseen this possibility of our extensive data collection, we had to add two 
variables in retrospect:
1. We developed the Frailty Index with the data we had prospectively collected. We did use 
 the procedure recommended for a Frailty Index construction.4 Regarding the predictive 
 value of our FI for the outcome measures, we may conclude that we have succeeded in 
 constructing an adequate FI.5,6
2. We had to construct a general psychiatric outcome measure. The Clinical Global 
 Impression (CGI) is frequently used prospectively in outcome studies.7,8 However, 
 the scores had to be assigned retrospectively, which is not usual, but has been carried 
 out previously,9 based on admission reports and discharge letters. We have used an 
 expert panel to score the CGI-I. Expert panels are usually set up for diagnostic tests. 
 The procedure we used is in line with recommended procedures for diagnostic tests.10,11
 3. Refl ections on study outcomes
I have chosen to keep these refl ections in line with the order of chapters in my thesis. I will 
refl ect on the most remarkable and clinically relevant fi ndings in 3.1 - 3.3.  In the case of 
geriatric syndromes in depression, I have searched for recent research to fi nd out whether 
it sheds new light for patients like Mrs A. Finally, I will refl ect on the clinical implications 
of our study results and briefl y on the research implications of our research in 3.4. and 3.5
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 3.1 Geriatric and psychiatric characteristics in patients with 
  medically unexplained somatic symptoms and somatoform disorders
Generally, at the time we started our research, MUS meant unexplained somatic symptoms 
and were linked to psychiatric diagnoses, while MES were linked to somatic diagnoses.12
 We believed that this kind of perspective was not adequate for older persons; we 
hypothesised that medically unexplained symptoms are not always as unexplained as they 
seem. We expected frailty and multimorbidity to be present in patients with MUS, but also 
co-occurrence of psychiatric diagnoses such as depressive and anxiety disorders in addition 
to somatoform disorders. Our pilot study confi rmed these hypotheses. 
Complex, ‘diffi cult patients’
It may be found surprising that patients with partially explained symptoms were referred 
to our clinic, but we have to realise that our referred patients are the most complex ‘diffi cult 
patients’ for doctors. They have chronic health problems, visit their general practitioner 
frequently, have psychiatric diagnoses and functional impairment.13-15 They are often 
unsatisfi ed with the consultations with their doctors.15,16 For general practitioners it is hard 
to disentangle their ‘Gordian knots’, not in the least because of the lack of time.
 Moreover, it is by no means easy to link a symptom to a specifi c disease,12,17 or diagnose 
a symptom as MUS or MES.18,19 The mean number of symptoms in our study population was 
6, which is not uncommon for older adults,20,21 but makes it diffi cult to attribute symptoms 
to conditions. Most patients had a depressive or anxiety disorder and these disorders are 
associated with the number, (rather than the nature) of somatic symptoms of patients in 
primary care and are often underdiagnosed.22,23
The patients with partly explained symptoms have a surplus of complexity: they had a high 
level of multimorbidity, but of moderate severity, which makes it even more diffi cult to link 
symptoms to specifi c diseases. In addition, these patients had moderate gait speed and 
handgrip strength, which indicates a (pre-)frailty state,24 again adding to complexity.25,26
MUS, multimorbidity and frailty
In our pilot study we differentiated between two different subpopulations: the relatively 
young and fi t patients with unexplained symptoms and the older, less healthy patients, 
with partially explained symptoms, who fi t with the picture of older adults with a combination
of multimorbidity, frailty (although of a moderate level) and functional impairment.6,24,25 
 The OPUS study included a broad range of persons with MUS, with overall a moderate 
level of frailty and multimorbidity. 
We presume that the pilot subpopulation with ‘partially explained symptoms’ formed a 
substantial part of the OPUS MUS population, representing the most diffi cult patients as 
described above. Frailty may not be recognised and according to the theory of ‘Frailty Identity 
Crisis’, not understanding or denial of frailty may lead to – in the view of the physician – exces-
sive health-seeking behaviour and thus identifying this kind of patient as an MUS patient.27 
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We advise to make use of the concept of ‘medically insufficiently explained somatic 
symptoms’, rather than ‘medically unexplained somatic symptoms’. It fi ts better in older 
persons as this includes the patients with partially explained somatic symptoms as in our 
pilot study. This would also be in line with the change in de DSM 5, where the burden of 
symptoms is essential and not them being unexplained or not.66
Measurement scales for MUS and hypochondria
Contrary to our hypothesis, the patients with ‘partially explained symptoms’ although having 
a higher disease burden, tended to ‘worry’ less (hypochondriac cognitions) about their 
health, as measured with the Whiteley Index. The same pattern was found in the OPUS 
study: the MUS population scored higher on the Whitely Index than the MES population. 
This is actually in line with the concept of somatisation, where excessive worrying – hypo-
chondria - is a core symptom.28,29 
 These results indicate that the Whitely index can be used as measure for somatisation 
in older adults, although we should remain aware that persons with substantial medical 
conditions may have reason to worry about their general health condition.  
 The other somatisation questionnaires we used, the PHQ-15 and BSI-53-SOM, are 
based on the number of somatic symptoms. These scales were originally designed to 
measure the most prevalent somatic symptoms in primary care, which in younger persons 
were frequently unexplained30 (but less so in older adults31) and were based on the fact 
that the more somatic symptoms persons have, the higher the prevalence of psychiatric 
disorders.23 A recent review found that few physical symptom-based scales are validated in 
older persons with MUS and that there is a substantial overlap with symptoms of geriatric 
syndromes.32
 This means that we have to be aware that somatic symptom-based questionnaires 
based on the number of symptoms are two sided coins: they measure somatic symptoms 
that could be linked to somatic conditions, but that could also be linked to psychiatric 
disorders. This means the can only be use in the individual patient’s perspective.
 3.2 Geriatric characteristics in randomised controlled trials on antidepressants
Our systematic review led to the conclusion that frailty, multimorbidity, disability, cognitive 
dysfunction and undernutrition were rarely taken into account in RCTs with antidepressant 
drugs for major depressive disorder. We were therefore unable to analyse their effect on 
treatment outcomes. 
 The question must then be asked whether there have been any developments relevant 
for patients like Mrs A since the publication of our systematic review. 
From nutritional status, sarcopenia... 
Cross-sectional studies on undernutrition and depression still confi rm the positive associ-
ation between undernutrition and depression in older adults.33,34 However, there has been 
greater focus on positive and reciprocal associations between depression and obesity in 
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cross-sectional and longitudinal studies.35-37 This surprised me, because of the U-shaped 
association between depressive symptoms and BMI in the general population, with two 
notable fi ndings: the amount of obese persons is by far larger than the number of under-
weight persons, but the average severity of depressive symptoms was much higher in the 
underweight group.92
 By a back door, we return to undernutrition and frailty as in the last fi ve years, ‘sarcopenic 
obesity’38 has been found to be related to prevalence39, onset of depressive symptoms40
and non-remission of depressive disorders41 in older adults. Sarcopenia, which we also 
ascertained in mrs A, is a progressive and generalised skeletal muscle decline with low 
muscle strength as the core criterion. Handgrip strength is used as a screening instrument 
for sarcopenia and walking speed or the TUG are used as a measure for physical performance,
indicating the severity of sarcopenia.42 Obviously, sarcopenia and frailty are closely connected
and overlap.42,43 Sarcopenia is as well associated with inactivity, undernutrition as with 
obesity, 42,44,45 and also with depressive symptoms.46,47 It increases with older age and is 
associated with adverse health outcomes.42 Finally, it helps to realise that underweight is 
not the same as undernutrition and overweight or obesity do not preclude undernutrition.48 
… to frailty
There is increasing evidence of an association between frailty and prevalence or severity of 
depressive symptoms (and to a lesser extent depressive disorders).49
 The association is found to be strongest in cross-sectional studies49-53 and to a lesser
extent in longitudinal studies, in which frailty is found to predict depressive symptoms49,54-56 
and vice versa.49,57-59
 Almost all studies on frailty and depression are based on Fried’s Physical Frailty Phenotype
(PFP) model.24 There is discussion on the nature of the association between the PFP and 
depression, as the fi ve items in the PFP are also symptoms of depressive disorders. They can 
be seen as overlapping phenomena and as such the PFP can also be seen as a two-sided coin. 
Slow gait speed is an example. From 2005 onwards, it was found to be linked to depressive 
disorders in older persons, possibly linked with vascular diseases and/or white matter 
lesions.60-65 Psychomotor retardation is also one of the symptoms of a depressive disorder. 
The same is true for weight loss, fatigue and loss of energy.66 
 In addition the combination of low gait speed, low HGS and level of activity were found 
to be predictive of non-remission of depressive disorders54,67, but also the combination of low 
gait speed and cognitive dysfunction.68
 Overall, we hypothesise that frailty and depression are two separate, but often
co-occurring and co-infl uencing phenomena, in line with Brown, who regards ‘the charac-
teristics of frailty in adults with late life depression to represent the clinical manifestations 
of greater biological aging’. They are risk factors for one another and when both are present
they add to the risk of adverse health outcomes such as nursing home placement or 
mortality.69-71 Potentially underlying common causes include infl ammation, mitochondrial 
dysfunction and dopamine defi ciency.72,73
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Multimorbidity, functional status and cognitive dysfunction
In addition to ongoing research on the reciprocal associations of diabetes mellitus, cardio-
vascular diseases and depression,74,75 in recent years there has been a growing interest in 
the association between multimorbidity and depression or depressive symptoms. 
Multimorbidity includes psychiatric diseases76-79, specifi c disease clusters with depression
and pulmonary diseases, anxiety disorders, somatoform disorders, musculoskeletal diseases, 
cardiovascular diseases and diabetes are found.78,80,81
 The risk of depression or depressive symptoms is shown to be twice as high in persons 
with multimorbidity as compared with patients without multimorbidity.82 
 The lack of treatment studies taking functional status into account in depression is 
refl ected by the fact that very few functional assessment instruments have been validated
in late life depression,83 instead of ongoing evidence that treatment outcomes of depression 
are associated with functional impairment84,85 and long after patients themselves judged 
recovery to normal daily functioning one of the most important outcomes for depression 
treatment.86 
 There is new evidence for the relevance of cognitive dysfunction as an outcome measure 
in depressed patients because it often persists, even after remission of a depression.87
It is also relevant as a predictor of treatment outcomes in depression87-89 and new studies 
show that late life depression in particular is predictive of incident dementia.90 Treatment 
of depression is not yet found to reduce this risk.91
Back to Mrs A 
All this new research has confi rmed or shed new light on the associations between geriatric 
syndromes and depression, but it has not yet been translated into treatment studies. 89
 Mrs A shows us the clinical reality of a frail patient with a depression: she had not one 
geriatric syndrome, but all four at the same time. This is quite usual, as they overlap. Her 
seemingly minor somatic problem, hammertoes, impaired her mobility severely, leading 
to inactivity and sarcopenia, frailty and functional loss, later accompanied by depression 
and undernutrition, showing a cascade and intermingling of problems. 
 Nevertheless, maybe against expectations, the integrated treatment trajectory has added 
to her quality of life, as her mood, anxiety, nutritional status, mobility, condition, social and 
overall functioning improved initially. 
 In the end, the diagnosis of dementia had to be added, which is an example of the 
association between depression, cognitive dysfunction, dementia and cerebral vascular 
damage. But also of the diffi culty in diagnosing the cause and predicting the course of 
cognitive dysfunction in patients like mrs A. 
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 3.3  An acutely admitted clinical population in geriatric psychiatry: a frail population
Geriatric characteristics and the association with psychiatric measures
As we hypothesised, the acutely admitted population was strikingly frail, undernourished
and had a high level of multimorbidity. The high prevalence of undernutrition in our
population, more so in the depressed patients, might be a confi rmation of the earlier 
mentioned U-shaped curve, that underweight is associated with more severe depressive 
symptoms than overweight or obesity.92 This potential interaction requires further study.
 The mean level of the CGI at admission was 5.2. This means markedly ill and not severely
or extremely ill;8,93 this surprised us, because only the persons with the most severe 
psychiatric symptoms are admitted to acute wards in a mental hospital. But consider 
examples of the reasons for admission: ‘Mr B lies in bed and can’t take care of himself’, 
or ‘Mrs C has lost 15 kilograms of weight and we can’t take care of her in the outpatient
setting anymore’. Now that we have studied these patients, we can see that geriatric 
syndromes and multimorbidity added implicitly and substantially to the reason for admission,
aggravating total symptom burden at admission beyond the impact of psychiatric symptoma-
tology alone.
 Contrary to our hypothesis, the severity of the geriatric syndromes was not correlated 
with the severity of the psychiatric symptoms at admission. This means that the geriatric 
syndromes are on the one hand highly prevalent in our patients, but at the same time 
should be regarded as phenomena in themselves, mutually correlated, requiring specifi c 
geriatric interventions. 
 Also contrary to our hypothesis, but in line with the above-mentioned result, neither 
geriatric syndromes nor multimorbidity were predictive of the psychiatric outcome at 
discharge, although we had an indication that the FI was a predictor of less improvement in 
patients with a depressive disorder. However, as the subpopulation was small, we considered
it was not justifi ed to show this result in our article.  
Frailty, multimorbidity and functional status and general health outcomes
We hypothesised that a substantial number of patients would have to move to a higher level
of residential care, compared to the situation before admission, and that the mortality rate 
in our study population would be notably high. These presumptions were confi rmed, but 
the results were more serious than we expected.  
 We could confi rm the predictive value of frailty and multimorbidity for adverse discharge
destination and mortality. This is in line with earlier studies (introduction) and more 
recent longitudinal studies of depression69-71,94-96 and with some studies on other psychiatric 
disorders.97,98
 Overall, we conclude that the predictive value, especially of frailty, on these health out-
comes is as strong in a population of older adults who are acutely admitted to psychiatric 
wards, as in general populations and in medical hospital populations. Although we are 
aware that our study population does not represent all older inpatients with psychiatric 
disorders, we have shown that these patients exist and are a highly vulnerable population.
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3.4  Implications for clinical practice
Patients presenting themselves with several different medical symptoms, presumed medically 
explained or unexplained, are complex and clinicians should be aware of the possible presence
of psychiatric disorders, geriatric syndromes and multimorbidity. Our experience is that 
these patients are often unaware of the chronic conditions they have, why medication has
been prescribed and do not know how to cope with their conditions. Taking the time to explain
‘what is wrong and what could be done about it’, is the fi rst step towards acceptance of 
and adherence to treatment recommendations. 
 It would be best to address geriatric syndromes and multimorbidity in outpatient care 
because these problems can get out of hand, resulting in severe consequences. Intervention 
at an early stage could probably even prevent admission to psychiatric wards. In brief, 
intervention starts with diagnosing and detecting underlying treatable causes of geriatric 
syndromes and multimorbidity. Treating frailty with undernutrition and sarcopenia with 
adequate protein/caloric intake and a physical activity programme with a resistance-based 
training component are proven core interventions for frailty99,100 and can even address 
depressive symptoms as a ‘side-effect’.101
We have shown in our inpatient population that patients with other psychiatric disorders 
than depression are not spared the burden of geriatric syndromes or multimorbidity. It is 
likely that outpatients, for example with psychotic or bipolar disorders, do not only suffer 
from multimorbidity, but also that inactivity102,103 leads to sarcopenia, frailty or functional 
impairment. 
Frailty and multimorbidity, if irreversible despite treatment, can help in targeting 
psychiatric treatment based on patients’ expected health outcomes and life expectancy. 
 Screening Instruments
For awareness purposes and to obtain an indication of the presence and severity of 
geriatric syndromes and multimorbidity, we recommend the use of easy-to-apply screening 
instruments in geriatric psychiatric settings. 
 For frailty, we advise the use of walking speed to obtain a quick impression of possible 
frailty. Our three clinical studies underline the value in an older psychiatric population. The 
second recommendation is the use of the Clinical Frailty Scale. It is a short 9-point screening
instrument, validated against an FI, the CIRS-G and a functional assessment scale in a 
general population,104,105, but not yet in geriatric psychiatry. It contains short descriptions 
of older adults, including impressions of ADL, IADL and physical fi tness and is easy to 
apply in the consultation room. 
For an impression of multimorbidity, we recommend that the physical record and medi-
cation list of the general practitioner in the medical record should be taken over. This gives 
a general overview of possible multimorbidity, actual diseases and polypharmacy. 
 With regard to functional status, we have found that the Barthell Index has a ceiling 
effect in acutely admitted patients, therefore presumably this is even more the case in 
outpatients. Our advice would be to implement the WHODAS 2.0, which includes IADL 
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items, is already recommended in the DSM 5 and of which the 36-item and 12-item versions 
are validated in all age groups.66,106,107
 For nutritional status, we advise measuring length and weight for BMI and using the 
MNA-sf. 
 Beyond the scope of our research, but to complete the recommended screening 
measures, for cognitive screening we would advise the Montreal Cognitive Assessment 
(MoCA) rather than the MMSE,108 because it is more valid in the detection of mild cognitive 
impairments, probably also in psychiatry.109,110
 As an overall instrument, possibly replacing some of the separate instruments mentioned,
the TOPICS-SF could be used. This is the Patient Routine Outcome Measure for older 
patients111,112, a valid and reliable measure, advocated previously by the Dutch Geriatric Society. 
Comprehensive Geriatric Assessment and integrated, interprofessional care
Ideally, geriatricians and psychiatrists work together with other disciplines in inter-
professional teams, like the ones we used to work in. All disciplines bring their own 
knowledge, skills and responsibilities.113
 A Comprehensive Geriatric Assessment (CGA, Introduction) could be performed 
when deemed necessary, possibly including measurements such as the CIRS-G, the 
full PFP or an FI. Subsequently, all disciplines involved could make up one integrated 
treatment plan to initiate the joint recommendations for their patient.
 We had the advantage of working in one mental health care organisation at the 
time we conducted our patient care and research. But times have now changed. Policy-
makers and insurance companies have incorporated a strict partition between mental 
and somatic health care and this has been accompanied by rigorous cost cutting in 
mental health care. In this new reality, interprofessional care should be initiated between 
different collaborating organisations, including collaboration with professionals in primary
care. This is quite a challenge.
 However, there are some hopeful examples of integrated, collaborative care between 
mental health and other medical services on depression and somatic diseases, in which 
both improved signifi cantly better in the intervention than the usual care groups114-116 and 
can be cost effective.117 These initiatives should serve as an example for care in older 
adults with psychiatric and geriatric problems.      
 3.5  Implications for research
In our cohort study we used an FI, as we deemed the overlap of the PFP with psychiatric 
symptoms undesirable. Although this proved to be a good choice, I do regret that we did 
not take the opportunity to compare the two frailty models. There is debate about which 
frailty model to use in psychiatry, because of the overlap of symptoms of the PFP with 
different psychiatric disorders118. The FI has been used in two longitudinal studies on 
health outcomes in depression70,71 and recently the FI has been suggested for broader 
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use in psychiatry.119 The PFP model is easy to apply, but it is also a two-sided coin as we 
have discussed in 3.2. For this reason I recommend studies comparing the two models, 
not only in depressed patients, but also in other older patients with psychiatric disorders. 
The Clinical Frailty Scale could be validated in these studies and its feasibility evaluated.
We advise to evaluate all measures in in- and outpatient settings. 
 As suggested earlier, the potential interactions between related geriatric syndromes, 
e.g undernutrition and psychiatric disorders requires further study.
 For vulnerable, complex patients with chronic health problems who are unable to cope, 
regardless of whether the complaints are MUS or MES, integrated and interprofessional 
diagnostic and treatment trajectories could be further designed and explored. 
 We advise to transfer insights from cross-sectional and longitudinal population-based
studies to treatment studies for patients with different psychiatric disorders. These 
recommendations would mean taking topics into account that are important for patient’s 
lives and general health status. It requires the starting up and evaluating of integrated, 
interprofessional research, with study designs other than the traditional RCT. 
Meanwhile, we ourselves continue to use our databases to explore more questions. We 
have analysed the usability of the MNA-sf in geriatric psychiatry (e.g. as it contains two 
psychiatric items) and concluded that the MN-sf can be used without restrictions in mental 
health care (Heiningen, article in progress), although specifi c issues of validity and reliability
still require further research. Recent analyses have indicated that the MNA at discharge 
was predictive of mortality, in contrast to the MNA at admission (van Dulst, article in 
progress) and we also intend to compare the Charlson Index and CIRS-G in the OPUS 
population.
There is therefore a lot of work still to be done. Most of all, I hope for an inquisitive attitude 
and thinking beyond boundaries. Integrated, interprofessional patient care and research on 
a larger scale on the complex intermingling of geriatric syndromes, multimorbidity and
psychiatric disorders might improve health outcomes in our patients. We have demonstrated
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 VERHAAL VAN EEN PATIËNTE
Kennismaking
Mevrouw A was een 73-jarige getrouwde vrouw. Zij was verwezen naar onze polikliniek 
voor een gecombineerde intake door een psychiater, klinisch geriater en psycholoog. 
 De reden van verwijzing was haar sombere stemming. Ze was inactief, vermoeid en 
sliep slecht. Ze had zich teruggetrokken uit activiteiten waar ze normaal gesproken plezier 
aan beleefde, zoals bridgen en afspreken met vriendinnen. Haar eetlust was verminderd, 
waardoor ze in drie maanden tijd 10 kilo was afgevallen. Bovendien was mevrouw A in 
toenemende mate achterdochtig en angstig: ze was bang om alleen thuis te zijn en raakte 
in paniek wanneer haar echtgenoot boodschappen deed. Ze verstopte voorwerpen, omdat 
ze bang was voor diefstal. Recent viel het op dat mevrouw A moeite had met het bedienen 
van de wasmachine, dat ze niet goed meer kookte en ze vergat dingen die haar kort tevoren 
verteld waren. Doordat ze hamertenen had aan beide voeten werd ze belemmerd in haar 
mobiliteit en was ze erg in conditie achteruit gegaan. 
 Wij concludeerden dat mevrouw A een depressieve stoornis had, vergezeld van angst, 
achterdocht en cognitieve stoornissen. Een MRI scan van haar hersenen liet zien dat er forse 
witte stof afwijkingen waren. Daarnaast stelden we de aanwezigheid vast van meerdere 
geriatrische syndromen: ondervoeding, functieverlies in dagelijks functioneren, verminderde 
mobiliteit, met als gevolg verlies van spierfunctie (sarcopenie) en kwetsbaarheid, naast 
hypertensie als bijkomende chronische aandoening. 
 In ons interprofessionele team bespraken we de verschillende componenten van haar 
problemen. We stelden een uitgebreid behandeladvies op waarbij we instaken op de  
complexiteit van de interactie tussen de geriatrische en psychiatrische problemen. Om haar 
ondervoeding te behandelen stelden we voor om een diëtiste in te schakelen en in verband met 
haar hamertenen regelden we een aanpassing van haar schoenen door een podotherapeut,  
nadat we hierover met haar eigen orthopeed overlegd hadden. Om haar depressieve stoornis 
te behandelen stelden we voor een antidepressivum te starten, aanvullend op ondersteuning 
door een sociaal psychiatrisch verpleegkundige (SPV) om haar te leren met haar angst om 
te gaan en om haar en haar echtgenoot te adviseren hoe huishoudelijke taken in te vullen.
 Mevrouw A en haar echtgenoot volgden onze adviezen op, met uitzondering van het 
inroepen van ondersteuning door de SPV. Zij gaven er de voorkeur aan om zelf iemand in 
te schakelen die activiteiten met mevrouw A zou kunnen ondernemen en haar zou kunnen 
ondersteunen wanneer haar echtgenoot niet thuis was. Zij stemden wel in met een consult 




VERHAAL VAN EEN PATIËNTE 
Het verloop van de behandeling
Mevrouw A knapte binnen twee maanden na start van de behandeling op: haar stemming, 
angst en achterdocht verbeterden. Ze kwam aan in gewicht, deed weer meer zelf en werd 
mobieler. Ze pakte met hulp weer activiteiten op en haar kwaliteit van leven verbeterde.
Echter, haar behandeltraject werd gecompliceerd door een polymyagia reumatica
(‘spierreuma’). In eerste instantie werd gedacht aan terugkeer van haar depressieve 
symptomen, maar na een bezoek aan onze geriatrische poli werd dit herkend en behandeld. 
Patiënte knapte opnieuw op. 
 Desalniettemin werd na zes maanden duidelijk dat, ondanks het opknappen van de 
depressie, de geheugenproblemen verslechterden, net zoals de capaciteit om zelf huishoudelijke
taken uit te voeren. Neuropsychologisch onderzoek en een tweede bezoek door onze ergo-
therapeut bevestigden de achteruitgang. We stelden daarom de diagnose dementie vast, 
die al langer op de loer lag. Het ging waarschijnlijk om een gecombineerde Alzheimer/







Mevrouw A was een hoog complexe patiënte, met meerdere gezondheidsproblemen in het 
somatische (lichamelijke), psychische, sociale domein én in haar dagelijks functioneren. 
Zij is een voorbeeld van kwetsbare oudere mensen met een opeenstapeling van geriatrische 
syndromen, die interacteerden met haar depressieve stoornis. We hebben een geïntegreerde, 
interprofessionele benadering gekozen om al haar problemen zoveel mogelijk tegelijkertijd 
aan te pakken. Deze manier van werken is niet gebruikelijk in de ouderenpsychiatrie, terwijl 
die voor ons, zo vanzelfsprekend was. 
 In de praktijk zagen we regelmatig patiënten zoals mevrouw A. Ons onderzoek is dan ook 
geïnitieerd vanuit en uitgevoerd in de klinische praktijk. Wij hebben exploratief onderzoek
gedaan, omdat geriatrische syndromen en multimorbiditeit binnen de ouderenpsychiatrie 
nog onontgonnen terrein waren. 
 Doel van het onderzoek
Het doel van onze studies was de prevalentie van en verbanden tussen geriatrische 
syndromen en multimorbiditeit bij oudere volwassenen met psychiatrische stoornissen te 
onderzoeken én wat de impact ervan is op behandeluitkomsten. 
Veel lezers van deze Nederlandse samenvatting zijn waarschijnlijk niet ingevoerd in de 
begrippen en de meetschalen die ik in mijn onderzoek heb gebruikt. Daarom begin ik met 
een korte uitleg voordat ik de samenvatting inzet.
 Lichamelijke klachten
Naarmate mensen ouder worden ontstaan er meer lichamelijke klachten en wordt het 
steeds lastiger om uit te maken of deze klachten toe te schrijven zijn aan lichamelijke ziekten
of niet. Soms kan men de oorzaak van klachten niet achterhalen en spreekt men van 
‘onverklaarde lichamelijke klachten’: klachten waarbij na adequaat medisch onderzoek geen 
onderliggende ziekte gevonden wordt die de klachten voldoende verklaren. Onverklaarde 
klachten zijn verbonden met het concept van ‘somatisatie’: de neiging vast te houden 
aan het zoeken naar een lichamelijk verklaring voor deze klachten en daar ook telkens 
weer medische hulp voor te zoeken. De mate van somatisatie wordt gemeten met twee 
soorten meetschalen: enerzijds wordt gekeken naar het aantal en de ernst van lichamelijke 
klachten die iemand heeft, anderzijds naar de mate van bezorgdheid die mensen over hun 
klachten hebben. In ons onderzoek gebruikten we voor aantal en ernst van lichamelijke
klachten de Somatic Symptoms Severity Scale van de Physical Health Questionnaire 
(PHQ-15) en de kortere Brief Symptoms Inventory (BSI-53). Voor de mate van bezorgdheid 
gebruikten we de Whitely Index (WI). 
170
CHAPTER 9
 Tijdens ons onderzoek is het harde ‘onverklaard’ over gegaan naar het zachtere concept 
‘onvoldoende verklaard’: de klachten kunnen niet volledig, maar regelmatig wel deels, 
worden verklaard vanuit een bekende medische oorzaak. Zoals uit ons onderzoek zal blijken, 
sluit dit beter aan bij de oudere patiënt. 
 Wanneer iemand langer dan 6 maanden onvoldoende verklaarde lichamelijke klachten 
heeft en die klachten resulteren in een hoge mate van sociale, werkgerelateerde of functi-
onele beperkingen, werd dat tijdens ons onderzoek in de psychiatrie als een somatoforme 
stoornis gediagnosticeerd. 
 Comorbiditeit en multimorbiditeit
Wanneer er een oorzaak voor lichamelijke klachten wordt gevonden heeft iemand een aan-
doening of ziekte. In de psychiatrie is er veel aandacht voor specifi eke ziekten naast een 
psychiatrische stoornis, ook wel comorbiditeit genoemd. In de geriatrie heeft er geleidelijk 
een verschuiving plaatsgevonden: van aandacht naar comorbiditeit is er nu meer focus op 
het hebben van multipele (twee of meer) chronische ziekten: multimorbiditeit, chronische 
ziektelast. Dat komt bij 55% tot 98% van oudere mensen voor en blijkt vaak relevanter 
dan te focussen op specifi eke ziekten. Comorbiditeit wordt gemeten met bijvoorbeeld de 
Charlton Comorbidity Index en multimorbiditeit met de Cumulative Illness Rating Scale 
for Geriatrics (CIRS-G).
 Geriatrische syndromen
Een geriatrisch syndroom presenteert zich als een atypisch, meestal enkelvoudig symptoom.
Deze komen vaak voor bij oudere mensen. Ze worden door heel verschillende onder-
liggende problemen veroorzaakt, die regelmatig ook nog tegelijkertijd aanwezig zijn. Een 
voorbeeld is ondervoeding: dat kan voorkomen bij een depressie door verminderde eetlust, 
bij een chronische longziekte, omdat de ziekte veel energie vraagt, of bij cognitieve stoor-
nissen, omdat iemand vergeet om te eten. Het gevolg van geriatrische syndromen is dat 
mensen minder weerstand hebben tegen ziekten of veranderingen. 
 Een overkoepelend geriatrisch syndroom is kwetsbaarheid (engels: frailty): het hebben 
van een verminderde reservecapaciteit. Zo heeft iemand die kwetsbaar is een grote kans 
om in de war te raken (delier) bij een urineweginfectie. Kwetsbaarheid kent twee ‘modellen’. 
 Het eerste is een fysiek model, uitgewerkt in het Physical Frailty Phenotype (PFP) van 
Fried, dat bestaat uit de volgende items: loopsnelheid, handknijpkracht, vermoeidheid, 
laag activiteitsniveau en gewichtsverlies. De mate van kwetsbaarheid wordt uitgedrukt 
in een score van 0 - 5: 0 betekent dat iemand robuust is en 5 heel kwetsbaar. Van de PFP 
criteria worden trage loopsnelheid, lage handknijpkracht en gewichtsverlies (geoperatio-
naliseerd als ondervoeding) ook als afzonderlijke maat voor kwetsbaarheid gebruikt. 
 Het tweede model van kwetsbaarheid is dat van de ‘accumulation of defi cits’ van 
Rockwood; naarmate mensen in de loop van het leven steeds meer ‘defi cienties’ (beperkingen, 
schade, ziekten) oplopen worden zij kwetsbaarder. Dit wordt gemeten met een Frailty 
Index (FI), die van 0: robuust, tot 1 kan lopen: erg kwetsbaar. Een score tot 0.08 wordt als 




In ons onderzoek hebben we zowel de PFP criteria met loopsnelheid, handknijpkracht en 
ondervoeding als aparte parameters alsook een FI gebruikt.
De geriatrische syndromen waar wij onderzoek naar gedaan hebben zijn: 
 1.  kwetsbaarheid; 
 2.  functionele achteruitgang: verlies van vermogen om dagelijks goed te kunnen functio-
  neren in zelfzorg en huishouden (engels: functional impairment). Wij gebruikten 
  de Barthel Index om basale zelfzorg te meten, de Groningen Activiteiten Restrictie 
  Schaal (GARS) om naast basale ook meer complexe activiteiten te meten én de 
  Sickness Impact Profi le schaal (SIP) waarmee het dagelijks functioneren in heel brede
  zin kan worden vastgesteld (sociale activiteiten of slaap worden bijvoorbeeld mee-
  genomen); 
 3.  verminderd cognitief functioneren, bijvoorbeeld achteruitgang in geheugen, taalvaar-
  digheid, planning (engels: cognitive dysfunction). Dit werd gescreend met de Mini 
  Mental Status Examination (MMSE); 
 4.  ondervoeding (engels: under- of malnutrition). De voedingsstatus stelden we vast 
  met de Mini Nutritional Assessment schaal (MNA).
Geriatrische syndromen en multimorbiditeit zijn geassocieerd met elkaar en hebben veel 
impact op kwaliteit van leven en gezondheidsuitkomsten, zoals verpleeghuisopname of 
overlijden. Om ‘geriatrische syndromen en multimorbiditeit’ niet veelvuldig te herhalen in 
de tekst vatten we deze beide begrippen regelmatig samen met de overkoepelende term 
‘geriatrische karakteristieken’.
 Samenvatting 
Ons onderzoek is ingedeeld in drie onderdelen en bestaat uit vier verschillende studies. 
 Deel 1: Geriatrische en psychiatrische karakteristieken van oudere volwassenen met
 ‘onverklaarde’ lichamelijke klachten en somatoforme stoornissen 
In hoofdstuk 2 beschrijven wij kwetsbaarheid, lichamelijke klachten en multimorbiditeit bij 
oudere volwassenen die verwezen waren naar onze polikliniek voor onverklaarde lichamelijke
klachten. Eerst hadden we drie patiënten uitgesloten van verder onderzoek, omdat zij 
wél een duidelijke verklaring voor hun klachten hadden. Er werd onderzocht of de klacht 
waarmee de overige 32 patiënten zich presenteerden, inderdaad onverklaard of deels 
verklaard waren. Vervolgens keken we of dit geassocieerd was met verschil in kwetsbaarheid 
(handknijpkracht en loopsnelheid); multimorbiditeit (CIRS-G); functionele status (GARS) 
en niveau van somatisatie, in dit geval de mate van bezorgdheid (WI).
 De helft van de patiënten had daadwerkelijk een onverklaarde primaire klacht en de 
andere helft een primaire klacht die deels medisch verklaard kon worden. Deze laatste 
patiënten hadden een lagere loopsnelheid, lagere handknijpkracht, een hogere mate van 
multimorbiditeit en waren meer beperkt in het dagelijks functioneren dan de patiënten die 
een volledig onverklaarde klacht hadden. Deze laatste patiënten hadden juist een hoger 
172
CHAPTER 9
niveau van somatisatie (WI) dan de groep patiënten met een deels verklaarde primaire 
klacht, maar dit was net niet statistisch signifi cant. 
 Onze conclusie was dat geriatrisch assessment een toegevoegde waarde heeft in het 
diagnostische traject bij ouderen die met veronderstelde onverklaarde lichamelijke klachten 
verwezen worden, ook wanneer de klachten al jaren bestaan. De ‘onverklaarde’ klachten 
kunnen deels in het licht gezien worden van kwetsbaarheid en multimorbiditeit en zijn 
vaak niet echt onverklaard. 
Hoofdstuk 3 beschrijft dezelfde 32 patiënten als in hoofdstuk 2. Ditmaal richtten wij ons 
op ernst van de somatische klachten als maat voor somatisatie (PHQ-15) en op de impact 
van de primaire klacht op functioneren in brede zin (SIP). Daarnaast werd de aanwezigheid 
van psychiatrische stoornissen onderzocht. 
De PHQ-15 score was middelmatig, maar de impact van de primaire klacht op het dagelijks
functioneren was hoog. Bij alle patiënten werd een somatoforme stoornis gediagnosticeerd. 
Meer dan de helft van de patiënten had ook een depressieve stoornis en een derde
deel een angststoornis. De patiënten met een depressieve stoornis hadden méér en 
ernstigere lichamelijke symptomen en de klachten hadden een hogere impact op het 
functioneren dan die van patiënten zonder depressieve stoornis. 
 Wij concludeerden dat het identifi ceren van de psychiatrische stoornissen bij oudere 
mensen met ‘onverklaarde’ lichamelijke klachten relevant is, naast het identifi ceren van de 
eventuele lichamelijke oorzaak van de klachten. 
In hoofdstuk 4 onderzochten wij 118, breed geïncludeerde oudere volwassenen met 
onverklaarde lichamelijke klachten (MUS) en 154 oudere volwassenen met medisch 
verklaarde klachten (MES) uit huisartsenpraktijken in de ‘Older Persons with Unexplained 
Symptoms studie’ (OPUS). In deze studie hebben we geen onderscheid meer gemaakt 
tussen mensen met strikt onverklaarde of deels verklaarde klachten en zijn beiden vertegen-
woordigd in één groep: mensen met MUS. We vergeleken de MUS en MES groepen op:
fysieke kwetsbaarheid (PFP items), comorbiditeit (Charlson Index), het aantal voor-
geschreven medicijnen én op somatisatie (de ernst van lichamelijke symptomen, BSI-53). 
 De kans om kwetsbaar te zijn bleek drie keer zo hoog voor de mensen met MUS dan 
voor degenen die MES hadden. De mensen met MES hadden daarentegen een hoger niveau 
van somatisatie én meer lichamelijke ziekten dan de mensen met MUS, maar toch kregen 
beide groepen evenveel medicijnen voorgeschreven. 
 In de subpopulatie met MUS was het niveau van somatisatie geassocieerd met kwets-
baarheid, somatische comorbiditeit en een hoger aantal voorgeschreven medicijnen.
 De conclusie was dat MUS een uitdagend probleem is, met name naarmate mensen 
ouder zijn kunnen MUS gepaard kan gaan met kwetsbaarheid en kunnen MUS en MES 
verweven zijn. 
 Gebaseerd op de resultaten van hoofdstuk 2, 3 en 4 suggereren wij dat kwetsbaarheid en 
multimorbiditeit beschouwd moeten worden als potentiële verklaring voor non-specifi eke 




instantie onvoldoende verklaren waarom iemand zoveel last heeft, maar die wél adequate 
diagnostiek en behandeling behoeven. Een parallel interprofessioneel diagnostisch traject 
kan tot een geïntegreerd behandelplan leiden dat recht doet aan de complexiteit van deze 
oudere volwassenen. 
 Deel 2: Geriatrische karakteristieken in gerandomiseerde, gecontroleerde onderzoeken 
 met antidepressiva 
In hoofdstuk 5 beschreven wij de uitkomsten van onze systematische review. Wij onder-
zochten of kwetsbaarheid, somatische comorbiditeit, functionele status, cognitief (dys)
functioneren en ondervoeding meegenomen waren in gerandomiseerde gecontroleerde 
onderzoeken (RCTs) naar behandeling met antidepressiva, bij patiënten met een depres-
sieve stoornis van 60 jaar of ouder. Er werden 27 studies geïncludeerd. 
 Kwetsbaarheid en ondervoeding werden in het geheel niet meegenomen in de onder-
zochte studies. Functionele status werd meegenomen als uitkomstvariabele in vijf studies. 
Substantiële somatische comorbiditeit was reden voor exclusie in 20 studies en slechts 
twee studies includeerden expliciet een populatie met serieuze somatische comorbiditeit. 
Zes studies beschreven cognitief functioneren met behulp van de Mini Mental Status 
Examination (MMSE) als baseline variabele. Cognitief functioneren was de enige variabele 
die als co-variabele (n = 3), als stratifi catie variabele (n = 1) of als uitkomstvariabele (n = 7) 
werd meegenomen. 
 De conclusie was dat geriatrische karakteristieken zelden in beschouwing worden 
genomen in RCTs naar het effect van behandeling met antidepressiva op oudere leeftijd. 
Dit is opvallend, omdat al langer bekend is dat er een relatie tussen depressie en functionele 
status, cognitief functioneren, voedingsstatus en comorbiditeit bestaat. Bovendien waren 
RCTs die oudere ouderen includeren ondervertegenwoordigd. Dit noodzaakt tot werving 
van juist deze oudere populatie in onderzoeken, alsmede het meenemen van geriatrische 
karakteristieken als determinanten en uitkomstmaat in toekomstige studies. 
 Deel 3: kwetsbaarheid, multimorbiditeit en functionele status bij oudere volwassenen, 
 acuut opgenomen in een kliniek voor ouderenpsychiatrie 
In hoofdstuk 6 en 7 beschrijven we onze klinische cohortstudie met vijf jaar follow-up van 
120 patiënten, gemiddeld 75 jaar oud, die acuut opgenomen waren in een kliniek voor 
ouderenpsychiatrie. 41 Patiënten hadden een depressieve stoornis, 41 een cognitieve 
stoornis met neuro psychiatrische symptomen (NPS), 17 patiënten een psychotische 
stoornis en 21 een andere psychiatrische stoornis, bijvoorbeeld een angststoornis, afhanke-
lijkheid van middelen of een persoonlijkheidsstoornis. 
 Bij opname werden de volgende geriatrische karakteristieken onderzocht: kwetsbaarheid 
gemeten met een Frailty Index (FI), loopsnelheid (6 meter loop test) en handknijpkracht; 
multimorbiditeit met de CIRS-G; het zichzelf kunnen verzorgen in het dagelijks leven met 
de Barthel Index en voedingsstatus met de Mini Nutritional Assessment schaal (MNA). 
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CHAPTER 9
Als maat voor de ernst van de psychiatrische stoornis gebruikten we de Clinical Global 
Impressions Severity schaal bij opname (admission) (CGI-SA).
In Hoofdstuk 6 onderzochten wij om te beginnen de prevalentie van de karakteristieken bij 
opname, vervolgens of de geriatrische karakteristieken onafhankelijke voorspellers waren van:
 1. de psychiatrische uitkomst maat, namelijk de Clinical Global Impressions of 
  Improvement schaal (CGI-I) en
 2. ontslagbestemming: gunstig (in staat om weer terug te keren naar huis of naar het 
  zorgniveau van vóór de opname) of ongunstig (overlijden tijdens de opname 
  periode of opgenomen worden in een zorginstelling met een hoger zorgniveau dan 
  vóór de opname).
De helft van de patiënten bleek kwetsbaar te zijn, zowel gemeten met de FI, loopsnelheid als 
de handknijpkracht. De helft van de patiënten had minstens één probleem in de dagelijkse
zelfzorg. Het niveau van de CIRS-G was hoog, vergelijkbaar met patiënten die op acute 
geriatrische opname afdelingen in het algemeen ziekenhuis opgenomen worden. Meer 
dan 90% van de patiënten was ondervoed of had een risico op ondervoeding. De scores van 
de geriatrische karakteristieken waren onderling gecorreleerd, maar correleerden niet met 
de CGI-SA. Er was geen verschil in gemiddelde scores tussen de vier diagnosegroepen, met 
uitzondering van de MNA, die het laagst was in patiënten met een depressie. 
 Noch de FI, CIRS-G of de Barthell score waren voorspellend voor de CGI-I, waarbij 
rekening werd gehouden met (onder andere) leeftijd, geslacht en diagnosegroep.
 Daarentegen was de FI wél een sterke voorspeller voor een ongunstige ontslagbestem-
ming. Dit gold ook voor loopsnelheid en de CIRS-G, maar niet voor de Barthel Index. 
Wij concludeerden dat geriatrische syndromen en multimorbiditeit complementair zijn aan 
psychiatrische problemen in het begrijpen van - met name niet psychiatrische - uitkomsten 
van behandeling en dat zij kunnen helpen bij het voorspellen van het identifi ceren van 
patiënten die een hoog risico hebben op een ongunstige ontslagbestemming. 
In hoofdstuk 7 onderzochten wij het overlijdenspercentage van onze 120 opgenomen 
patiënten binnen vijf jaar na opname. De hoofdvraag was of de FI, onafhankelijk van leeftijd
geslacht, opleidingsniveau, diagnosegroep, CIRS-G, Barthel Index en de CGI-SA, een voor-
speller was van overlijden binnen vijf jaar na ontslag. 
 Het overlijdenspercentage was 49%. Dat betekent dat de levensverwachting van onze 
populatie veel lager is dan van leeftijdsgenoten in de algemene bevolking. De FI bleek hieraan
fors bij te dragen: per 0,1 punt stijging van de FI steeg de kans op overlijden binnen vijf 
jaar met 78%. 
 In secundaire analyses bleken noch loopsnelheid, handknijpkracht of MNA voorspellend 
te zijn voor overlijden wanneer bovenstaande co-variabelen meegenomen werden in de 
berekeningen.
 Wij concludeerden dat het vaststellen van kwetsbaarheid behulpzaam kan zijn bij het 




 Conclusie en aanbevelingen
Geriatrische syndromen en multimorbiditeit blijken voor te komen onder oudere volwassenen
met psychiatrische problemen, zowel bij mensen met onvoldoende verklaarde lichamelijke
klachten en - in hogere mate - bij opgenomen patiënten met ernstige psychiatrische stoor-
nissen. Er bleken onderlinge verbanden te zijn tussen de geriatrische karakteristieken, maar 
er bleken weinig verschillen in prevalentie te bestaan tussen patiënten met verschillende 
psychiatrische diagnoses. Kwetsbaarheid was, samen met multimorbiditeit, voorspellend 
voor het niet meer terug kunnen keren naar de eigen woonomgeving na ontslag en kwets-
baarheid was een sterke voorspeller voor overlijden binnen vijf jaar na opname. 
Kwetsbaarheid en multimorbiditeit zijn dus voor oudere mensen met psychiatrische stoor-
nissen net zo belangrijk als voor ouderen die in algemene ziekenhuizen zijn opgenomen.
Desalniettemin blijkt er in studies naar behandeling van depressie nauwelijks aandacht voor 
te zijn. 
Wij bevelen aan om in de klinische praktijk structureel aandacht te hebben voor geriatrische
syndromen en multimorbiditeit in de ouderenpsychiatrie. In de algemene ziekenhuizen is 
er verplichte screening op kwetsbaarheid, voedingstatus, functionele status en valgevaar. 
Zo zou er ook voor de GGZ een dergelijke screening ingevoerd kunnen worden. Daar kunnen
dan acties op uitgezet worden en zo nodig kunnen interprofessionele, geïntegreerde 
diagnose- en behandeltrajecten opgezet worden. Het lijkt verstandig om dit al voor de 
ambulante, niet opgenomen, patiënt te doen. Vroege herkenning betekent immers dat 
interventies om behandeluitkomsten te verbeteren tijdig ingezet kunnen worden. Daarnaast 
kan kwetsbaarheid, wanneer eenmaal aanwezig en niet goed te behandelen, gebruikt 
worden om in behandelperspectieven mee te laten wegen. 
 Voor wat betreft wetenschappelijk onderzoek adviseren wij samenwerking tussen 
psychiaters, psychologen, klinisch geriaters en andere betrokken disciplines. Focus zou 
moeten liggen op uitvoerbaarheid en resultaten van screening én op onderzoek naar de 
uitvoerbaarheid en resultaten van complexe interventies bij ouderen met geriatrische én 
psychiatrische problemen. 
 Voor onze oudere patiënten met psychiatrische stoornissen in de GGZ kan dit net zoveel 
betekenen als voor ouderen in algemene ziekenhuizen. 
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CHAPTER 9
Gerard helpt Carolien met het uitknippen en het in elkaar zetten van een dierentuin. Maar hoe?






Patiënten als mw A hebben mijn collegae en mij ertoe geïnspireerd om onderzoek te doen. 
Wat begon als eenvoudig klinisch onderzoek kreeg in 2011 de ambitie om er een promotie- 
onderzoek van te maken. Ik zou het traject in 2015 afronden. De deadlines werden allengs 
opgeschoven. In 2016 liep de drukte me zo over de schoenen dat ik het hele project een jaar 
in de ijskast heb gezet. We spraken af dat ik stap voor stap de laatste artikelen zou afronden 
en dat we het woord promotie even niet in de mond zouden nemen. Wie had toen gedacht 
dat de diagnose borstkanker eind 2018 en het 15 maanden lange behandeltraject in zekere 
zin de ‘sabbatical’ opleverde, die ik eigenlijk al lang gewenst had. Stap voor stap, wanneer 
ik puf had en als afl eiding bedoeld, maakte ik mijn laatste artikel af. Vervolgens volgden 
het eerste en laatste hoofdstuk van het proefschrift. Het is gelukt, mijn promotie traject is 
afgerond. Wat een opluchting en wonder tegelijk. 
Onderzoek doen zag ik al als kind bij ons thuis. Mijn vader, Gerard Benraad was internist in 
het CWZ en had een eigen praktijk op de Wilhelminasingel. Hij werkte aan onderzoek over de 
relatie bloeddruk en hormonen met Piet Kloppenborg en Theo Benraad. Beiden werkten op 
de Katholieke Universiteit, promoveerden en werden allengs hoogleraar. Maar Gerard bleef 
gewoon internist met passie voor kunst, muziek, schaken, wijn, jagen en onderzoek doen in 
het kader van klinische patiëntenzorg met mijn minstens zo slimme moeder, Chrisje Benraad-
Braat aan zijn zijde. 
 Scheiding werk privé was nog niet zo’n item. De heren maakten er een aangename 
activiteit van: met een biertje of jonge jenever en een blokje kaas gingen zij aan de slag met 
minstens 10 cm dikke uitdraaien van data. Af en toe hielp ik mee. In grote kasboeken vulde 
ik data met potlood in, die daarna door secretaresses in kaarten geponst werden om te laten 
uitrekenen. Dat bleek niet de realiteit van 21e eeuw. Het werd veel investeren in eigen tijd, 
er kwam geen borreltje aan te pas. Maar de passie om datgene wat ik in de patiëntenzorg 
meende te zien om te zetten naar onderzoek in de hoop dat mijn hypothesen bevestigd 
werden, heeft me niet losgelaten, sterker nog, dat gaf de drive om door te gaan.
Er zijn zoveel mensen die mij in de loop van de tijd geholpen hebben, dat ik daar bij stil wil staan. 
De afgelopen twee jaar stonden vooral in het teken van de behandeling van mijn borstkanker. 
In die periode heb ik zoveel kaarten, bloemen, bezoeken, app berichten gehad, van alle mensen
die hieronder genoemd worden. Om dit niet door elkaar te laten lopen met de steun voor 
mijn onderzoek, noem ik dat apart hier. Heel veel dank aan jullie allemaal!
 In dit kader gaat mijn dank zeer uit naar alle professionals en afdelingen van het Radboud-
umc waar ik zorg gehad heb, mijn huisarts, fysiotherapeut, de trainers van de Gym Society, 
bedrijfsarts en maatschappelijk werk. Jullie hebben me allemaal geholpen er zodanig doorheen
te komen, dat ik ook nog een proefschrift kon afronden. Ook apart aandacht voor mijn 
collegae, die mijn werk zo lang moesten overnemen en die me nu het gevoel geven dat ik er 




Om te beginnen bedank ik alle patiënten, waarvan de gegevens in ons onderzoek gebruikt 
mochten worden. In het bijzonder dank aan mw A en haar familie, die toestemming gaven 
om haar als ‘verhaal van een patiënte’ te beschrijven. 
 Promotieteam 
Richard Oude Voshaar, jij begon bij ons als getalenteerde AIOS, kwam razendsnel langszij 
en weg was je, naar Groningen als hoogleraar. Jij hebt ons geholpen met de pilot studie en 
voordat je vertrok ben jij de OPUS studie gaan trekken, toen Dorine en ik een aantal mensen 
verzamelden die mee wilden helpen de studie op te zetten. Jij nam het idee van kwetsbaarheid
voor de ouderenpsychiatrie mee vanuit je opleiding bij ons. Daar ben ik trots op en je zette je 
voor mij in bij ieder onderdeel van mijn onderzoek. Jouw opgewektheid en scherpte werkten 
aanstekelijk!
Jan Spijker, jij kwam mee uit Pro Persona en was vanaf de systematische review betrokken 
en bracht jouw kennis over depressie mee. Jij was de rustige kracht en je gaf me vanaf het 
moment dat je deel uitmaakte van ons team het stabiele vertrouwen dat het wel goed zou 
komen.
 René Melis, wat was je standvastig en vriendelijk als je weer moest uitleggen welke 
methode en waarom ik die moest gebruiken in mijn analyses. Ondanks het feit dat het 
volgens jou niet ‘mijn natuurlijke habitat’ was om onderzoeker te zijn, heb je me een fl inke 
duw in die richting gegeven en me heel wat statistiek en methoden bijgebracht. 
 En dan natuurlijk vooral dank aan jou, Marcel Olde Rikkert. Tijdens één overleg, in een 
koffi etentje op het station in Nijmegen, zag jij haarscherp hoe ik de al verzamelde data om 
kon zetten in vraagstellingen die relevant, interessant en te publiceren waren. We voegden er 
de systematische review aan toe. Ik heb daarmee onderzoek gepubliceerd uit vier verschillende 
studies. Dat is niet veel promovendi gegeven, maar verklaart ook de lengte van het traject. 
Jouw aanbod om over te stappen naar het Radboudumc heb ik enthousiast aangegrepen. 
Ik kreeg daarmee de methodologische ondersteuning voor het derde onderdeel van mijn 
onderzoek. Ik kon het schrijfwerk bovendien in mijn re-integratie periode afronden. 
 Jullie hielden me samen inhoudelijk op het pad, maar gaven me de ruimte en tijd, dat 
heeft me enorm geholpen om het laatste stuk van de weg af te leggen.
 Manuscriptcommissie
Anne Speckens, Mirko Petrovic en Rob Kok, jullie zijn bereid geweest om mijn manuscript 
kritisch te lezen en te beoordelen. Bedankt voor de tijd en moeite die jullie daarin gestoken 
hebben. Ik hoop op discussie tijdens mijn verdediging.
 GGz Nijmegen en Pro Persona
Gedurende de periode waarin ik in GGz Nijmegen en later Pro Persona werkzaam was 
kreeg ik steun van opvolgende leden van raden van bestuur. Jos Poelman stelde geld ter 
beschikking voor de manipel Ouderen en Christoph Hrachovec zorgde dat ik een dag per 




ons het onderzoek naar onverklaarde klachten af te maken. Radboud Marijnissen, jij deed 
onderzoek op een overlappend gebied, wat mij hielp én samen hebben we een mooie,
geïntegreerde opleiding voor ouderenpsychiaters en klinisch geriaters vormgegeven, mét 
Mario Braakman en Marja Simons. Lonneke Wouts heeft jou met verve opgevolgd.  
 Samen onderzoek doen
Natuurlijk op de eerste plaats grote dank aan de andere twee ‘musketiers’, zoals we 
inmiddels gedoopt werden: Peter Hilderink en Dorine van Driel. Wat mooi dat we alle drie 
gepromoveerd zijn vanuit de passie voor onze patiënten met onverklaarde klachten. Inter-
professioneel samenwerken lag ons. Dorine, naast ons gezamenlijke onderzoek stuurde jij 
ook samen met mij de zorg aan in Nijmegen en nam later deel in de programmaraad. We 
steunden elkaar daarin echt, hoe verschillend onze leiderschapsstijl ook was. Peter, terwijl 
Dorine en ik ons in de organisatie stortten, was jij slim genoeg om te focussen en maakte als 
eerste de promotie af. Je bent een heel goede psychiater, ik heb veel van je geleerd. 
 Wat een monnikenwerk, zo’n systematische review. Een absolute afrader om naast 
klinisch werk te doen. Daar mag ik Floor Kamerman, die me bijstond als tweede reviewer en 
Barbara van Munster, die me inhoudelijk hielp met de methode wel speciaal voor bedanken. 
 Voor het onderzoek naar de opgenomen patiënten wil ik graag Mieke Karlietis, Luc 
Disselhorst, Gerja van Hunen, Jos Vloedmans en Jacques van Limbeek danken, met wie 
ik het heb opgezet. Daarnaast dank aan allen die ons hielpen met de data verzameling. 
Speciaal wil ik Brechtje Pastoors, Loes van Wolferen, Nicky Laurensen, Max Franken, 
Lars van Heijningen en Rosanne van Dulst bedanken. Jullie hielpen met wetenschappelijke
opdrachten en stages in mijn onderzoek. Het was stimulerend om jullie mee te nemen en 
het hielp me enorm.
 Ook dank aan Robbie Janssen en mijn twee neven, Max en Berend Benraad, die me hielpen
met het omzetten van de gegevens op papier naar een database. 
 Dank aan alle medewerkers in het Maria Mackenzie Centrum en later het circuit Ouderen,
te veel om op te noemen. Die sfeer, het enthousiasme, samen de schouders eronder, de 
gezelligheid. We hebben bijna 20 mooie jaren gehad. Marlou Boelens, zonder jou had ik alle 
ballen nooit in de lucht kunnen houden. Mieke, Luc en Brechtje wil ik als collegae klinisch 
geriaters in het bijzonder danken voor onze gezamenlijke passie in de patiëntenzorg in Pro 
Persona en in de Maartenskliniek. 
 Bedankt ook, alle onderzoekers van de afdeling geriatrie in het Radboudumc. ik had 
natuurlijk geen tijd om besprekingen bij te wonen, maar door jullie voortdurend vragen hoe 
het ervoor stond, heb ik het gevoel gekregen en gehouden dat ik er toch bij hoorde: Anke, 
Carlijn, Daan, Dorien, Fokke, Jana, Lara, Marieke, Esther, Marit, Minke, Rianne, Roel, Sanne, 
Noralie. Speciaal dank aan Miriam Haaksma, die op het laatst bij mijn onderzoek aanhaakte 
en de rol van René deels overnam. Wat kun jij duidelijk uitleggen en wat handig dat je soms 
even snel uitzocht hoe iets moest in SPSS. 
Richard van Driel maakte dit mooie boekje en Marleen Luiten las mee, gaf tips en
corrigeerde eindeloos. Dank jullie allebei, het resultaat is er naar!
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CHAPTER 9
 Familie en vrienden
Ik noem even een paar mensen in het bijzonder: mijn broer en schoonzus Bart en Meeke en 
de kinderen, alle Schrovers. Jullie informeerden zo vaak hoe het ervoor stond en verklaarden 
me niet voor gek dat ik probeerde het onderzoek af te maken. Mijn supervriendin Els met 
Wim, we kunnen elkaar zo heerlijk vinden in onze brede belangstelling in jullie en mijn vak. 
Bovendien behoed je me voor nog eens een klus als dit onderzoek op te pakken, Els. Chuck 
en Heleen, we wandelen, sparren. musiceren en koken. En dan Arno, tuinman en vriend, 
jij hielp me om in de tuin te blijven aarden. En natuurlijk dank aan Yvonne en Miep, onze 
hulptroepen in het huishouden. 
Joke, Marion en Willemijn, mijn fi losofi e vriendinnen sinds 35 jaar: jullie volgden me 
op de voet en vonden het vanzelfsprekend dat ik de titanenarbeid, af zou maken. Mijn 
leesclubgenoten, dankzij jullie lees ik nu ook Nederlandse boeken, samen met de gezellige 
avonden, bezorgde me dat veel afl eiding! Beste Rotary club Rijk van Nijmegen vrienden, 
jullie verruimen mijn blik op de wereld en geven me vertrouwen nu ik voorzitter ben, hoe 
mooi is dat. 
 De meiden
Bedankt Marleen, Marij en Louise, samen met Bernadette vriendinnen voor het leven, al 
50 jaar. In januari werd Bernadette ziek en overleed in juni. Wat deelden wij veel met elkaar 
en wat een steun was je voor mij, altijd en overal. Ik had zo graag gewild dat jij het manus-
cript nog had kunnen lezen, mijn Nederlandse samenvatting corrigeren en naast me zou 
staan als paranimf. Tijdens het laatste bezoek aan jou had ik verteld dat ik overwoog om 
Judith als paranimf te vragen, nu jij het niet meer kon zijn. Daar had jij stilletjes op gehoopt. 
Judith, net in opleiding voor reumatoloog, vond het super en, eenmaal voor de next generation 
gekozen, heb ik ook Annelies, onze enige aanstaande dokter in de familie en dochter van 
Bart, gevraagd. Leuk om met twee jonge meiden aan mijn zijde het traject af te maken.
 Mijn gezin
Jullie bedank ik wel apart voor wat jullie voor me gedaan hebben de afgelopen twee jaar: er 
gewoon zijn, het glas half vol houden, mee naar het ziekenhuis, extra uit Groningen komen enz.
Koen en Christien, jullie waren de spiegel qua onderzoek: ik was vaak te druk. Ik werkte 
altijd, terwijl ik dat zelf nog wel mee vond vallen. Ik geloof dat jullie toch best trots zijn op je 
moeder zijn, die het toch maar gefl ikt heeft. Jullie studeren nu allebei vakken die ons allemaal
interesseren: kunstgeschiedenis en geschiedenis. Wat hebben we levendige discussies aan 
tafel, het lijkt net mijn eigen studententijd. Ik ben in ieder geval trots op jullie! 
Frank, mijn liefste, humorist en optimist, hoewel jij me keer op keer confronteerde met 
het feit dat het mijn en niet jouw keuze was om onderzoek te doen, ving jij meer dan het 
halve huishouden op. Toen ik te kennen gaf dat ik er de brui aan wilde geven werd je boos: en 
wij dan, de tijd die wij erin gestoken hebben, nee, ik moest het afmaken. Dat heb ik gedaan. 
 Op naar de tango, het nederlands elftal, Down the Rabbit Hole, die ons dit jaar door de 
neus zijn geboord en veel tijd voor andere leuke dingen. Wat een vooruitzicht, wat heerlijk 
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- Pilot study: Case Record forms are stored in Pro Persona Mental Health Care, Research 
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- Clinical Cohort Study: Case Record forms are stored in Department of Geriatrics, as 
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Review (Chapter 5)
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For many years I worked as a geriatrician in a 
centre for psychiatry for older adults. Here I worked
together with a psychiatrist and a psychologist.
We observed that symptoms of patients with 
medically unexplained symptoms (MUS) were 
not always as unexplained as they seemed and 
that these patients often had more than one 
psychiatric diagnosis and a high burden of their 
complaints. What psychiatric, psychological and 
geriatric problems did these patients have? How 
could we treat these patients and help them to 
cope? 
Meanwhile, my colleague geriatricians and I also observed that acutely 
admitted patients on our inpatient wards were often undernourished, 
frail, had cognitive dysfunction and often a high burden of multi-
morbidity. We became convinced that these geriatric syndromes and 
multimorbidity did not only co-occur, but were often so intermingled 
with psychiatric disorders, that they had substantial consequences 
for treatment outcomes.
As we were unable to fi nd studies that confi rmed our observations, 
we decided to look into this ourselves. Our observations became 
questions and our questions became hypotheses. We then initiated 
interprofessional research in outpatient clinical practice on patients 
with MUS and on our inpatient wards on acutely admitted patients 
with different psychiatric diagnoses.  
This doctoral thesis describes our quest and focusses on prevalence
and implications of geriatric syndromes and multimorbidity for our 
patients. It sheds new light on the connection between psychiatry, 
geriatrics and psychology and the necessity to integrate care for complex
patients with psychiatric disorders. 
Carolien Benraad, 2021
